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Transcriptional Landscapes In Lymphocyte Development And Differentiation: 
Tcf-1 Enforces Epigenetic Identity In Developing T Cells And T-Bet Resolves 
Functionally Distinct Memory B Cells 
Abstract 
An important role of cellular differentiation is to establish distinct and durable cell subsets that serve 
different functions over the course of an immune response. Here, I investigate the problem of cellular 
differentiation by considering 1) how epigenetic repression is overcome to establish unique preimmune 
lymphocyte identity and 2) the durability of intraclonal and interclonal diversification resulting from an 
immune response. The epigenetic states of hematopoietic cells contain cell-type specific accessible 
chromatin structures which are developmentally constructed from repressive, compacted chromatin. 
However, these structures feature binding sites for lineage-specific transcription factors, suggesting these 
factors play a role in their generation. I used measurements of chromatin accessibility in sequential 
stages of T cell development from bone-marrow derived progenitors alongside alternative lymphocyte 
lineages to identify the central role that TCF-1 plays in creating T-cell specific chromatin during 
differentiation. Genetic deficiency of TCF-1 reduced the accessible T cell chromatin state and the T cell 
gene program, whereas the ectopic expression of TCF-1 in fibroblasts caused T cell chromatin to become 
accessible and T cell genes to be expressed. These findings demonstrate that TCF-1 can overcome 
repressive chromatin to establish a naïve T cell identity distinct from other lymphocyte lineages. Despite 
our improved understanding of preimmune lymphocyte differentiation, much less is known about the 
course of lymphocyte differentiation beyond the naïve stage. During immune responses, some activated B 
lymphocytes express the transcription factor T-bet, but the clonal relationship to their T-bet- counterparts 
and the durability of the T-bet+ phenotype is unclear. I found that T-bet+ B cells are generated early after 
influenza infection and develop into a persistent memory pool. Immune repertoire profiling of influenza 
hemagglutinin-specific T-bet+ and T-bet- memory B cells demonstrates that most clones are unique to 
their respective subset, but lineage tree analysis of the remaining shared clones shows that T-bet+ clones 
can stably bifurcate from T-bet- cells. Further, genetic fate-mapping indicates that T-bet expression in B 
cells is stable. Together, these and other findings suggest that T-bet+ B cells are a distinct and durable 
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An important role of cellular differentiation is to establish distinct and durable cell 
subsets that serve different functions over the course of an immune response. Here, I 
investigate the problem of cellular differentiation by considering 1) how epigenetic 
repression is overcome to establish unique preimmune lymphocyte identity and 2) the 
durability of intraclonal and interclonal diversification resulting from an immune 
response. The epigenetic states of hematopoietic cells contain cell-type specific 
accessible chromatin structures which are developmentally constructed from repressive, 
compacted chromatin. However, these structures feature binding sites for lineage-
specific transcription factors, suggesting these factors play a role in their generation. I 
used measurements of chromatin accessibility in sequential stages of T cell 
development from bone-marrow derived progenitors alongside alternative lymphocyte 
lineages to identify the central role that TCF-1 plays in creating T-cell specific chromatin 
during differentiation. Genetic deficiency of TCF-1 reduced the accessible T cell 
chromatin state and the T cell gene program, whereas the ectopic expression of TCF-1 
in fibroblasts caused T cell chromatin to become accessible and T cell genes to be 
expressed. These findings demonstrate that TCF-1 can overcome repressive chromatin 
to establish a naïve T cell identity distinct from other lymphocyte lineages. Despite our 
improved understanding of preimmune lymphocyte differentiation, much less is known 
about the course of lymphocyte differentiation beyond the naïve stage.  During immune 
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responses, some activated B lymphocytes express the transcription factor T-bet, but the 
clonal relationship to their T-bet- counterparts and the durability of the T-bet+ phenotype 
is unclear. I found that T-bet+ B cells are generated early after influenza infection and 
develop into a persistent memory pool. Immune repertoire profiling of influenza 
hemagglutinin-specific T-bet+ and T-bet- memory B cells demonstrates that most clones 
are unique to their respective subset, but lineage tree analysis of the remaining shared 
clones shows that T-bet+ clones can stably bifurcate from T-bet- cells. Further, genetic 
fate-mapping indicates that T-bet expression in B cells is stable. Together, these and 
other findings suggest that T-bet+ B cells are a distinct and durable memory subset and 
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CHAPTER 1: Overview of cellular differentiation 
 
1.1 Cellular differentiation in the immune system and embryology 
 
The theme of the 8th Midwinter Conference of Immunologists, held in California in 
1969, was the Regulation of Cellular Differentiation in the Immune System. Seminal 
discoveries made in the 1960s shed light on the importance of cooperation between two 
distinct populations of lymphocytes, B and T cells, in the function of the adaptive immune 
response. One can only speculate that the organizers felt it worthwhile to provoke new 
patterns of thought on the matter by exploring connections to more established 
disciplines. In fact, Ray Owen chaired the first session on “Principles of Cellular 
Differentiation” with only two speakers: Clifford Grobstein (from UCSD) and Robert 
Auerbach (from University of Wisconsin, Madison). The session was reported as 
providing a “very fruitful interaction between two speakers disciplined in embryology and 
an audience who were specialists in immunology (1).” These fruitful interactions included 
discussion of the replication of the differentiated state, the different phases of cellular 
development, and mechanisms of communication. Parallels were drawn between 
embryonic development and the cellular interactions of thymus and bone marrow 
derived lymphocytes as well as the stem cell concept in antibody formation; that is, 
restrictive differentiation, environmental responsiveness, and cell multipotentiality. In his 
closing remark, Grobstein noted, “both disciplines seek answers to similar questions of 
differentiation, for example, the kind of regulation that occurs in cells … the nature of the 
cue…and the steps in the instructive pathway (1).” 
The intertwining of embryology and immunology has not faltered; it has instead 
grown stronger with the continued discovery of important and distinct lymphocyte 
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subsets and the increasing appreciation for the epigenetic control of immune cell 
differentiation, even serving at times as a model for metazoan development. Therefore, 
the purpose of this overview is to accomplish a number of objectives: 1) to frame current 
problems in lymphocyte differentiation in the time-tested framework of embryology 2) to 
highlight the importance of studying lymphocyte differentiation, and 3) to describe the 
systems I will use to investigate two aspects of lymphocyte differentiation.   
The central theme of this dissertation is the cellular differentiation of the 
lymphocytes of the adaptive immune system, both in their initial pre-immune 
development and in their further antigen-experienced specialization. Comparisons will be 
made in this overview to the developmental process occurring in embryogenesis, as this 
is a tradition of thought extending back to Aristotle and greatly enhanced by brilliant 
minds that followed. For both embryogenesis and the adaptive immune system, the 
process of cellular differentiation is fundamental for the establishment of proper function 
and form. In each process, a group of apparently homogenous cells becomes 
permanently transformed in character and acquires a specialized function. In 
gastrulation, the inner cell mass of the blastocyst forms the nervous system, the 
notochord, the integument, and the gut. In hematopoiesis, stem cells form myeloid cells, 
erythrocytes, granulocytes, and the T and B lymphocytes of the adaptive immune 
system. In both cases, all of the parts contain specific types of cells, in the correct 
proportions and position relative to one another, and carrying out the proper specialized 
function. Therefore, the form of the question has remained the same in both processes 
of development: to what extent and by what process do cells differentiate from their 
progenitors and from each other? 
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1.2 Cellular differentiation, regional specification, and morphogenesis 
 
Cell differentiation is the expression of gene products by a population of cells that 
are different than those made by their progenitors and different from those made by 
other populations of cells. Differentiation pervades nearly every aspect of multicellular 
organisms occurring not only in the embryo, but also in the continual process of tissue 
repair and homeostasis. Cell differentiation is a complex process requiring genetic and 
epigenetic mechanisms of gene control, and embryonic development has laid the 
conceptual groundwork, defined terms, and provided a framework for exploring these 
mechanisms in all forms of differentiation. 
Other developmental processes occur in the embryo but have more limited 
parallels to lymphocyte differentiation. They are important, and I will touch on them 
briefly. In early development, the core problem is regional specification. This is the 
process whereby cells in certain regions of the embryo are turned onto certain pathways 
of development. The most obvious parallel in the development of the adaptive immune 
system is the regional specification that occurs when lymphocyte precursors enter the 
thymus and are specified to become T lymphocytes. Whether a type of regional 
specification occurs in the peripheral lymphatics during the lifetime of mature 
lymphocytes is an interesting question, but not one that will be addressed in this 
dissertation. Regional specification is not to be confused with cell differentiation, as 
these are both important but distinct problems.  
The developmental process of least concern to us, because it has the least 
obvious parallel, is morphogenesis or the creation of form. This term is used to describe 
the cell and tissue movements that shape the organism. However, leukocytes are unique 
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in that cells operate more or less as individual, mobile units. As such, comparisons made 
of lymphocyte movements to the behavior of tissues would have to be made at an 
abstract level. However, lymphocytes clearly demonstrate coordinated behaviors such 
as the orderly trafficking of immature T lymphocytes through thymic structures during 
development or the aggregation of mature B cells in follicles in peripheral lymphatics. 
Although the mechanical and physical components of morphogenesis are not as directly 
applicable to lymphocytes, the chemically directed components of this process are more 
closely shared. Despite the importance of morphogenesis in embryonic development, 
morphogenesis is largely the consequence of cellular differentiation. 
1.3 Cellular differentiation is a developmental hierarchy 
 
In embryogenesis, the parts to be developed in the basic body plan are not 
specified all at once but are formed as a hierarchy of developmental choices. Perhaps 
not surprisingly, a developmental hierarchy also exists in hematopoiesis. Figure 1 
illustrates the subdivisions of the developmental choices made during hematopoiesis. 
Setting aside discussions about details of the diagram, the familiar cell-types the 
developed immune system are found at the bottom of the tree. These cell-types are 
preceded by a series of prior commitment choices. At each of these a choice is made 
between increasingly restricted alternative states arising from a subdivision of an earlier 
less committed progenitor. Every decision is made among a small number of alternatives 
and a new state of commitment is adopted with further restriction of potency. Upon 
reaching terminal differentiation, potential has been exhausted, and the cell persists in 
its final state until its death. The difficulty of deducing the arrangement of these fate 
decisions lies in the largely covert nature of the cell state that can only be uncovered by 
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experimentally probing for remaining lineage potential. Despite this difficulty, the 
organization of cell fate choices into a hierarchy has provided a useful framework for 
understanding the gene control mechanisms of differentiation, and these molecular 
mechanisms will be discussed below. 
 
 
Figure 1. The hierarchy of development in hematopoiesis. 
The formation of blood cells occurs by a process of progressive determination and fate 
restriction. The property of self-renewal is lost at the onset of differentiation, but 
hematopoietic progenitors initially maintain their pluripotency for all subsequent lineages. 
As differentiation proceeds alternative fate choices are gradually lost as cells commit to 
a lineage. The hematopoietic system is therefore built up as a result of a hierarchy of 
decisions and several fate choices will be made before the cells differentiate into the 
mature cell types shown at the bottom. The mechanisms underlying this process are 
discussed in Chapter 2. For some cell-types, such as B and T cells, further differentiation 
will occur after encountering antigen in an immune response and this will be discussed 













1.4 Differentiation is organized at the genetic level by transcription factors 
 
The process of restrictive differentiation that occurs during both embryogenesis 
and hematopoiesis is the consequence of the regulatory system controlling gene 
expression. Differentiation is the establishment of a new regulatory state that can be 
thought of as the cumulative activity of particular sets of DNA-binding transcription 
factors coordinating their activity at non-coding DNA and determining gene expression. 
Regulatory states are interpreted by the DNA sequence elements composed of clusters 
of transcription factor binding sites called cis-regulatory modules (CRM) or enhancers. It 
is the binding of a transcription factor to a CRM that allows the transcription factor to 
modulate the expression of nearby target genes, and the integration of all transcription 
factors at the CRM produces a unique regulatory output. However, the availability of a 
CRM for binding by the transcription factor, and therefore the contribution of the CRM to 
the regulatory state, is controlled by the proteins that package DNA, collectively called 
chromatin. The regulatory state encoding the prior cell identity can therefore be made 
irrecoverable by two mechanisms: 1) transcription factors acting in the prior regulatory 
state either cease to be expressed or 2) the previously available CRMs are made 
inaccessible by the closing and compaction of chromatin. These mechanisms provide 
directionality to differentiation, allowing signaling inputs to activate transcription factors 
on the newly accessible chromatin and not at previously active chromatin. Thus, 
restrictive differentiation is a consequence of the interplay between transcription factors, 
DNA sequence elements known as CRMs, and the chromatin. 
The hierarchical and ordered nature of development is also the consequence of 
the integration of transcription factor activity at chromatin-controlled CRMs. The 
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interpretation of the current regulatory state at the available CRMs results in a regulatory 
output that may induce new transcription factors or other regulatory genes. The addition 
of transcription factors to a regulatory state specifies new modes of gene regulation that 
can have multiple outcomes: 1) the process of differentiation continues by inducing the 
expression of additional lineage-related regulatory genes or transcription factors, 2) the 
cell is made competent for an alternative lineage by becoming receptive to new signal 
inputs, or 3) the developmental process ends without inducing new transcription factors 
and by expressing structural genes associated with terminal differentiation. Thus, the 
contribution of transcription factors to differentiation is inextricable from the 
developmental sequence because their activity is dependent on the developmental 
history of the cell to establish a responsive regulatory state and to prime the chromatin 
for action at appropriate CRMs. 
However, cellular differentiation is rarely the result of the expression of a single 
gene. Thomas Hunt Morgan used the term “gene battery” in 1934 to refer to the 
functionally related effector genes that are coordinately expressed in a given cell type 
upon differentiation. The CRMs regulating these gene batteries share lineage-specific 
transcription factor binding sites, but the chromatin is often closed at these CRMs. How 
is the cell-type specific accessibility at these gene batteries established during 
development? Recent research has demonstrated that lineage-specific transcription 
factors known as Pioneer Transcription Factors (PTFs) or Lineage-Determining 
Transcription Factors (LDTFs) establish accessible chromatin at the CRMs of their 
corresponding lineage through positive interactions with the normally repressive 
chromatin (2, 3). LDTFs add new modes of regulation to the already existing regulatory 
state by acting on the “tabula rasa” of the chromatin to create de novo accessibility and 
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establish competent and active CRMs. Because LDTFs are not inhibited by closed 
chromatin they can reprogram cells or cause trans-determination when ectopically 
expressed, and their identification has opened the door for new therapeutic options 
involving cellular engineering through the manipulation of cell identity. Identifying the 
LDTFs acting in T cell development will the focus of chapter 2. 
Questions of mechanism have remained at the forefront of the field since the 
advent of molecular biology in the 1980s, and for good reason. The models of genetic 
control proposed by Jacob and Monod in 1961 (4) and Britten and Davidson in 1969 (5) 
cannot be adequately tested at the cellular level. Advanced molecular techniques such 
as microarrays and next generation sequencing have only intensified the investigation 
into the molecular workings of differentiation. However, the questions being addressed 
by these tools were the questions initially proposed by earlier embryologists. The basic 
observation of development is the cell is the fundamental unit by which biological 
systems are organized at the organismal level. As such, breaking down any cellular 
system, such as the immune system, requires an understanding of the differentiative 
events at the cellular level. Without this framework, making sense of the molecular 
mechanisms driving differentiation would not be possible. For that reason, I will discuss 
two additional embryological concepts, albeit familiar to an immunologist, that will be 
explored in chapter 3. 
1.5 Additional embryological concepts: the fate map and clonal analysis 
 
The first of these concepts is the fate map. Fate mapping is fundamental to 
embryology and just as important to immunology. Regional specification is the core 
problem of embryonic development and the fate map is a diagram indicating what each 
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specified region of the early embryo will turn into. To create a fate map, the trajectory of 
the cells must be tracked throughout development. For some organisms, the fate of each 
individual cell can be tracked with great precision whereas other organisms tolerate 
some degree of cell mixing between adjacent regions and thereby reducing the 
resolution of the fate map. As long as the random mixing of cells is minimal, the fate map 
tells you what organs and limbs each cell will become and allows faithful cell lineages to 
be constructed. To the immunologist, fate mapping can establish critical lineage 
relationships that are normally obscure for a number of reasons: 1) the longitudinal study 
of immune cell differentiation, especially those located in tissues, is often not possible, 2) 
a specific immune response does not develop in isolation as an embryo does but is 
surrounded by cells differentiating at various stages from other immune responses, and 
3) the terminal fate is normally indistinguishable even while differentiating cells take 
different developmental trajectories to the terminal fate. The fate map can also help 
determine whether a cell state is stable or merely represents a temporary phenotype, 
and this is especially useful for studying lymphocyte differentiation. For both embryology 
and immunology, the cell lineage established by fate mapping places the genetic and 
epigenetic mechanisms of differentiation into the context of prior and future molecular 
events. Thus, the interpretation of experiments on developmental decisions depends on 
the fate map. However, fate mapping alone does not provide information on commitment 
as it only reveals what will become of cells if left in place. 
The second concept, clonal analysis, is related to the fate map, but differs 
because it allows us to say something about commitment and determination. 
Determination means that a cell is intrinsically committed to develop into a specific cell 
type or a structure. To illustrate, a single cell may form cell type A or cell type B, or 
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neither, but the undifferentiated cell could not have been determined if the clone 
develops into both cell types. An important consideration to make concerns the inverse 
of this principle: if the cell differentiates into one cell type, but not the other, then this 
clonal restriction does not mean determination has occurred. However, not all 
developmentally significant forms of clonal restriction need occur through an internal, 
genetic mechanism of determination. Clonal restriction can also occur by the existence 
of an extracellular barrier limiting mixing of unrestricted cells and thereby maintaining 
stable and distinct cell identities. Moreover, fate mapping is often done in the embryo by 
labelling groups of cells, but the analysis of a clone provides information about the 
individual behavior, the resulting lineages, and the contribution of a cell to a particular 
structure. This information is particularly important for studying lymphocyte immune 
responses as they are typically polyclonal, and clonal analysis can distinguish which 
clones contribute to certain effector or memory cell populations. 
1.6 Cellular differentiation is central to adaptive immune system function 
 
Why frame the lymphocytes of the adaptive immune system immunology in terms 
of embryonic development? Given the importance of the immune system in protecting us 
from pathogens, it’s no surprise the mammalian immune system relies on cellular 
specialization through stable cellular differentiation as the basis of its functional 
organization. Therefore, the study of differentiation itself and the mechanisms governing 
differentiation, are of upmost concern to an immunologist. As encapsulated in the clonal 
selection theory (6), the differentiation of lymphocytes occurs in two phases. The first 
phase is the establishment of a preimmune pool of T and B cells bearing clonally 
distributed receptors for antigen. At homeostasis, prior to antigen or pathogen exposure, 
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the cells of the immune system develop from the progressive determination of post-
embryonic stem cells according to control principles similar to those in operation during 
organismal development. The development of the embryo is a self-directed, hierarchical 
process, and similarly the immune system differentiates according to an internally 
regulated and genetically encoded developmental hierarchy. As such, both 
developmental programs are conducted without much regard to the outside world. The 
precise gene regulation necessary for this process of differentiation is supported by the 
regulated packaging and post-translational modification of chromatin and histones 
directed by lineage-specific transcription factors. In chapter 2, I explore the lineage-
specific transcription factors guiding chromatin accessibility and chromatin modifications 
in the context of the developmental sequence that transforms uncommitted 
hematopoietic progenitors to mature, preimmune T cells. 
In the second phase of lymphocyte differentiation, sufficient antigen receptor 
occupancy causes the activation of the lymphocyte, initiates mitosis, and primes the cell 
to receive differentiative signals. The response is not random; activated lymphocytes 
differentiate according to the circumstances of the infectious challenge and the type of 
pathogen encountered. Although stereotyped responses exist, new subsets of cells are 
still discovered as techniques are developed that afford more precise resolution. 
Accordingly, chapter 3 addresses the extent to which lymphocytes, particularly memory 
B cells, develop into multiple subsets in response to infection, and interrogates the 
differentiative relationship between these subsets. 
The concepts discussed in this overview have been adapted from Jonathan Slack’s 
From Egg to Embryo (7) and Eric Davidson’s The Regulatory Genome: Gene Regulatory 
Networks in Development and Evolution (8). 
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CHAPTER 2: TCF-1 ESTABLISHES T CELL EPIGENETIC IDENTITY 
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2.2.1 The diversity of blood cells develops from hematopoietic progenitors 
 
Eukaryotic organisms express genes in incredibly diverse patterns that are 
necessary for biological complexity (10). This transcriptional diversity is largely controlled 
by the interactions between transcription factors and their cognate DNA binding sites 
within accessible chromatin regions. However, eukaryotic genomes are compacted to fit 
over a meter of DNA within the limited volume of the nucleus and this compaction is 
inherently repressive to processes that require access to the DNA sequence (11). 
Despite the inherently repressive state of chromatin, a number of lineage-instructive 
transcription factors alone or in cooperation with their partners can access a subset of 
their binding sites even if it is partially occluded by nucleosomes, recruiting chromatin-
remodeling enzymes and exposing the underlying DNA. The distinctive collection of 
such accessible sequences controls the transcriptional output of a cell type and 
determines its functional characteristics (12).  
Hematopoiesis is an excellent system for studying lineage-instructive 
transcription factors and their roles in establishing chromatin accessibility as the 
differentiation of the diverse and well-defined cell-types of the blood is continuous 
throughout life. Hematopoiesis originates primarily in the fetal liver but is relocated to the 
bone marrow at birth, serving as the source of hematopoiesis through adult life (13). The 
process of hematopoiesis begins with the hematopoietic stem cell (HSC) (14) that is 
subdivided by lifespan into two major cell subsets. Long-lived HSCs (LT-HSCs) are self-
renewing and can generate all the major lineages of the blood through asymmetric 
division, whereas short-term HSCs (ST-HSCs) generate all blood lineages but self-
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renew only for approximately eight weeks (15). A mixture of LT-HSCs and ST-HSCs can 
be distinguished by the absence of surface markers expressed on mature cell types 
(Lineage, or Lin), and the presence of Sca-1 and the cytokine receptor Kit (LSK, Lin-
Sca1+Kit+). Further, the SLAM marker CD150 more definitively identifies LT-HSCs within 
the LSK compartment (16). 
As in other developmental systems, hematopoiesis follows a developmental 
hierarchy in which lineage potential and self-renewal is lost as cells differentiate. Thus, 
LT-HSCs give rise to ST-HSCs with diminished capacity for self-renewal and ST-HSCs 
in turn give rise to multipotent progenitors (MPPs) which have no capacity for self-
renewal but are multipotent (17). At this point, a fate choice is available, and the cell 
either continues differentiation towards an erythrocyte lineage or the myeloid and 
lymphoid lineage depending on cytokine cues. Cell that lose megakaryocyte potential 
but retain lymphoid and myeloid potential are thus named lymphoid-primed MPPs 
(LMPPs) (18). The LMPP subset expresses Flt3 and gives rise to the common lymphoid 
progenitor (CLP) that was originally thought to be lymphoid restricted, but actually 
retains significant myeloid cell potential (19). The cell surface marker Ly6D further 
differentiates CLPs into those with restricted potential for the B lineage (LyD+ CLPs) 
versus those with T, NK, B, and DC potential (20). However, many developmental 
decisions at this early stage are still plastic and not yet fully determined. For instance, a 
subset of common myeloid progenitors (CMP) expressing Flt3, but lacking CD150 
expression possesses T cell potential that can be revealed using single cell assays in 
vitro under T-inductive conditions (21). Despite possessing this T cell potential, this 
subset does not have the ability to home to the thymus (21), the site of T cell 
specification and development (22, 23). This clonal analysis is a good illustration that an 
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apparent clonal restriction in vivo does not necessarily coincide with developmental 
restriction as potential is determined by both intrinsic genetic mechanisms and external 
instructive mechanisms. Therefore, progenitors must possess T lineage potential as well 
as the ability to reach the organ of T cell specification to develop into T cells. 
2.2.2 T cell development occurs in the thymus 
 
T cell development is unique among the blood lineages because it is completed 
in a specialized organ, the thymus, and homing to the thymus from blood-mobilized bone 
marrow progenitors is necessary for T lineage specification (24). T cell development 
begins when these rare progenitors settle the thymus, but very few are estimated to 
reach the thymus each day (25). However, migration to the thymus appears to be a 
regulated process and not a stochastic one as not all bone marrow progenitors are 
equally capable of thymic settling. For instance, HSCs do not settle the thymus yet hold 
profound T cell potential. Conversely, LMPPs and CLPs both settle the thymus and 
possess T cell potential (26). However, it is unclear which, if either, are the true 
progenitors. Unlike HSCs, both subsets express the chemokine receptors C-chemokine 
receptor-7 (CCR7) and C-chemokine receptor-9 (CCR9) which are essential for thymic 
settling (27, 28). P-selectin glycoprotein 1 (PSGL) is also necessary for thymic homing 
and promotes homing when the thymic niche empties (29, 30). 
The inception of T-lineage cells occurs when bone marrow-derived multipotent 
precursors seed the thymus and give rise to early thymic progenitors (ETP) (31, 32). 
ETPs reside within the CD4-CD8-CD44+CD25-Kithi double negative 1 (DN1) subset and 
are defined by the absence of lineage-associated markers and CD25 while also 
expressing Kit and CD44 (LinloKithiCD25-). ETPs are rare, making up 0.01% of 
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thymocytes, but can generate all thymic lymphoid populations. However, ETPs are not 
determined or developmentally restricted to the T lineage. ETPs must pass through 
additional stages of differentiation before becoming mature T cells and they retain 
differentiative potential for alternative fates, including NK and myeloid cells, which is 
revealed when ETPs are removed from T-inductive signals (33-36). 
The potential to develop into alternative fates is gradually lost as T cell 
differentiation proceeds, and the process of development is associated with an orderly 
trafficking through anatomic structures of the thymus. ETPs migrate from the 
corticomedullary junction in the perimedullary cortex to the inner cortex while 
differentiating into DN2 cells (CD44+Kit+CD25+) (37). However, DN2 cells are 
heterogenous as was first demonstrated by examining the expression of the lymphocyte-
restricted kinase Lck using a GFP reporter (38). Lck- DN2 cells retain DC and NK 
lineage potential that is revealed after removing Notch signals whereas Lck+ DN2 cells 
do not, even if removed from Notch signals. Thus, a key regulatory event seems to occur 
in the DN2 compartment. DN2 heterogeneity is further refined by using the level of Kit 
expression with DN2a cells being Kithi and retaining alternative lineage potential whereas 
DN2b cells are Kitint and are firmly committed to T cell development (39). Further, the 
regulatory event occurring between DN2a and DN2b that enforces lineage commitment 
is the initiation of Bcl11b expression through the combinatorial activity of transcription 
factors at the Bcl11b locus (40). 
DN2b cells then become DN3 cells, move to the subcapsular zone, and undergo 
rearrangement of the T cell receptor (TCR) at the β, γ, and δ loci as these loci become 
accessible and the recombination activating gene 1 (RAG1) and RAG2 are expressed 
(41, 42). A small number of developing T cells will rearrange the γ and δ loci and 
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become γδ T cells, but most DN3 cells (>95%) will rearrange the β locus and continue 
development to become conventional αβ T cells (43, 44). Cells rearranging the β locus 
are held at the β selection checkpoint until a productive, in-frame, recombination of the β 
locus leads to expression of the β chain of the TCR that pairs with a surrogate α chain 
(pre-T-α) for trafficking to the cell surface (45). The signaling accompanying this process 
causes DN3 cells to downregulate RAG expression and enforce allelic exclusion of the 
other β chain allele (46). DN3 cells passing β selection differentiate into DN4 cells and 
undergo a burst of proliferation that replicates the successful β-chain rearrangement into 
multiple daughter cells before the TCR co-receptors CD4 and CD8 are upregulated and 
the DN4 cell becomes a CD4+CD8+ double positive (DP) cell and migrating back to the 
cortex (47). The TCRs are tested for MHC binding in a process of positive selection 
wherein DP cells that bind MHC II become CD4 single positive cells and MHC II 
restricted whereas DP cells that bind MHC I become CD8 single positive cells and MHC 
I restricted (48-50). Cells that fail to bind MHC will fail to receive survival signals from the 
TCR and therefore ‘die by neglect.’ However, binding that is too strong to MHC will 
cause the cell to undergo negative selection and undergo apoptosis or possibly 
differentiate into regulatory T cells if MHC II restricted (51). Finally, T cell development 
ends in the medulla and fully competent mature T cells emigrate from the thymus by 
entering the blood stream (52). 
2.2.3 Transcription factors acting in T cell development 
 
Notch1, an evolutionarily conserved signaling pathway involved in multiple 
developmental processes, initiates the T cell fate decision when Notch1 on the surface 
of bone marrow progenitors settling the thymus interacts with Delta-like Notch ligands on 
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the epithelial cells in the thymus (53). Mammals have four Notch homologues, Notch 1-
4, and two families of ligands, Delta-like and Jagged, but the engagement of Notch1 with 
Delta-like ligands in the thymus is critical for T cell development. DL-1 and DL-4 both 
induce Notch1 signals and induce T cell development, but DL-4 is the most abundant 
ligand in the thymus (54). Notch receptors that engage ligand undergo cleavage events 
mediated by a metalloprotease and γ-secretase to release the intracellular domain of 
Notch1 (ICN) for translocation to the nucleus. ICN binds the transcription factor CSL 
(CBF1/Su(H)LAG1), also known as RBPJ (recombination signal combining protein-J), 
and recruits mastermind-like (MAML) protein to act as a scaffold for the binding of co-
activators such as p300 and the activation of the T cell gene program (55, 56). Notch 
signals and transcriptional activation by ICN is crucial for generating ETPs and ectopic 
expression of ICN is sufficient to induce T cell development in bone marrow progenitors 
outside the thymus but is also oncogenic (57, 58). Notch1 also represses the 
development of alternative fates. For instance, Notch1 inhibits B cell development in the 
BM when ICN is ectopically expressed in bone marrow progenitors (59). Removing ETP 
or DN2a cells from Notch1 signals allows non-T cell fates to develop indicating that 
alternative fates are suppressed by Notch1 signals in early T cell progenitors (60). 
The Ets family transcription factor PU.1 is a winged helix-turn-helix transcription 
factor critical for establishing a gene regulatory program in bone marrow progenitors 
conducive for T cell specification (61). The role of PU.1 in B and myeloid cell 
development is well-established, and both lineages highly express PU.1 (62). However, 
PU.1 is also expressed in early T cell progenitors in the DN stages but must decline for T 
cell commitment to proceed (63). The dose of PU.1 in T cell progenitors strongly 
influences fate commitment, and enforced PU.1 expression blocks commitment and 
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diverts DN3 thymocytes to the myeloid lineage, but only when Notch1 signaling is 
abrogated (63). Thus, while necessary for bone marrow progenitors to initiate T cell 
specification, PU.1 must be precisely regulated to remove undue influence on pre-T cells 
to develop into alternative fates (64). As such, PU.1 is downregulated at the DN2a and 
DN2b transition, and TCF-1 and RUNX1 are important for this repression (65, 66). 
However, the mechanisms of the timing of this downregulation are unclear as TCF-1 and 
RUNX1 are both expressed highly in ETPs. 
Other ubiquitous transcription factors, including E proteins, play an important role 
in early T cell development (67). Members of the basic helix-loop-helix family (bHLH), E 
proteins regulate transcription in many hematopoietic lineages and are suppressed by ID 
proteins that dimerize with E proteins but lack a DNA-binding domain. Two splice 
variants of the E2A gene, E12 and E47, are encoded by the Tcfe2a locus and are critical 
for early B and T cell development (68). E2A regulates Notch1 transcription in early T 
cell progenitors and synergizes with Notch to regulate key T cell genes (69). Another 
bHLH member, HEB, is highly expressed in the thymus, but HEB deficiency manifests at 
a later block in T cell development compared to E47 deficiency (70). ID3, an Id family 
member, is induced by pre-TCR signals and inhibits E protein activity and Notch1 
transcription (71). As such, E2A binding drops dramatically in β-selected thymocytes. 
Zinc finger transcription factors, such as GATA3, also play important roles in T 
development (72). GATA3-deficient hematopoietic progenitors generate normal numbers 
of LMPPs and CLPs but show a deficiency in early T cell development (73). Conversely, 
GATA3 does not enhance T cell development when overexpressed in bone marrow 
progenitors unlike Notch and other key T cell transcription factors. Similar to PU.1, 
GATA3 levels must be precisely controlled as overexpression of GATA3 diverts cells to 
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the mast cell lineage when Notch signals are removed (74). Another zinc finger 
transcription factor, Bcl11b, is likewise important for T-lineage commitment. Bcl11b is 
expressed in DN2a cells at the point of T cell commitment and deletion of Bcl11b in DN 
T cells causes an incomplete developmental block at the DN2a stage (75, 76). 
Importantly, stem cell genes and alternative lineage fates such as myeloid and NK cells 
increase when Bcl11b is deleted in DN2a progenitors (77). Deletion of Bcl11b later, in 
DN3 and DP stages, causes diversion of T cells to the NK fate while also losing the T 
cell gene program (77). Together, this indicates that the role Bcl11b plays in T cell 
commitment is primarily in repressing alternative lineages and maintaining T cell identity 
in a manner similar to PAX5 in the B lineage (78). 
2.2.4 HMG Box transcription factors: TCF-1 and LEF-1 
 
The High Mobility Group (HMG) Box transcription factors are a superfamily 
dating back 1 billion years and can be divided into two major groups based on 
sequence-dependent and sequence-independent DNA recognition, including the 
TCF/SOX and HMG/UBF families, respectively (79). Members of the TCF/SOX family 
have one HMG Box binding domain that binds the (A/T)(A/T)CAAAG motif whereas 
HMG/UBF members contain multiple HMG Box domains and bind DNA non-specifically 
(80). HMG Box domains bind unwound non-B-type DNA and alter DNA architecture by 
inducing bends in the DNA backbone upon binding (81). This distortion of DNA is the 
result of DNA contacts made between the HMG Box and the minor groove of the DNA 
helix. HMG Box containing transcription factors have been proposed to play an 
architectural role, bending the DNA backbone to allow binding of other transcriptional 
regulators to the DNA and the formation of nucleoprotein complexes and occurs, for 
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example, at the TCRα enhancer (82). 
The two lymphoid-specific HMG Box transcription factors are T cell factor 1 
(TCF-1) and lymphoid-enhancing factor-1 (LEF-1). TCF-1 is encoded by the gene Tcf7 
and was identified in the early 1990s by Hans Clever who cloned TCF-1 from a human T 
cell line as a transcription factor bound to the CD3ε enhancer (83). LEF-1 was also 
identified in 1990 soon after at the human immunodeficiency virus (HIV) promoter and 
was originally named TCF-1α while the mouse homologue was denoted as LEF-1 (84). 
TCF-1 and LEF-1 are highly conserved in the HMG Box domain and share 98% 
similarity and are believed to have arisen through gene duplication (85). High level of 
TCF-1 expression is restricted to the T-lineage and LEF-1 is B and T-specific (86). 
Genetic deletion of TCF-1 results in dramatically reduced thymic cellularity and multiple 
blocks in T cell development (87). T cell development in LEF-1 deficient mice is largely 
normal, but exhibit defects in B cell development (88). Moreover, LEF-1 may 
compensate for TCF-1 as the genetic deficiency of both transcription factors causes an 
absolute block in T cell development (89). 
Canonically, TCF-1 and LEF-1 are the transcriptional effectors of the 
evolutionarily conserved Wnt signaling pathway (90). The Wnt pathway regulates 
numerous developmental systems including embryonic patterning, cell-fate decisions, 
and tissue homeostasis (91). Wnt proteins are released and bind to Frizzled/low density 
lipoprotein receptor related protein complex on the cell surface of target cells (92). In the 
target cell, the transcriptional regulator β-catenin is maintained at low levels in the 
cytoplasm through constant degradation. Degradation is lifted when Wnt signals are 
received by the complex containing glycogen synthase kinase-3β (GSK-3), Axin, 
Adenomatous Polyposis Coli. The accumulation of β-catenin allows for nuclear 
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translocation and binding to TCF-1 and LEF-1 to activate transcription. In the absence of 
nuclear β-catenin, TCF-1 and LEF-1 are believed to be transcriptionally repressive by 
associating with the Groucho/TLE family of repressors (93). Thus, β-catenin displaces 
Groucho/TLE and converts TCF-1 and LEF-1 to transcriptional activators (94). However, 
loss-of-function studies for β-catenin does not diminish T cell development despite the 
clear role of TCF-1 in activating target T cell genes (95, 96). 
Finally, there are multiple isoforms for TCF-1 including multiple splice variants of 
TCF-1 ranging from 25-55 kD. Further, TCF-1 has two promoters, 1 kb apart, that drive 
transcription of two major isoforms (97). The upstream promoter transcribes the ‘full-
length’ TCF-1 isoform, called p45, and the downstream promoter transcribes the shorter, 
p33, isoform of TCF-1. The 5’ coding region of the full-length isoform encodes the β-
catenin interaction domain that the p33 isoform lacks. Thus, the p33 isoform is 
speculated to be the repressive isoform of TCF-1. However, the mechanisms governing 
the abundance of each isoforms is unclear. 
The distinct phases of T cell development in the thymus are controlled by the 
upregulation of transcription factors including TCF-1, GATA3, and Bcl11b as well as the 
repression of alternative-lineage factors such as PU.1 and Bcl11a. Notch signaling is 
indispensable in driving specification but is transient and only active up through the β-
selection checkpoint. The earliest T cell-specific transcription factor is TCF-1, encoded 
by Tcf7, which is steeply upregulated in T cell progenitors by Notch1 signaling and 
sustained until maturation. TCF-1 can positively regulate GATA3 in addition to Bcl11b, 
which is necessary for T lineage commitment (40, 75). Transcription factors required in 
other hematopoietic differentiation programs such as E2A and its relatives, Ikaros, Gfi1, 
Myb, and RUNX1 are also essential in T cell development (98, 99). Despite the broad 
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knowledge on the functions of these transcription factors at distinct developmental 
stages, it remains unclear which ones shape the chromatin accessibility of mature T 
cells in the thymus. 
Numerous studies in macrophages and B cells illustrate the emergence of 
accessible chromatin commanded by lineage-determining transcription factors (12, 100-
106). The pervasive patterns of PU.1 binding to thousands of genomic regions are 
closely related to the permissive chromatin state in macrophages (101). EBF1 can 
induce lineage-specific chromatin accessibility in B cell progenitors (103, 104). In 
addition to instructing development, transcription factors can also play key roles in cell 
reprogramming. For example, C/EBPα can induce transdifferentiation of B cells into 
macrophages at high efficiency by activating regulatory elements of macrophages (105).  
Despite numerous studies of CD4+ T helper cell differentiation (107-111) and 
CD8+ T effector responses (112-117), and many reports on the dynamics of histone 
modifications during T cell development (118-120), we have a limited understanding of 
transcription factors shaping the chromatin accessibility of mature T cells in the thymus. 
2.2.5 Scope 
 
By mapping chromatin accessibility at eight stages of thymic T cell development 
in mice, we found the significant enrichment of TCF-1 motif and binding events at 
genomic regions that become accessible at the earliest stage of development and 
persist until T cell maturation. While TCF-1-deficient mice show a severe reduction in 
thymocyte numbers (87) and ectopic TCF-1 in bone marrow progenitors can drive the 
expression of T-lineage genes (121), the mechanism through which TCF-1 controls T 
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cell identity remains unclear. Some T-like cells continue to develop in the absence of 
TCF-1 although they are functionally limited in terms of differentiation, and memory T 
cells lacking TCF-1 are also defective (122). In line with these studies, we found that T-
like cells in TCF-1-deficient mice cannot establish the open chromatin landscape and 
transcriptional profile of normal T cells. Moreover, TCF-1, but not RUNX1 or GATA3, 
could dictate a coordinate chromatin opening in single cells that follow a T cell trajectory 
amongst a vast landscape of possible states, suggesting a unique property for this 
lineage-determining transcription factor. Gain of function experiments in fibroblasts 
further revealed the ability of TCF-1 to bind to previously occupied nucleosomes, 
generating de novo chromatin accessibility even at condensed chromatin regions and 
inducing the expression of T cell-restricted genes ordinarily silenced in fibroblasts. 
Remarkably, a subset of these binding events further erased the pre-existing repressive 
marks in fibroblasts, highlighting the ability of this transcription factor to substantially 
target closed chromatin. Collectively, our results identify the role of TCF-1 in the making 
of chromatin accessibility at T cell genes and reveal an unprecedented means through 
which this protein controls the epigenetic identity of T cells. 
2.3 RESULTS 
 
2.3.1 Three waves of chromatin remodeling during T cell development 
 
To elucidate the developmental stages in which the open chromatin landscapes 
of mature CD4+ and CD8+ T cells are established in the thymus, we assessed chromatin 
accessibility at eight stages of development including ETP (also referred to as DN1), 
DN2a, DN2b, DN3, DN4, DP, CD4+, and CD8+ T cells using ATAC-seq (STAR Method). 
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To identify T cell-specific regulatory elements, we compared these maps with those of 
progenitor cells including hematopoietic stem cells (HSC), multipotent progenitors 
(MPP), and common lymphoid progenitors (CLP) in addition to B and NK cells. Initial 
steps of the analysis led to the characterization of 35,869 open chromatin regions with 
differential accessibility levels across cell states. Our unsupervised clustering of these 
regulatory elements revealed patterns of gain and loss of chromatin accessibility as cells 
progress from early to terminal stages of T cell fate determination (Figures 2A and S1A-
B). We aggregated patterns of gain and loss in chromatin accessibility into broader 
meta-clusters capturing selective opening in early, intermediate, and late phases of 
development. Our data show that the sustained accessibility of mature T cells is 
established in three distinct waves: “early” at ETP (1,705 regulatory elements, cluster 9), 
“intermediate” after commitment at DN2b (1,399 regulatory elements, cluster 19), and 
“late” at the single-positive stage (1,917 regulatory elements, cluster 10) (Figure 2 A-B). 
In addition, a set of genomic regions that became open early was shared between T and 
NK cells (1,445 regulatory elements, cluster 7). Notably, our data revealed a pattern of 
gain and loss of accessibility as 75% (9,071) of regulatory elements that became 
accessible at the early ETP stage were dismantled before T cell maturation (“Open Early 
in T” meta-cluster, Figure 2A). These results demonstrate an unexpected dynamic in the 
remodeling of the regulatory landscape with distinct expansions and restrictions of 
regulatory elements during T cell development.  
2.3.2 TCF-1 is the top enriched transcription factor in mature T cell clusters 
 
We reasoned that the transcription factors that can bind to nucleosomal DNA in 
progenitors and create the chromatin accessibility landscape of terminally differentiated 
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cells should be enriched within regulatory elements that selectively become open in that 
lineage. To find transcription factors with such characteristics, we inferred their 
occupancy in cell and stage-specific regulatory elements by performing motif analysis 
(106). B-cell specific open chromatin regions were enriched with motifs of EBF1, a 
transcription factor which has been previously reported to create the accessibility of 
regulatory elements in B cells (Figure S1C) (103, 104). Furthermore, Tbox, ETS, and 
GATA motifs were highly enriched among regulatory elements of NK and progenitor-
specific cells (Figure S1C). In T cells, recognition sites for TCF, a high-mobility group 
(HMG) family of proteins, were the top enriched motif in the early, intermediate, and late 
waves of chromatin opening that persisted until T cell maturation (clusters 9, 19, 7, and 
10) (Figure 2C-E). Notably, E2A, ETS and Runx recognition sites were among the 
second and third motifs in these clusters (Figure S1C). Similar analysis on chromatin 
accessibility maps of human T cells revealed the enrichment of TCF motifs within T cell-
specific open chromatin of human naïve T cells, suggesting the conserved role of this 
transcription factor in humans and mice (Figure S1D). 
Among TCF family transcription factors, TCF-1 is induced early at the inception 
of T lineage cells. To further substantiate direct binding of TCF-1 in comparison to other 
T cell related transcription factors including GATA3, RUNX1, and PU.1, we calculated 
the number of genomic regions within each cluster bound by these transcription factors 
using ChIP-seq (STAR method). As predicted by the enrichment of its motif, TCF-1 
bound to around 70% of the genomic regions within the early and intermediate T cell 
specific clusters in addition to 24% of the late T cell cluster. This contrasts with RUNX1 
and GATA3 binding events at less than 17% of the genomic regions within T cell-specific 
clusters (Figure 2F). Moreover, the highest odds ratio was associated with TCF-1 
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binding events in early and intermediate T cell clusters in particular clusters 9, 7, and 19 
(Figure 2F). Of note, the early regulatory elements deactivated before maturation were 
enriched with PU.1 binding, reminiscent of earlier findings that most active chromatin 
features at PU.1 binding events are 'dismantled' as PU.1 is downregulated in early DN 
stages (120). Together, the pervasive binding of TCF-1 corroborates the strong 
enrichment of TCF motifs at accessible regulatory elements of mature T cells.  
We further sought to explore the relationship between the activation of regulatory 
elements and their associated genes. The ontology of genes proximal to T cell-specific 
clusters was mostly related to T cell receptor signaling and naïve T cell development 
with no ontology distinguishing different waves of chromatin opening (Figure S1E). The 
gene expression levels proximal to dynamic regulatory elements did not present 
significant differences during development, suggesting a larger transformation for the 
regulatory landscape than the transcriptional output (Figure S1F). While the T cell 
commitment factor Bcl11b has low expression levels in ETP, multiple T cell-specific 
regulatory elements proximal to this gene became accessible at the earliest stage and 
co-localized with TCF-1 binding (Figure 2G). The three waves of chromatin remodeling 
during development is attested to the Bcl11b locus as the rightmost elements including 
the Bcl11b promoter became accessible in the ETP and were retained until T cell 
maturation. The middle of the locus was mostly accessible in intermediate stages, and 
the leftmost elements of the locus gained accessibility late in the developmental process. 
Collectively, these results demonstrate the dynamic of expansions and restrictions of 
regulatory elements during T cell development and foreshadow the importance of TCF-1 
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Figure 2. TCF-1 binding occurs at three waves of chromatin remodeling during T 
cell development. 
(A) A dynamic remodeling of the chromatin landscape with distinct expansions and 
restrictions of regulatory elements at early, intermediate and late stages of T cell 
development. Accessibility heatmap of 35,869 enhancers are measured by bulk ATAC-
seq in HSC, MPP, CLP, ETP, DN2a-b, DN3, DN4, DP, SP, B and NK cells. Rows 
represent regulatory loci and columns the significance of each element’s accessibility level 
in every sample. Enhancers are organized in groups with k-means (k=20) clustering using 
FDR as a proxy for signal enrichment. Lower values represent higher chromatin 
accessibility. Number of clusters was chosen based on Average Silhouette Width statistic. 
Clusters were further assembled into meta-clusters depending on their accessibility 
pattern such as open in progenitor, early, intermediate and late in T as well as B or NK 
cells. Clusters that are open in mature T cells and specific to T cell development are 
highlighted in red.  
(B) ATAC-seq profiles of normalized tag counts around enhancers (+/- 2kb window and 
10bp bin size) in clusters 9, 19 and 10 across all 13 cell types.  
(C-E) TCF is the top enriched motif at T cell-specific regions that become accessible at 
early, intermediate and late waves of gain in chromatin accessibility during T cell 
development. De novo motif discovery using HOMER in each group using remaining 
elements in other clusters as background unveiled putative cell-type specific transcription 
regulators.  
(F) Widespread binding of TCF-1 at the open chromatin of T cells. Percentage of 
enhancers in each cluster that are bound by TCF-1, PU.1, GATA3 and RUNX1 ChIP-seq 
peaks (left) and their corresponding odds ratio (right). Contingency tables were calculated 
using ChIP-seq data summarized in STAR Method. 
(G) Example of the Bcl11b locus and several TCF-1 bound enhancers that exhibit diverse 
accessibility levels during T cell development. The three waves of chromatin remodeling 
during development is attested to at the Bcl11b gene as the rightmost elements including 
the Bcl11b promoter became accessible in ETP and were retained until T cell maturation, 
the middle elements were mostly accessible in intermediate stages, and the leftmost 
elements gained accessibility late in the developmental process.
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2.3.3 TCF-1-deficient T cells cannot establish the open chromatin landscape of normal T 
cells 
Germline deletion of TCF-1 leads to a severe reduction in thymocyte numbers 
(87). Although some T lineage-like cells continue to develop in the thymus of TCF-1-
deficient mice, they are functionally limited in terms of differentiation and persistence of 
memory T cells during infection (87, 122). It remains unclear whether the chromatin 
accessibility landscape and transcriptional outputs of these T-like cells is different from 
those of normal T cells. Therefore, we next measured chromatin accessibility at TCF-1 
binding events in wildtype and TCF-1-knockout DP T cells. Our data revealed the loss of 
chromatin accessibility at 5,000 regulatory elements and the gain at 1,165 genomic loci 
in TCF-1-deficient T cells (Figures 3A and S2A). We sought to elucidate the 
relationship between regulatory elements that required TCF-1 for their accessibility and 
the three waves of chromatin opening during T cell development (clusters in Figure 2A).  
Regulatory elements that lost chromatin accessibility in the absence of TCF-1 were 
strongly enriched within early or intermediate waves of chromatin opening during T cell 
development, suggesting that this transcription factor is required for patterning the 
chromatin at early stages (clusters 7, 9 and 19) (Figure 3B). Examples of affected 
regions included the well-annotated Tcrb enhancer (123) and the distal Bcl11b 
enhancers (124) (Figure 3C). Performing de novo motif analysis revealed TCF as the 
top enriched motif in the lost sites supporting the notion that TCF-1 is directly 
responsible for chromatin accessibility (Figure 3D). TCF-1-bound regions with gains in 
accessibility in the knockout cells were also enriched with the TCF motif but were 
associated with elements accessible in B and NK cells or T cell regulatory elements 
deactivated in mature T cells, supporting the previously reported repressive role of TCF-
1 at some genomic locations (Figures 3B, 3D) (125). Together, these data demonstrate 
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that TCF-1 is required for patterning the chromatin of T cells at early stages of 
development in the thymus. 
To elucidate how changes in chromatin accessibility relate to the dynamics of 
gene expression, we evaluated the transcriptome of wildtype and TCF-1-deficient T cells 
using RNA-seq (Figure S2B-C). We then interrogated changes in the expression of 
genes proximal to TCF-1-dependent open chromatin regions using gene-set-enrichment 
analysis. Genes proximal to regions that became less accessible in the absence of TCF-
1, such as Tcrb and Bcl11b, displayed reduced expression in cells lacking this 
transcription factor (Figure 3E). Conversely, genes such as Adam19 that became more 
accessible also showed an increase in transcription in TCF-1 deficient T cells (Figure 
S2D). Together, these results indicate that while some T-like cells continue to develop in 
the absence of TCF-1 in the thymus, they cannot establish the open chromatin 
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Figure 3. TCF-1-deficient T cells cannot establish the open chromatin landscape 
and transcriptional output of normal T cells.  
(A) We generated three replicates of ATAC-seq in wildtype and TCF-1 germline deleted 
DP T cells and evaluated the chromatin accessibility levels at TCF-1 binding sites based 
on ChIP-seq. We applied variance stabilizing transformation and library size normalization 
on the raw ATAC-seq counts and used DESeq2 to delineate differentially accessible 
regions at TCF-1 binding sites(126) (fold-change > 1.5 and p-value < 1e-3). While 5,000 
genomic regions were less accessible, 1,165 regions were more accessible in TCF-1 
deficient T cells.  
(B) Loss of TCF-1 selectively diminishes the accessibility of genomic regions that become 
open at early or intermediate stages of development and sustain accessibility in mature T 
cells. The overlapping genomic regions identified by DESeq in (A) and open chromatin 
clusters in Figure 2 were found and used to measure the odds ratio. 
(C) Representative examples included the well-established enhancers of Tcrb and Bcl11b.   
(D) De novo motif analysis using HOMER unveiled TCF-1 as the most significantly 
enriched motif in regions that both gained and lost accessibility.  
(E) TCF-1 dependent changes in gene expression correlate with changes in chromatin 
accessibility. We measured gene expression using RNA-seq in replicates for wildtype and 
TCF-1 deficient T cells. We used DESeq2 to identify differentially expressed genes (fold-
change > 1.5 and p-value < 1e-3). Our analysis unveiled 1,167 down- and 1,293 up-
regulated genes in TCF-1 deficient compared to wildtype T cells. Genes were ranked 
based on log2 fold change estimated by DESeq2 and used as the pre-ranked gene list in 
GSEA analysis. The GSEA gene sets were genes within 10kb of top 200 regions with 
highest fold-change in chromatin accessibility between wildtype and KO cells.  
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2.3.4 TCF-1 binding exerts a strong harmonizing impact on the chromatin of single T 
cells 
 
If a transcription factor is required for patterning the regulatory landscape of a 
lineage, it may need to exert a harmonizing impact on the chromatin of individual cells 
making the same fate decision. To interrogate which T cell transcription factor may have 
such features, we first exploited maps of chromatin accessibility at the population level 
and reasoned that at a given regulatory element, the strength of bulk ATAC-seq signal 
reflects the fraction of cells in the population with open chromatin. We compared the 
normalized intensity of chromatin accessibility in bulk ATAC-seq at genomic regions 
uniquely bound by T lineage transcription factors TCF-1, GATA3, or RUNX1 (Figure 
4A). Our analysis revealed that TCF-1 binding events rendered the highest average 
level of chromatin opening in comparison to RUNX1 and GATA3, advancing the notion 
that TCF-1 may unify chromatin accessibility across single T cells (Figure 4A).  
While chromatin accessibility maps of bulk T cells measure the average patterns 
of open regulatory elements at the population level, it remains unclear if Tn5 insertions 
linearly reflected the fraction of individual cells with open chromatin. To address this 
concern, we tested our hypothesis using single-cell (sc)ATAC-seq (127). In this 
approach, individual cells stained for viability were captured and assayed using a 
programmable microfluidics platform (Fluidigm) (Figure S3A-B). Collapsing reads from 
single T cells to aggregate scATAC-seq data closely reproduced measures of 
accessibility profiled by ATAC-seq generated from 50,000 T cells (Figure 4B). A 
representative genomic region such as the Tcrb enhancer confirmed the strong 
correlation between bulk and single-cell measurements (Figure 4C). Furthermore, data 
from single T cells recapitulated several characteristics of bulk ATAC-seq data, including 
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fragment-size periodicity corresponding to integer multiples of nucleosomes (Figure 
S3C). Together, we performed three independent single-cell captures and 110 T cells at 
the DP stage passed various quality control thresholds, suggesting high-confidence 
single-cell chromatin accessibility maps in T cells (Figure S3D). 
Single-cell chromatin accessibility data are sparse, binary, and high dimensional, 
leading to unique computational challenges. To overcome these difficulties, we 
developed a method using a geometric distance metric and quantified cell-to-cell 
chromatin accessibility variation (Figure 4D, STAR Methods). To interrogate which T cell 
transcription factor can create harmonizing effects, we exploited our method on 
binarized scATAC-seq count data in every cell and calculated the average distance 
between pairs of T cells at genomic regions uniquely bound by TCF-1, RUNX1 or 
GATA3. We reasoned that binarizing scATAC-seq count data at transcription factor 
binding events reflects the openness or closeness (1 or 0) of a locus in a single cell. Due 
to biases in the number of observed fragment counts between cells based on the GC 
content or mean accessibility of a given peak set, we normalized the distance between 
individual cells at each set of transcription factor binding events to that of a background 
set comprising an equal number of peaks with matching GC content and mean 
accessibility. Our single-cell analysis revealed that TCF-1-bound regions were 
associated with the least variability among individual T cells in comparison with GATA3 
and RUNX1 (Figure 4E). We further applied another analytical technique called 
“chromVAR” which was recently developed to address the same question (128). Unlike 
our method in which the difference in accessibility of a genomic region between every 
cell-pair contributes to the variability score, chromVAR relies on the aggregate of 
accessibility signal across a genomic set. Despite differences in the inference of 
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variability at transcription factor binding sites, chromVAR also identified TCF-1 as the 
least variable transcription factor in exerting chromatin accessibility across single T cells 
(Figure 4E). Together, two analytical strategies developed by us and others corroborate 
the enrichment of TCF-1 binding at regulatory elements that their accessibility is 
conserved across single T cells. 
As an alternative strategy, we ranked T cell specific genomic regions in the early 
T cell cluster (cluster 9) based on the fraction of cells harboring open chromatin and 
evaluated whether they were bound by T cell transcription factors TCF-1, GATA3, and 
RUNX1 (Figure 4F). The top regulatory elements open across majority of single cells 
were bound consistently by TCF-1 in contrast with GATA3 and RUNX1 (Figure 4F). We 
reasoned if TCF-1 indeed plays a role in creating accessibility at genomic regions with 
the highest similarity across individual cells, its deletion should have a stronger effect on 
the accessibility of these regions at the bulk level. Indeed, the most similar genomic 
regions across individual T cells, i.e. being open at the highest fraction of cells, were 
more affected by loss of TCF-1 compared to the least similar genomic regions (Figure 
4F). In line with consistent TCF-1 binding and a stronger effect size in chromatin 
accessibility in the absence of TCF-1, the TCF motif was selectively enriched within the 
top 100 most similar genomic regions. Furthermore, the genes proximal to these 
genomic regions with the highest similarity across individual T cells were associated with 
T cell biology and included T cell relevant genes such as Bcl11b (Figure 4F). Together, 
studying maps of chromatin accessibility at bulk and single cell levels with distinct 
analytical strategies suggests that TCF-1 could dictate a harmonizing impact on the 











0 2 4 6
Ensemble of scATAC−seq 

























































































Bcl11b, CD4, CD8b, CD247
Nr4a3, Ank3,CD40lg, Phldb2, St6gal1, Angpt2
TCF 531e-13
111e-13SOX
Top 100 enhancers 
ranked by similarity across single DP T cells
Bottom 100 enhancers 

































































































Cells in principal 
coordinate space
Average distance from spatial median
(at transcription factor binding events)
Average distance from spatial median




-1 0 1 2 3
ChIP-seq
in DP T cells
Bulk ATAC-seq






Figure 4. TCF-1 binding has the highest coordinate impact on open chromatin of 
single T cells. 
(A) TCF-1 binding events harbor the strongest chromatin accessibility measured by bulk 
ATAC-seq in DP T cells. Genome-scale binding of TCF-1, RUNX1, and GATA3 in DP T 
cells was measured by ChIP-seq. An equal number of genomic regions with unique 
binding of each transcription factor were subsampled from ChIP-seq data sets. The 
normalized tag count for ATAC-seq in DP T cells was calculated for each group of 
transcription factor binding.  
(B) The aggregate maps of scATAC-seq data closely reproduced measures of 
accessibility profiled by ATAC-seq generated from 50,000 DP T cells. Open sites 
identified from bulk ATAC-seq in 50,000 DP T cells were merged with peaks 
characterized by aggregating the samples from 110 single DP T cells passing QC 
measures. Normalized enrichment was subsequently calculated in downsampled bulk 
ATAC-seq and aggregated scATAC-seq enabling the assessment of the correlation level 
between the two assays.  
(C) Aggregated single cell ATAC-seq profile recapitulates chromatin accessibility on the 
bulk level at Tcrb enhancer.  
(D) A novel method to infer transcription factor-associated chromatin accessibility 
variation across single cells.  
(E) Chromatin accessibility across individual T cells is the least variable at TCF-1 binding 
events using our method (D) or chromVAR (128). 
(F) Fraction of cells with binarized open chromatin was measured across all pairs of 
elements to rank regulatory elements. TCF-1, GATA3 and RUNX1 ChIP-seq 
enrichments were assessed in the same order as well as changes in chromatin 
accessibility based on bulk ATAC-seq signal in wildtype and TCF-1 KO T cells. De novo 
motif analysis using HOMER at the 100 enhancers exhibiting the highest similarity at the 
single cell level revealed the enrichment of TCF while TCF was not enriched at 100 least 
similar enhancers. T cell related genes were associated with the top enhancers.  
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2.3.4 TCF-1 can create de novo chromatin accessibility in fibroblasts 
 
It has been shown that when TCF-1 is forcibly expressed in bone marrow 
progenitors, it can drive the expression of T-lineage genes (121). Yet, it is not clear 
whether this alteration in the gene expression program of multipotent progenitors relates 
to the ability of TCF-1 to bind to silent chromatin and/or drive the epigenetic commitment 
to the T cell lineage. To examine if TCF-1 can create de novo open chromatin, we 
assessed this transcription factor in a gain-of-function model in nonhematopoietic 
somatic cells. We reasoned that fibroblasts could serve as an ideal model since the 
chromatin state in fibroblasts is distinct from cells of the hematopoietic system and T 
cell-specific genes are repressed in these somatic cells, allowing us to better evaluate 
the role of TCF-1 in targeting condensed chromatin.  
To evaluate the genome-scale binding of TCF-1, we ectopically expressed this 
transcription factor in a fibroblast cell line using a retroviral transduction system and 
performed TCF-1 ChIP-seq (Figure S4A). To define genome-scale TCF-1 binding 
events, we used the irreproducible discovery rate (IDR) method with a threshold of 2% 
(129) (Figure S4B). We further mapped the position of nucleosomes using microccocal 
nuclease (MNase)-seq in pre-induced cells. The ectopic expression of TCF-1 led to 
more than 40,000 TCF-1 binding events across the genome of fibroblasts where 73% of 
these events colocalized with previously nucleosome-occupied DNA (Figures 5A and 
S4C). The extent to which TCF-1 bound to nucleosome-occupied regions in fibroblasts 
was comparable to reprogramming transcription factors such as Oct4 (85%), Sox2 
(80%), and Klf4 (65%) (130). As an independent measure, we found that 67% of TCF-1 
summits, the center of TCF-1 peak, were within 75bp of a nucleosome dyad in contrast 
with CTCF binding which is favored towards nucleosome-free regions, suggesting that 
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TCF-1 binding is selectively enriched at previously occupied nucleosomes (Figure 5B). 
Furthermore, TCF was the strongest motif within TCF-1-bound sites with different levels 
of nucleosome occupancy (p-value<1e-930) (Figure 5C). TCF recognition sites bound 
by TCF-1 in fibroblasts were significantly closer to the nucleosome dyads compared to 
random TCF sites not bound by this transcription factor, reminiscent of PU.1 binding 
events being shielded by nucleosomes in cells that do not express this protein (131) 
(Figure S4D). Together, the ectopic expression of TCF-1 in fibroblasts revealed the 
widespread binding of TCF-1 at genomic regions previously occupied by nucleosomes 
harboring TCF consensus binding sites. 
To measure the impact of widespread TCF-1 binding on silent genomic loci, we 
mapped the accessibility of chromatin by ATAC-seq post transduction with Empty or 
TCF-1 vectors. Using differential enrichment analysis, we found that 6,888 genomic 
regions previously occupied by nucleosomes gained accessibility while 1,618 sites 
became less accessible after TCF-1 expression in fibroblasts (Figures 5D-E, S4E). We 
further performed de novo motif analysis and observed that more than 80% of the 
gained sites harbored a TCF motif while the lost sites were enriched with AP-1 and Runx 
family motifs (Figure 5F). In concordance with motif presence, 80% of the gained sites 
were also bound by TCF-1 based on the TCF-1 ChIP-seq while only 3% of lost sites 
colocalized with TCF-1 binding (Figure 5G), suggesting an indirect role of TCF-1 on 
sites losing chromatin accessibility. To infer nucleosome position and occupancy within 
TCF-1 binding events, we further applied the NucleoATAC algorithm (132) to our 
chromatin accessibility data and found 7,395 genomic regions with significant loss of 
nucleosomes after TCF-1 expression (Figure S4F). A striking example of de novo 
regulatory elements induced by TCF-1 includes the T cell receptor alpha locus where the 
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binding of TCF-1 at previously occupied nucleosomes led to gains in chromatin 
accessibility at multiple genomic regions (Figure 5H). Together, our data suggest that 
TCF-1 can bind to thousands of previously nucleosome-occupied DNA and this binding 
can lead to de novo chromatin accessibility.  
We next sought to examine whether de novo chromatin accessibility in fibroblasts 
has any relevance to T cell biology. Our data revealed that TCF-1 binding events in T 
cells and fibroblasts are highly correlated (Figure S4G) and more than 800 de novo 
regulatory elements in fibroblasts (~11%) overlapped with open chromatin in T cells 
while only 40 regions (~0.5%) corresponded to the open chromatin in B cells (Figure 
S4H). Furthermore, the de novo regulatory elements in fibroblasts were selectively 
enriched for regions belonging to the early wave of chromatin opening during T cell 
development (cluster 9) (Figure S4I). For example, the promoter of Ccr7, which is 
among the regulatory elements that gain accessibility at the early cluster 9, is bound by 
TCF-1 and becomes accessible in TCF-1-expressing fibroblasts (Figure 5I). Together, 
TCF-1 can invoke a subset of T cell regulatory elements to become open in distant 







Figure 5. TCF-1 can bind to nucleosomes and create chromatin accessibility in 
fibroblasts. 
 (A) TCF-1 ChIP-seq TCF-1 (p33) expressing NIH3T3 using retrovirus (RV) as well as in 
Empty vector controls 48 hours post transduction resulting in the identification of 40,562 
reproducible peaks. The region surrounding TCF-1 summits was segmented in three 
non-overlapping 200bp windows centered around each summit. Normalized MNase-seq 
enrichment was calculated for each window and summits were ordered from high to low 
enrichment. (B) The majority of TCF-1 binding events occur within the boundaries of 
DNA wrapped around nucleosome. The distance between TCF-1 as well as CTCF 
(serving as control) and the closest nucleosome summits were calculated as an 
alternative strategy of assessing the ability of TCF-1 to directly bind nucleosomes. The 
vertical dashed red line is set to 75bp which is typically half the size of histone octamer 
bound DNA denoting the edge of nucleosomes. (C) TCF-1 motif is equally preserved in 
genomic loci presenting nucleosome high, medium and low enrichment. K-means 
clustering (k=3) was applied on TCF-1 summits using the normalized MNase-seq 
enrichment in the three non-overlapping 200bp windows centered around each summit. 
We chose the open chromatin regions presenting no overlap with TCF-1 summits as 
background in our de novo motif analysis using HOMER and found TCF as the only 
motif significantly enriched in each cluster.  
(D-I) TCF-1 can create de novo open chromatin in fibroblasts. (E) We performed ATAC-
seq in triplicates in Empty and TCF-1 RV NIH3T3 cells. To identify differentially 
accessible regions, TCF-1 ChIP-seq and ATAC-seq peaks were merged to facilitate 
differential enrichment at both TCF-1 bound and unbound regions of the genome. We 
used DESeq2 and based on fold-change > 1.5 and p-value < 1e-3, 6,888 regions gained 
while 1,618 lost accessibility in TCF-1 RV cells. (F) De novo motif discovery unveiled 
TCF-1 as the most significantly enriched motif in gained sites and AP-1 as well as Runx 
motifs in lost sites. (G) TCF-1 bound to 5,575 (80%) gained sites in contrast to only 40 
(3%) lost sites. (H) TCF-1 directly binds nucleosomes at Tcra related enhancers and 
creates de novo open chromatin. (I) Example of the Ccr7 gene promoter that becomes 
accessible at the earliest stage of T cell developmental and is naturally bound by TCF-1 
in T and Tcf1-RV NIH3T3 cells with a corresponding increase in accessibility.  
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2.3.5 TCF-1 binding at chromatin domains with H3K27me3 and H3K9me3 repressive 
marks 
 
 The widespread binding of TCF-1 in fibroblasts led to thousands of de novo 
open chromatin regions.  Yet, it is not clear whether these TCF-1-dependent regulatory 
elements were previously repressed or instead poised for activation with permissive 
histone modifications in fibroblasts. To address this question, we examined the pre-
existing patterns of histone modifications in fibroblasts using maps of 5 histone 
modifications including: H3K4me3, primarily associated with promoters; H3K4me1 and 
H3K27ac characteristic of poised and active promoters and enhancers; and the 
repressive marks H3K9me3 and H3K27me3. Correlation and principal component 
analysis (PCA) at TCF-1 bound sites indicated a preferential colocalization of gained 
sites with previously repressed domains containing H3K27me3 or H3K9me3 
modifications (Figures 6A and S5A-B). To create a more quantitative picture of the 
chromatin state prior to TCF-1 binding, we developed an unsupervised learning workflow 
and partitioned TCF-1 binding events into 11 clusters corresponding to 7 distinct 
chromatins states (Figures 6B, S5C-D, STAR Methods). Although less than half of TCF-
1 binding events associated with active and poised enhancers or promoters (~40%), 
16,800 (~42%) occurred within repressed and heterochromatin genomic regions. 
Strikingly, the gains in chromatin accessibility by TCF-1 were strongly enriched at these 
repressed domains (Figures 6B and S5E).  
The widespread binding of TCF-1 at genomic regions with pre-existing repressive 
marks was unexpected. To further assess whether TCF-1 is also capable of erasing the 
repressive histone modifications, we next mapped H3K27me3 and H3K9me3 repressive 
marks in addition to the active enhancer mark H3K27ac in TCF-1 expressing cells. We 
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found that more than 1,400 TCF-1 binding events overlapping de novo open chromatin 
were associated with gain in H3K27ac and loss of H3K27me3 and H3K9me3 repressive 
marks at the center of TCF-1 binding (Figure 6C-D). Together, the integration of 
nucleosome mapping, chromatin accessibility, transcription factor binding, and histone 
modifications in fibroblasts suggest a fundamental role of TCF-1 in creating de novo 










































































PCA at Tcf-1 binding events
B
Promoter





























































00.15 00.21 00.9 00.8 00.5
H3K27me3 H3K9me3 H3K27ac ATAC-seq


















































































































































Tcf-1 RV Empty RV
47 
 
Figure 6. TCF-1 can bind to repressed chromatin and make it open. 
(A-B) TCF-1 binds to repressed chromatin and promote accessibility. (A) The 
enrichment of ATAC-seq in NIH3T3 TCF-1 RV versus Empty RV cells and vice versa 
was also calculated around each summit for assessing different levels of chromatin 
accessibility. Principal component analysis showed that gain in accessibility occurs at 
TCF-1 binding sites located in repressed chromatin and loss in accessibility happens in 
previously active regulatory regions. (B) K-means clustering (k=11, designated as the 
optimal number of clusters by Average Silhouette Width coefficient) of TCF-1 summits 
on the adjusted significance levels of the enrichment in each histone mark identified 
chromatin states ranging from PRC (H3K27me3) (4,110, 10.2%), hetero/PRC 
(H3K27me3 and H3K9me3) (8,957, 22%), hetero (H3K9me3) (4,242, 10.4%), trivalent 
(H3K27ac, H3K4me1 and H3K9me3) (6,634, 16.4%), poised enhancers (H3K4me1) 
(7,458, 18.3%), active enhancers (H3K4me1 and H3K27ac) (7,343, 18.2%) and 
promoters (H3K4me3) (1,818, 4.5%). Normalized enrichment profiles of histone 
modification using ChIP-seq as well as ATAC-seq were also calculated for 10bp non-
overlapping bins spanning the +/- 3kb region centered around TCF-1 summits.  
(C-D) More than 1,400 TCF-1 binding events colocalize with a gain in both chromatin 
accessibility and the active mark H3K27ac with a corresponding loss of 
H3K27me3/H3K9me3 repressive marks. To assess differences in the enrichment of 
H3K9me3, H3K27me3 and H3K27ac ChIP-seq signal around TCF-1 binding events 
between pre-induced and TCF-1 RV NIH3T3 cells, we used the diffR function from 
normR package using an FDR threshold of 5e-2. The average profiles for histone 
modifications, chromatin accessibility and TCF-1 binding using ChIP-seq were 




2.3.6 T cell-restricted genes are actively transcribed after TCF-1 expression 
 
To evaluate whether the ectopic expression of TCF-1 and its widespread binding 
at over forty thousand genomic regions corresponds to any change in gene expression, 
we measured the transcriptional changes in fibroblasts (Figure S6A). After TCF-1 
transduction, we found that 1,478 genes were upregulated while 1,296 genes were 
downregulated (Figure S6B). To further assess the identity of these up- and down-
regulated genes, we generated two gene sets containing top “T cell genes” and 
“fibroblast genes” by performing differential expression analysis in DP T cells and pre-
induced fibroblasts. Using gene-set-enrichment analysis, we found that the fibroblast 
gene-set was enriched within the down-regulated genes, suggesting the repression of 
the fibroblast gene expression program by TCF-1 (Figure 7A). Conversely, the T cell 
gene set was enriched within genes upregulated by TCF-1 (Figure 7B). The leading 
edge in this enrichment analysis included genes essential for T cell commitment and 
development including Bcl11b, Rorc, and Cd247 (Figure 7C).  Together, TCF-1 can 
initiate the reprogramming of fibroblasts towards T cells.  
To examine whether TCF-1 upregulated genes in fibroblasts have any relevance 
to transcriptional profiles during T cell development, we delineated ‘thymocyte-specific 
genes’ as a group of genes that were selectively expressed in at least one stage of T cell 
development but not in bone-marrow progenitors using the ImmGen expression data 
(133) (Figure 7D). We found that TCF-1 was capable of upregulating 81 thymocyte-
specific genes with ontologies associated with tissue development, cell proliferation and 
immune system processes (Figures 7D and S6C). Examples include Bcl11b, Ikzf4, 
Il2rb, Klf4, and Rorc. Additional 597 genes upregulated by TCF-1 were expressed at 
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multiple cellular states (Figures 7D left panel). It is well established that TCF-1 has 
recurring roles in T cell development, peripheral T cells and cells with stem properties 
(134, 135). We further evaluated the expression of the 1,478 genes up-regulated by 
TCF-1 in fibroblasts for their expression in hematopoietic progenitors together with naïve 
CD4+ and naïve, effector and memory CD8+ T cells using RNA-seq data (Figures S6D-
E). After performing unsupervised clustering, we found that 753 genes are ordinarily 
expressed in one of these hematopoietic stages. Among these, 475 genes (63%) 
including Ccr7, Il15ra, and Icosl are selectively expressed in the T cell program (Figures 
S6D-E). In addition, 42 genes that were upregulated by TCF-1 in fibroblasts were 
selectively downregulated in TCF-1-deficient DP T cells, suggesting that TCF-1 is 
required and sufficient for the expression of these genes (Figure S6F). Together, our 
data suggest that de novo open chromatin regions are invoked by TCF-1 to induce the T 
cell-specific gene expression program in fibroblasts.  
2.3.7 Genes up-regulated by TCF-1 reside in previously repressed chromatin domains in 
fibroblast 
 
Our data in TCF-1 expressing fibroblasts led to two unexpected observations: (a) 
TCF-1 can generate chromatin accessibility at previously repressed domains and (b) 
TCF-1 can induce the expression of thousands of genes. To relate the chromatin state at 
the TCF-1 binding events to changes in transcriptional outputs in fibroblasts, we 
calculated the enrichment of up- and down-regulated genes among genes whose 5kb 
extended regions fell within TCF-1 binding events in different chromatin states. We 
found that the genes up-regulated by TCF-1 were significantly enriched for TCF-1 
binding events at chromatin domains with repressive chromatin marks (Figure 7E). 
Conversely, genes downregulated by TCF-1 were mostly associated with promoters and 
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the trivalent state with high H3K4me1 and H3K27ac surrounded by H3K9me3 (Figure 
S6G). Of note, a statistically significant proportion of genes were proximal to TCF-1 
binding events that led to gain in H3K27ac and loss of H3K27me3/H3K9me3 
modifications in contrast to those that did not alter the chromatin state (Figure S6H). 
Remarkably, genes of the T cell program were strongly enriched within genomic regions 
previously within repressed chromatin domains or harboring high nucleosome 
occupancy (Figures 7F and S6I). Examples of T cell genes ordinarily blanketed by 
repressive H3K27me3 and H3K9me3 in fibroblasts and actively transcribed after TCF-1 
expression included the receptor required for cell trafficking within and out of the thymus, 
Ccr7, and an essential transcription factor for T cell development Rorc (Figures 7G and 
S6J). Thus, TCF-1 can induce the expression of T cell genes in an unrelated non-
hematopoietic cell type by accessing repressive chromatin domains and converting 







Figure 7. T cell-specific genes innately repressed in fibroblasts are upregulated by 
TCF-1.  
(A-C) Ectopic expression of TCF-1 upregulates T cell genes and downregulates 
fibroblast genes. Differential expression analysis between WT DP T cells and Empty RV 
NIH3T3 cells delineated T cell and fibroblast gene sets (STAR methods). RNA-seq 
between Empty and TCF-1 RV NIH3T3 cells (see Figure S6) and GSEA analysis on the 
fibroblast gene set (A) and the T cell gene set (B). Leading edge analysis (C) in top T 
cell genes included essential genes in T cell development and commitment such as 
Bcl11b and Rorc. 
(D) TCF-1 upregulates thymocyte-specific genes that are expressed at different stages 
during normal T cell development. Thymocyte-specific genes were defined (STAR 
methods) and the overlap tested between TCF-1 RV upregulated genes in NIH3T3 (see 
Figure S6B) and thymocyte-specific genes. These genes were clustered using ImmGen 
microarray expression profiles (middle and right). Gene expression profiles of genes not 
overlapping thymocyte-specific genes but expressed in progenitors (597 genes) were 
also plotted (left).  
(E-F) TCF-1 can upregulate genes initially buried within repressed chromatin. TCF-1 
summits assigned to chromatin states (see Figure 6B) were linked to proximal genes 
(STAR methods). (E) Enrichment of upregulated genes by TCF-1 within each chromatin 
state. (F) Enrichment of T cell genes upregulated by TCF-1 (B) in each chromatin state 
was compared to fibroblast genes (A). 
(G) Example of T cell genes ordinarily blanketed by H3K27me3 and H3K9me3 in 






It has been known for more than 2 decades that TCF-1 is a key transcription 
factor in T cell development (87). As a major mediator of Notch signaling in the 
specification of bone-marrow progenitors to a T cell fate, TCF-1 is required for the 
expression of transcription factors essential for T cell commitment and specification such 
as GATA3 and Bcl11b (121, 136). Yet, it has been unclear whether the mechanism by 
which TCF-1 controls T cell fate is the specific transcriptional regulation of a small 
number of genes or whether this protein has a more fundamental role shaping the global 
epigenetic identity of T cells. Here, by reading between the ‘open’ lines of the genome 
during thymocyte development, we found that TCF-1 is the most enriched transcription 
factor at thousands of regulatory elements that become accessible at the earliest stage 
and persist until T cell maturation. While it remains unclear whether all genomic regions 
with H3K9me3 modifications comprise heterochromatin (137), we found that TCF-1 
binding across the genome of fibroblasts leads to gains in chromatin accessibility at 
genomic regions enriched with H3K27me3 and H3K9me3 repressive marks and lacking 
H3K27ac and H3K4me1/3 activating marks. This unique ability of TCF-1 targeting 
repressed chromatin might be attributed to the ability of HMG proteins to introduce a 
strong bend into DNA (82). The de novo change in accessible elements caused by TCF-
1 coincided with transcription of hundreds of T cell genes. A subset of de novo open 
chromatin regions was also associated with gain of the active enhancer mark H3K27ac 
and loss of the repressive marks H3K27me3 and H3K9me3, corroborating the ability of 
TCF-1 in targeting silent chromatin. Transcription of Ccr7, a gene that plays an essential 
role in intrathymic migration and proper T cell development (138), was induced when 
TCF-1 was ectopically expressed in fibroblasts. Notably, the promoter of Ccr7 that 
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became accessible in TCF-1 expressing fibroblasts is among the first wave of chromatin 
remodeling in T cell development. Similarly, the up-regulation of Bcl11b, a T-cell 
restricted transcription factor essential for T cell commitment, highlights the role of TCF-
1 as an early inducer and stabilizer of T cell identity by promoting epigenetic changes 
that drive key transcriptional regulators of the T cell program. Although TCF-1 has been 
known to induce selected genes involved in T cell biology, these results reveal a 
previously unappreciated broad mechanism by which TCF-1 controls T cell fate through 
genome-wide programming of the epigenetic identity of T cells. Our integrative strategy 
exploiting development and reprogramming in T cell progenitors may also provide a 
foundation to delineate cell fate determining transcription factors shaping the 
accessibility landscape of other cell types.  
It has been recently shown that TCF-1 is essential for repressing CD4+ related 
genes in CD8+ T cells through intrinsic HDAC activity (125). Of all TCF-1 binding events 
that had differential accessibility in the absence of TCF-1 in T cells, we found that a 
majority (80%) exerts an activating role (i.e., losing accessibility in knockout cells) with a 
smaller number gaining accessibility, supporting this previously reported repressive role 
of TCF-1. Strikingly, both gained and lost sites in our data were enriched with TCF-1 
binding and TCF motif, suggesting the direct role of this transcription factor at 
recognizing its binding sites across the genome. While further analysis is required to 
examine the sequence features and epigenetic modifications classifying the activating 
versus repressive TCF-1 binding events, our work reveals the pervasive role of TCF-1 at 
establishing de novo open chromatin during development and reprogramming. 
Conrad Waddington proposed a metaphor for cellular differentiation coining the 
term “epigenetic landscape” and envisioning a cell rolling down a hill like a ball with 
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successive bifurcations that resulted in irreversible cell fate` decisions (139). Exploiting 
the single cell technology, we interrogated whether a lineage-determining transcription 
factor can exert harmonizing and coordinate impact on the chromatin of single cells 
following the T cell trajectory. To infer cell-to-cell variability on open chromatin 
associated with transcription factors, we developed an analytical method and found that 
TCF-1 target sites but not those of RUNX1 or GATA3 confer the lowest cell-to-cell 
variability across individual T cells. Stated in a different way, open chromatin events that 
are highly conserved across single cells (revealed by single cell ATAC-seq) are likely to 
be causal to the identity of that cell type since, in this case, T cells appear not to function 
effectively without TCF-1 driven epigenetic events (122).  Despite the limitation that our 
knowledge of transcription factor binding is still gathered from bulk assays such as ChIP-
seq, our data demonstrate a distinct pattern at genomic regions with TCF recognition 
sites and TCF-1 binding, suggesting the role of this transcription factor at coordinating 
the chromatin accessibility of individual cells. 
Our data clearly demonstrate that the TCF motif and TCF-1 binding events are 
strongly enriched at T-cell specific regulatory elements that become accessible early and 
persist until T cell maturation. Furthermore, loss of TCF-1 selectively affected the 
accessibility of the early regulatory elements. These findings together with the early up-
regulation of TCF-1 in T cell development and the ability of this protein to reprogram the 
gene expression profile of fibroblasts may describe TCF-1 as a “pioneer” transcription 
factor (140). Nonetheless, we propose that the epigenetic complexities and the 
requirement for combinatoriality among transcription factors suggest that even ‘master 
regulators’ or ‘pioneer factors’ may require additional events to fully enact the program of 
cell lineage that they initiate (141-143). Here, we found that TCF-1 was endowed with an 
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unprecedented ability to target chromatin regions with repressive marks and in this 
manner, is more potent than the previously characterized pioneer factors in other 
developmental settings which are often impeded by heterochromatin (130, 144). 
Nevertheless, not the entire collection of ~1 million TCF recognition sites are bound by 
TCF-1 in fibroblasts and only a fraction of the T cell-specific regulatory elements became 
accessible in this context. It is worth noting that no other transcription factor including the 
previously studied pioneer factors has been reported to bind to the entire set of possible 
binding sites present in the genome (130, 145). We postulate that higher order 
chromatin conformation and epigenetic modifications such as DNA methylation may 
impede TCF-1 binding to the entire set of its cognate sites (146, 147). Moreover, the 
three waves of chromatin remodeling during T cell development enriched with TCF-1 
binding suggest multiple modes of action for this transcription factor. The regulatory 
elements in the intermediate wave that remain closed at an earlier stage may indicate a 
requirement for the cooperation between TCF-1 and its partners. Similarly, although 
more than thousand TCF-1 binding events in fibroblasts abolished the pre-existing 
repressive marks, the remaining TCF-1 binding events did not modify the chromatin 
state, indicating the requirement of cooperating partners at these regulatory sequences. 
The regulatory syntax that TCF-1 follows to read the genetic code may be ascertained 
by machine learning techniques delineating rules of transcription factor engagement 
from DNA sequence and shape, histone modification, chromatin conformation, and 
transcription factor binding data during development and reprogramming. Collectively, 
our integrative data highlight a widespread means by which TCF-1 initiates the T lineage 




2.5 MATERIALS AND METHODS 
 
Mice: Mice used were C57BL/6J (CD45.2+) and B6.SJL-Ptprca Pepcb/BoyJ (CD45.1+) 
purchased from the US National Cancer Institute animal facility. All mice analyzed were 
6-12 weeks and were used without randomization or ‘blinding’ of researchers to mouse 
or sample identity. Tcf7-/- (TCF-1-/- ΔVII) mice were kindly provided by A. Bhandoola (87). 
All animal work was in accordance with the Institutional Animal Care and Use Committee 
for the University of Pennsylvania in accordance with guidelines set forth by the NIH. 
Cell culture: NIH3T3 cells were purchased from ATCC for this study and used at a low 
passage number (<12) and were maintained in high glucose DMEM 1x medium with L-
glutamine and sodium pyruvate (Corning) with 100 U mL-1 penicillin and 100 μg mL-1 
streptomycin (Gibco) and 10% bovine serum (Gibco). 293T (ATCC) cells were 
maintained in high glucose DMEM 1x medium with L-glutamine and sodium pyruvate 
(Corning), and 100 U mL-1 penicillin and 100 μg mL-1 streptomycin (Gibco) with 10% fetal 
calf serum (Gemini). All cells were grown at 37°C and 5% CO2.  
Retroviral Transductions: Gateway compatible MSCV-IRES-VEX (MSCV-ccdB-VEX) 
and empty vector controls (MSCV-VEX) retroviral vectors were obtained from A. 
Bhandoola (121). Mouse Tcf7 cDNA (NM_009331) of the short isoform of TCF-1 (p33) 
was obtained from Origene and cloned into MSCV-ccdB-VEX (MSCV-TCF7-VEX) 
according to Gateway Clonase II instructions (Invitrogen). Sequences were verified 
using MacVector v15.5.0. Cells were transduced by addition of virions to culture media 
supplemented with polybrene at 8 μg mL-1 and 10 mM HEPES. As transduction 
efficiency in NIH3T3 was >99%, all assays on transduced NIH3T3 cells were performed 
without cell sorting. 
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Retroviral Packaging: 293T cells were plated in 4 mL DMEM media in 10 cm dishes 
prior to transfection. Immediately prior to transfection, chloroquine was added to a final 
concentration of 25 μM. The retroviral construct and the pCL-Eco plasmid were 
transiently co-transfected using Lipofectamine 3000 (Invitrogen). The cells were returned 
to the incubator for 6 hours. Subsequently, the medium was changed to fresh media. 
Virions were collected 24 and 48 hr after transfection, snap-frozen, and stored at -80°C 
for future use. 
Assay for Transposase-Accessible Chromatin (ATAC): ATAC-seq was performed as 
previously described with minor modifications (148). Fifty thousand cells were pelleted at 
550 x g and washed with 1 mL 1x PBS, followed by treatment with 50 μL lysis buffer 
(10 mM Tris-HCl [pH 7.4], 10 mM NaCl, 3 mM MgCl2, 0.1% IGEPAL CA-630). After 
pelleting nuclei, the pellets were resuspended in 50 μL transposition reaction with 2.5 μL 
Tn5 transposase (FC-121-1030; Illumina) to tag and fragment accessible chromatin. The 
reaction was incubated in a 37°C water bath for 45 minutes. Tagmented DNA was 
purified using a MinElute Reaction Cleanup Kit (Qiagen) and amplified with 12 cycles of 
PCR. Libraries were purified using a QIAQuick PCR Purification Kit (Qiagen). Libraries 
were paired-end sequenced (38bp+37bp) on a NextSeq 550 (Illumina). For accessibility 
in NIH3T3 cells, two biological replicates were performed at both 48 and 96 hr time 
points after transduction. Three technical replicates were performed between WT and 
TCF-1 KO DP T cells. 
Single Cell ATAC: Single cell ATAC-seq was performed as previously described (127) 
using the C1 Single-Cell Auto Prep System with the C1 Open AppTM program (Fluidigm). 
Briefly, cells were FACS sorted to high viability and purity. Cells were then stained with 
mammalian LIVE/DEAD Viability/Cytotoxicity Kit (Invitrogen) for 10 minutes on ice at a 
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final concentration of 5 μM Ethidium homodimer-1 and 5 μM Calcein AM in 1x PBS. 
After staining, cells were diluted in RPMI-1640 to a concentration of 400,000 cells mL-1. 
C1 Cell Suspension Reagent (Fluidigm) was added to a final concentration of 20%. 
Brightfield and fluorescent images of each capture site was taken with a Leica DMi8. 
The Lysis/Tagmention step in the C1 protocol was lengthened to a duration of 60 
minutes using the Open AppTM software (Fluidigm). After single cell ATAC-seq chemistry 
was performed on the Fluidigm C1, tagmented DNA was harvested and amplified for 14 
PCR cycles (Fluidigm). Libraries were paired-end sequenced (38bp+37bp) on a NextSeq 
550. Three captures of DP T cells were performed over the course of this study. 
Chromatin Immunoprecipitation (ChIP) assay: ChIP-seq was performed as previously 
described (149). Briefly, chromatin samples prepared from fixed cells were 
immunoprecipitated with antibodies recognizing mouse TCF-1 (C46C7; CST), H3K9me3 
(AM39161; Active Motif), and H3K27me3 (07-449; EMD Millipore). Antibody-chromatin 
complexes were captured with protein G–conjugated beads, washed, and eluted. After 
reversal of cross-linking, RNase and proteinase K treatment were performed and DNA 
was purified and quantified for library preparation. Input sample was prepared by the 
same approach without immunoprecipitation. Libraries were then prepared using the 
UltraTM DNA Library Prep Kit (NEB). Two replicates were performed for each condition. 
Indexed libraries were validated for quality and size distribution using a TapeStation 
2200 (Agilent). Single end sequencing (75 bp) was performed on a NextSeq 550.  
RNA-seq: Cells were washed once with 1x PBS before resuspending pellet in 350 μL 
Buffer RLT Plus (Qiagen) with 10% 2-Mercaptoethanol (Sigma), vortexed briefly, snap-
frozen on dry ice, and stored at -80°C. Subsequently, total RNA was isolated using the 
RNeasy Plus Micro Kit (Qiagen). RNA integrity numbers were determined using a 
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TapeStation 2200 (Agilent), and all samples used for RNA-seq library preparation had 
RIN numbers greater than 9.5. Libraries were prepared using the SMARTer® High-Input 
Strand-Specific Total RNA-seq for Illumina kit (Clontech). Libraries were single-end 
sequenced (75 bp) on a NextSeq 550. Three biological replicates were performed for 
TCF-1 RV and Empty RV transduced NIH3T3 cells. Two technical replicates were 
performed in WT and TCF-1 KO DP T cells. 
Cell staining and flow cytometry: Single-cell suspensions were prepared from thymi of 
mice by dissociation of tissue through 70 μM mesh filters (Falcon) in RPMI 1640 
(Corning) +1% FBS (Gemini), and surfaces were stained following standard protocols. 
The fluorochrome-conjugated, anti-mouse antibodies were as follows: PE CD4 (RM4-4), 
APC CD8a (53-6.7), PE c-Kit (2B8), APC CD25 (PC61), and Streptavidin BV605. For 
intracellular detection of TCF-1 in RV-transduced NIH3T3, cells were harvested after 
trypsin dissociation (Gibco), fixed with 1% PFA for 10 minutes on ice to preserve VEX 
signal, fixed and permeabilized with the FoxP3/Transcription Factor Staining Buffer Set 
(eBioscience), and incubated with PE-conjugated anti-TCF-1 (S33-966). All antibodies 
used for flow cytometry were purchased from BioLegend or BD Biosciences. Data were 
collected on an LSRII running DIVA software (BD Biosciences) and were analyzed with 
FlowJo software v10.2 (TreeStar). 
Cell sorting: Antibodies used in the lineage cocktail (Lin) include biotinylated antibodies 
against B220 (RA3-6B2), CD19 (1D3), CD11b/Mac1 (M1/70), Gr1 (8C5), CD11c (HL3), 
NK1.1 (PK136), TER119 (TER-119), CD3ε (2C11), CD8α (53-6.7), CD8β (53-5.8), TCRβ 
(H57), γδTCR (GL-3). After surface staining with the lineage cocktail, cells were 
incubated with Streptavidin Microbeads (Miltenyi Biotec). DN cells were then negatively 
isolated from total thymocytes using magnetic separation columns (Miltenyi Biotec). 
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Negatively selected cells were then stained with c-Kit and CD25 followed by Strepavidin 
BV605 to reveal escaping Lin+ cells. The DN3 population was defined and cell-sorted as 
Lin– Kit– CD25+. Total thymocytes were stained with CD4+ CD8+ to define and sort the 
DP population. Dead cells were excluded through 7-amino-actinomycin D (7-AAD) 
uptake. Doublets were excluded through forward scatter–height by forward scatter–width 
and side scatter–height by side scatter–width parameters. Purity was verified after 
sorting, and all cell populations were sorted to a purity of >98%. Sorting was performed 
on FACS Aria II (BD Biosciences) and were analyzed with FlowJo v10.2 (TreeStar). 
High-throughput sequencing data pre-processing: Quality assessment of raw reads 
was achieved with FastQC (150) and contaminants were removed using Trimgalore 
(151) with parameters ‘-q 15 --length 20 --stringency 5’. For RNA-Seq samples, ‘--
clip_R1 3’ was added to the Trimgalore parameters facilitating the removal of the 3nt 
bias introduced to the 5’ end of reads. Human (GRCh37, November 17 2015) and 
mouse (GRCm38, May 23 2014) reference genomes were downloaded from UCSC 
repository (152) and mouse gene models were derived from Gencode vM11 (153). 
Bulk ATAC-seq samples were mapped to the reference genomes using Bowtie2 v2.2.9 
(154) with –X2000. STAR v2.5 (155) was used for aligning single-cell ATAC, RNA, ChIP 
and MNase-seq reads with parameters specifically optimized based on the properties of 
each protocol. RNA-seq samples were analyzed with parameters ‘--
outFilterMultimapNmax 1 --outFilterScoreMinOverLread 0 --
outFilterMatchNminOverLread 0 --alignEndsType Local’. On the other hand, ChIP-seq 
raw reads were aligned with parameters ‘--alignSJDBoverhangMin 999 --
alignSJoverhangMin 999 --alignIntronMax 1 --outFilterMultimapNmax 1 --
outFilterScoreMinOverLread 0 --outFilterMatchNminOverLread 0 --alignEndsType Local’ 
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to disable the usage of known and prevent calling novel splice junctions. The same 
parameters were also applied for mapping scATAC-seq and MNase-seq data combined 
with ‘--alignMatesGapMax 2000’ which limits the distance between aligned read mates 
to 2,000bp. 
Reads aligned to the mitochondrial genome as well as reads mapping to multiple 
genomic loci were discarded from downstream analyses. Additionally, Picard (156) 
minimized the PCR amplification bias in ATAC-, ChIP- and MNase-seq samples. In 
cases of paired-end MNase-seq samples, fragments smaller than 75bp were also filtered 
out. 
ATAC-seq samples derived from single DP T cells were filtered using previously 
described quality standards (127). In brief, libraries containing less than 10,000 
fragments or libraries with less than 15% of their fragments falling in open chromatin (as 
defined in the single cell accessibility section) were also removed from subsequent 
analyses (Figure S3C-D).  
Differential gene expression analysis: HTSeq v0.6.1 (157) facilitated counting RNA-
seq reads on Gencode vM11 (153) gene models with parameters ‘-s yes -t exon -m 
intersection-nonempty’. DESeq2 (126) was subsequently applied on gene counts to 
identify genes differentially expressed between DP WT and DP TCF-1 KO (Figure S2C), 
NIH3T3 Empty RV and NIH3T3 TCF-1 RV (Figure S6B) as well as DP TCF-1 WT and 
NIH3T3 Empty RV cells after removing entries that exhibited zero counts in all 
replicates. The quality of replicates was assessed by calculating pairwise spearman 
correlation coefficient (Figures S2B and S6A) as well as plotting the variability 
explained by the first two principal components (data not shown). 
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Additionally, gene expression levels were calculated in a variety of cell types ranging 
from hematopoietic stem cells to effector and memory T cells and normalized using the 
variance stabilizing transformation (VST) (126). K-means (k=12) clustering was then 
applied on the VST expression values of genes upregulated by TCF-1 in NIH3T3 cells to 
identify cell state specific patterns (i.e., clusters) of TCF-1 regulated gene expression. 
For the same set of genes, we also calculated RPKM normalized expression values that 
were used to filter out lowly expressed genes (RPKM < 0.5 in all samples) and 
visualizing the clusters (Figure S6D-E). Cluster 1 was removed from the analysis due to 
low expression levels in all hematopoietic lineages. Genes downregulated in the TCF-1 
KO DP T cells were overlapped with the genes upregulated by TCF-1 RV in NIH3T3 and 
the significance of the overlap was tested by Fisher’s exact test. (Figure S6F).  
Defining thymocyte-specific gene program: Normalized microarray expression data 
for bone marrow stem cell and thymocyte populations was downloaded from the 
Immunological Genome Project Consortium (133). Microarray probe IDs (affy mogene 
1.0st v1) were converted to Ensembl gene IDs using the Ensembl mouse gene mart 
(GRCm38.p5) in biomaRt (158, 159). Genes were considered expressed in a population 
if expression values were above 120 indicating >95% probability of true expression 
(160). To define thymocyte-specific genes (Figure 7D), genes were filtered based on 
expression values lower than 120 in all considered progenitor populations (LT-HSC, ST-
HSC, MPP, CLP) and with expression values higher than 120 in at least 1 thymocyte 
population (ETP, DN2a, DN2b, DN3a, DN3b, DN4, ISP, DP, CD4+, CD8+). Genes were 
further filtered based on having at least a 2-fold increase in expression between any two 
populations. The overlap of thymocyte-specific genes and genes upregulated by TCF-1 
RV in NIH3T3 was determined using the GeneOverlap package (161). Genes 
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upregulated by TCF-1 RV in NIH3T3, described in previous sections, but not overlapping 
with thymocyte-specific genes were filtered based on expression >120 in at least one 
progenitor population and plotted (Figure 7D). Thymocyte genes were grouped into 
patterns of expression by combining thymocyte-specific genes with both overlapping and 
non-overlapping with genes upregulated by TCF-1 RV in NIH3T3 and performing k-
means clustering using 5 centers. Gene ontology analysis (Figures S1E and S6C) was 
performed using the Gene Ontology gene set collection in MSigDB database v6.1 (162, 
163). 
Peak calling: Following ENCODE guidelines, for the characterization of reproducible 
TCF-1 peaks in NIH3T3 TCF-1 RV cells, macs2 v2.1.1 (164) was initially applied 
separately on each of the two ChIP-seq replicates as well as after merging both 
replicates with parameters ‘--nomodel --extsize 300 --keep-dup all --call-summits -q 0.9’ 
using the TCF-1 ChIP-seq on NIH3T3 Empty RV cells as control. The identified peaks 
were filtered with Irreproducible Discovery Rate (IDR) v2.0.2 (165) using an IDR 
threshold of 2e-2 resulting in a high-quality set of 40,562 reproducible peaks. 
TCF-1, GATA3, RUNX1 and PU.1 binding sites in mouse thymocytes were identified by 
applying macs2 with parameters ‘-p 1e-3 -q 0.05’ using the corresponding Input samples 
as control resulting in 56,817 TCF-1 peaks, 54,475 GATA3, 67,915 RUNX1, 98,036 
PU.1 in DN1 and 92,660 in DN2a. 
A proximity-based strategy was adopted for linking genes to regulatory elements and 
transcription factor binding sites. Gene models were downloaded from Gencode M11 
and both ends of each gene were extended by 5kbp. Open chromatin sites identified by 
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ATAC-seq as well as ChIP-seq derived transcription factor binding sites were assigned 
to genes if they were found to overlap with their extended models. 
Differentially accessible chromatin between DP WT and TCF-1 KO as well as 
between NIH3T3 TCF-1 and Empty RV cells: Macs2 with ‘-p 1e-7 --nolambda --
nomodel’ was applied on each DP WT and DP TCF-1 KO ATAC-seq replicate separately 
to identify accessible chromatin. Peaks were subsequently merged using BEDTools 
(166) and ATAC-seq read counts were calculated in the merged peaks for every 
replicate. The resulting count table was used to identify 6,165 (1,165 presenting more 
and 5,000 less enrichment in DP TCF-1 KO) loci differentially enriched in ATAC-seq 
signal between DP WT and DP TCF-1 KO with DESeq2 after applying a 0.001 and 0.55 
cutoff on p-value and logFC respectively (Figure 3A). 
The same approach and cutoff were applied in NIH3T3 cells (Figure S4D) for identifying 
8,506 genomic regions presenting differential ATAC-seq signal enrichment between 
Empty and TCF-1 RV (6,888 presenting more and 1,618 less enrichment in TCF-1 RV).  
Characterization of cell-state specific accessible chromatin: An IDR threshold of 5e-
2 was used, following the pipeline described in previous section, to identify accessible 
chromatin for every murine ATAC-seq sample (HSC, MPP, CLP, B, NK and all stages of 
T cell development from DN1 to naïve CD4+ and naïve CD8+ cells). Peaks were merged 
and filtered based on their overlap with annotated promoters (Gencode M11 TSSs 
extended by +4kb/-2kb) resulting in a collection of 55,481 distal regulatory elements. 




Each peak was assigned a 13-dimensional vector containing the ATAC-seq enrichment 
proxy in every cell type. Average Silhouette Width (ASW) statistic was used for deciding 
on the number of clusters prior to applying k-means. The initial set of regulatory regions 
was reduced after removing the members of clusters 7, 8, 10, 11, 13, 17 and 23 (Figure 
S1A). The remaining 35,869 loci were re-clustered after re-calculating ASW (data not 
shown) to produce the final set of groups (Figure 2A). Normalized (TPM) ATAC-seq 
profile for every regulatory element was calculated by segmenting a +/- 2,000bp window 
around its center in 10bp bins and calculating the normalized overlapping ATAC-seq tag 
counts (Figures 2B and S1B). 
De novo motif analysis using Homer with ‘-size given -len 6,8,10’ was applied on each 
cluster separately using the excluded set of clusters as background (Figure 2C-E, 
Figure S1C). Additionally, odds ratio and percentage of binding of TCF-1, GATA3, 
RUNX1 and PU.1 (DN1 and DN2a) was calculated for each cluster based on publicly 
available ChIP-seq data (Figure 2F). 
An alternative approach was used for identifying T cell specific accessible chromatin in 
human cells (Figure S1D). The lack of replicates for certain cell types restricted the use 
of IDR. Therefore, macs2 with parameters ‘-p 1e-7 --nolambda --nomodel’ was used for 
every cell type (HSC, MPP, CLP, B, NK, Naïve CD4+ and Naïve CD8+ cells) on each 
replicate separately. Peaks were merged with BEDTools and normalized ATAC-seq 
enrichment for every cell type was calculated after merging the replicate samples within 
each cell type. Gencode M11 gene models were used to separate the set of ATAC-seq 
peaks into distal and promoter related loci after extending the annotated gene 
transcription start sites by -4kb/+2kb. 
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Each peak was assigned a 7-dimensional vector containing the normalized ATAC-seq 
enrichment in every cell type. Within Sum of Squares (WSS) statistic was used (data not 
shown) for deciding on the number of clusters prior to applying k-means (k=10 for the 
distal sets and k=5 for the promoter sets). De novo motif analysis using Homer with ‘-
size given -len 6,8,10,12’ was applied on each cluster separately with remaining peaks 
in other clusters as background (Figure S1D). 
Querying chromatin accessibility at the single-cell level: To assess whether TCF-1 
binding events harbor the strongest chromatin accessibility as measured by ATAC-seq 
in DP T cells, we measured genome-wide binding of TCF-1, RUNX1 and GATA3 by 
ChIP-seq as previously described. An equal number of genomic regions with unique 
binding of each transcription factor were subsampled and the normalized tag count 
enrichment from ATAC-seq in DP T cells facilitated the comparison of the 3 regulatory 
proteins (Figure 4A). 
Based on this analysis, TCF-1 bound open chromatin was found to exhibit the highest 
levels of accessibility compared to RUNX1 and GATA3. This observation inspired us to 
further investigate with a single cell analysis. ATAC-seq data from 110 single DP T cells 
passing previously defined (127) quality standards (Figure S3D) were utilized to test the 
hypothesis that TCF-1 exerts a deterministic effect on the chromatin, forcing T cell fate 
commitment. Following pre-processing and alignment, DP single cell ATAC-seq reads 
were merged and using macs2 with parameters ‘-p 1e-3’, 22,774 accessible sites were 
identified.  
To assess the correlation between aggregated single cell and bulk ATAC-seq enriched 
sites identified from both experimental procedures were merged. Normalized enrichment 
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was subsequently calculated in bulk (downsampled to 11.6 million reads using samtools) 
and aggregated scATAC-seq with 11.6 million reads enabling the correlation level 
quantification between the two assays (Figure 4B). 
Our objective was to assess whether TCF-1-bound open chromatin had lower 
accessibility variance than background noise and chromatin bound by RUNX1 or 
GATA3. To this end, we generated 4 disjoint sets comprising of ATAC-seq peaks 
uniquely bound by TCF-1, RUNX1, GATA3 as well as peaks not bound by any of these 
three transcription factors. For each subset, binarized accessibility matrices were 
calculated based on the overlap between the identified peaks and ATAC-seq reads from 
each cell, thus 1 translates to accessible and 0 to inaccessible regions. 
TCF-1 binding events overlapped with more ATAC-seq peaks than RUNX1 or GATA3, 
therefore we subsampled 30 peaks from each TF-bound peak set. We repeated the 
subsampling process 500 times to increase accuracy. We then calculated the 
accessibility variance between cells at each subsample as follows. For each subsample, 
the binary accessibility vector of each cell formed a 30-dimensional vector. To measure 
cell to cell differences in accessibility levels, we calculated the pairwise Manhattan 
distance between accessibility vectors, forming a distance matrix. 
We subsequently centered the Manhattan distance matrix by subtracting column and 
row means and adding the overall mean. Then we spectrally decomposed the centered 
matrix to define principal coordinates and mapped all accessibility vectors to full principal 
coordinate space. We identified the location that minimized the average distance to all 
vectors, termed the spatial median (Figure 4D). Then, we calculated each vector’s 
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distance from the spatial median. Finally, we calculated the average distance from 
accessibility vectors to the spatial median using the R package vegan (167). 
Correction for Technical Biases: Variation associated with technical factors such as 
GC content and mean accessibility differences can often introduce obstacles in 
interpreting NGS data. To overcome such limitations, for every original peak, we 
selected 30 “technical control” ones. The set of peaks not bound by any TF were divided 
into 2-percentiles based on GC content. Every original peak was subsequently placed 
into a 2-percentile, and 30 technical control peaks within a 2-percentile of GC content 
were randomly subsampled with replacement. All technical control peaks were also 
within +/- 0.01 of the overall mean accessibility of the original 30 peaks. 
Correction for Background Noise: To measure accessibility variation beyond 
background noise, we calculated accessibility variation (with technical controls) for 500 
randomly selected subsamples of peaks bound by no TF. This can be viewed as a 
negative control.  
A variability equal to 1 implied that a TF was associated with no more variation than 
background noise. A variability below 1 implied that a TF was associated with less 
variation than background noise, and a variability above 1 implied greater variation than 
background noise. 
In addition to the methodology described above, we also applied chromVAR (168) for 
assessing the deterministic effect of TCF-1 on shaping the chromatin landscape during T 
cell development (Figure 4E). 
ChIP-seq oriented approach for assessing the deterministic effect of TCF-1 during 
T cell development: An alternative, unbiased strategy was also adopted which, unlike 
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the previous approach, was not formed on the basis of TCF-1 binding (Figure 4F). The 
T cell specific sites in cluster 9 (Figure 2A) were ranked based on the sum of binary 
counts across individual T cells. Using default parameters of bedtools intersect, the 
overlap of regions with ChIP-seq signal from transcription factors known to be important 
in T cell development such as TCF-1, GATA3 and RUNX1 was assessed. De novo motif 
analysis was performed on the top and bottom 100 enhancers that exhibit the highest 
and lowest homogeneity respectively at the single cell level using Homer with 
parameters ‘-size given -len 6,8,10,12’. Background control in this motif analysis was 
any other open chromatin sites in DP T cells. The top/bottom 100 enhancers were also 
linked to genes based on proximity (<10kbp) in order to enable GO term enrichment 
analysis using the GSEA software.  
Identifying the nucleosome occupancy level on TCF-1 binding sites: MNase-seq in 
mouse embryonic fibroblasts was used as a proxy for observing the nucleosome 
enrichment surrounding TCF-1 binding sites. To this end, the region around TCF-1 peak 
summits was divided into 3 windows of 200bp each; -300/-100, -100/+100 and 
+100/+300 following a upstream-central-downstream rationale. The nucleosome 
enrichment in every window was approximated by calculating the number of overlapping 
MNase-seq reads after extending their 3’ end to 147bp and normalizing based on the 
number of uniquely mapped reads in each sample. TCF-1 summits were subsequently 
ranked from high to low enrichment by summing the values of left, central and right 
windows. For visualization purposes, the normalized MNase-seq enrichment was also 
calculated for 10bp non-overlapping bins spanning the +/- 3kb region centered around 
TCF-1 summits (Figure 5A). 
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In the case of mouse embryonic fibroblasts, visualizing the prior nucleosome enrichment 
status on the genomic loci bound by TCF-1 after Tcf7 retroviral transduction clearly 
suggests that TCF-1 binding occurs on: a) nucleosome dense, b) nucleosome free and 
c) regions of intermediate nucleosome occupancy (Figure 5A). Instead of choosing an 
arbitrary threshold on the ratio of central versus left and right window nucleosome 
enrichment, k-means (k = 3) clustering was applied resulting in the formation of 3 TCF-1 
summit groups and validating the previously described observation (Figure S4C). A total 
of 29,661 (73.2%) TCF-1 binding events occur on sites with dense (10,593, 26.2%) or 
intermediate (19,068, 47%) nucleosome enrichment and 10,901 (26.8%) on nucleosome 
free regions. 
Dpos module from Danpos2 (169) was applied on the MNase-seq data with default 
settings to identify nucleosome positioning as well as calculate the nucleosome 
enrichment profile on a genome-wide scale. Regions called as nucleosomes exhibiting 
increased fuzziness (Dpos score less than 80) were removed from subsequent 
analyses. The distance of 40,562 TCF-1 summits in mouse embryonic fibroblasts to the 
closest nucleosome summit was calculated as an alternative strategy of assessing the 
ability of TCF-1 to directly bind on nucleosomes (Figure 5B). The typical length of DNA 
fragments wrapped around nucleosomes is 147bp. This allowed us to classify 27,145 
TCF-1 summits (66.9%) located less than 75bp (vertical dashed red line) away from 
nucleosome summits as bound to nucleosomes and 13,417 (33.1%) summits as 
unbound. As a control, we applied the same bound/unbound to nucleosomes 
classification scheme on CTCF summits derived from analyzing public ChIP-seq data, 
resulting in 20,370 (56.6%) bound and 15,616 (43.4%) unbound summits. 
72 
 
To assess the difference of nucleosome occupancy level around TCF-1 ChIP-seq peak 
summits between Empty RV and TCF-1 RV NIH3T3 cells, TCF-1 summits (IDR less 
than or equal to 0.02) were intersected with ATAC-seq enriched regions in both 
conditions. Summits overlapping ATAC-seq peaks in either set (n=15,763) were 
extended by +/- 500 bases and nucleosome occupancy in Empty and TCF-1 RV NIH3T3 
cells was measured using NucleoATAC algorithm (132). NucleoATAC infers nucleosome 
enrichment by integrating large and small ATAC-seq fragment positioning in accessible 
chromatin. Therefore, to quantitate nucleosome enrichment around TCF-1 summits with 
NucleoATAC algorithm, ATAC-seq signal from both Empty and TCF-1 RV NIH3T3 
samples is required. Out of 15,763 queried summits 7,395 were found to exhibit at least 
1.5 fold-change difference in nucleosome occupancy signal between Empty and TCF-1 
RV NIH3T3 cells (Figure S4F). 
T cell gene enrichment in nucleosome enriched based clusters of TCF-1 summits: 
Based on the previously described analysis regarding the pre-induced nucleosome 
enrichment levels around TCF-1 ChIP-seq derived binding events in TCF-1 RV NIH3T3 
cells, we identified 3 clusters of TCF-1 summits (Figure S4C). TCF-1 summits with high 
(n=10,593), intermediate (n=19,068) and low (n=10,901) nucleosome enrichment. In 
parallel, the previously described differential gene expression analysis between Empty 
RV NIH3T3 and DP T cells, identified 3,349 genes as DP T and 4,040 as NIH3T3 cell-
specific. To calculate the enrichment of the 2 gene sets in the 3 nucleosome enrichment 
clusters, TCF-1 peak summits were associated with genes, as described in previous 
section, resulting in 27,794 interactions between 24,330 TCF-1 summits and 10,212 
genes. To remove redundancy in the association between genes and nucleosome 
clusters we filtered out genes associated to zero or more than one clusters. The 
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remaining were used to calculate the enrichment of DP T cell-specific genes in high, 
intermediate and low MNase clusters with Fisher’s exact test (Figure S6I). 
Motif distances from nucleosome summit: MEME-FIMO (165) and TCF-1 position 
probability matrix (MA0769.1) from JASPAR (170) facilitated the discovery of 1,102,896 
putative TCF-1 binding sites (motifs) in the mouse genome using a p-value threshold of 
1e-4. 17,816 motifs were found to overlap with TCF-1 ChIP-seq peaks specific to TCF-1 
RV NIH3T3 and 7,782 with peaks specific to DP T cells. To avoid biases associated to 
imbalanced number of motif occurrences in peaks, a one-to-one association between 
motifs and summits was created by selecting the closest to summit motif per peak with a 
maximum distance threshold of 100bp. This resulted in the finalized sets of motifs bound 
in TCF-1 RV NIH3T3 (n=10,665) and DP T cells (n=6,115). The remaining unbound 
putative TCF-1 sites were grouped into motif hotspots using a distance threshold of 
500bp. For every hotspot the motif with the highest FIMO score was selected as its 
representative (random selection for ties) resulting in the formation of the final ‘Random’ 
set of unbound motifs (n=862,733) that were used as control. 
Nucleosome positions were called using Danpos2 (169) as previously described. The 
distance between motifs from NIH3T3, DP T and Random sets to their closest 
nucleosome dyad was calculated using BEDTools (166). The visual comparison of the 
distribution of distances between each cell type specific set and the Random set was 
achieved by randomly selecting 1,000 samples from each set with replacement, plotting 
the density of distances and repeating this process 1,000 times (Figure S4D). To assess 
whether there is a statistically significant difference in the median motif distance from the 
nucleosome dyad between each cell-specific (target) set and the Random set, we 
carried out two separate bootstrapping procedures, one for each target set. Distances 
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from the target and Random set were combined into a pooled vector. Both target and 
Random sets were transformed by subtracting each set’s mean from every member of 
the relevant set and adding the mean of the pooled vector. This way, both sets are first 
centered around their mean and then shifted by the pooled mean resulting in the proper 
transformation for testing the null-hypothesis (no difference between median motif 
distances from the nucleosome center of the two sets) without making any assumptions 
about their variance. Subsequently, we randomly selected 1,000 samples (with 
replacement) from each transformed set and compared the difference between median 
distances. After repeating this process 100,000 times we divided the number of times we 
observed a difference between the median distances larger than (or equal to) the raw 
difference (no subsampling) to calculate the p-value (Figure S4D). 
Characterization of the chromatin state in NIH3T3 cells prior to Tcf7 retroviral 
transduction: In addition to having established the pre-Tcf7 overexpression 
nucleosome occupancy environment in NIH3T3 cells, querying the chromatin state 
landscape is a critical step towards unveiling the properties of TCF-1 binding in a 
genome-wide, quantitative way. To this end, the enrichment of H3K4me3, H3K4me1, 
H3K9me3, H3K27me3 and H3K27ac versus Input in the +/- 1kb (and +/- 250bp) region 
surrounding TCF-1 summits has been calculated by modeling read counts with a 
binomial mixture model of two components with normR (171). The first component 
models the background and the second one the signal, independently for each histone 
mark, resulting in a five-dimensional vector of p-values adjusted for multiple 
comparisons for every summit. H3K27me3, H3K9me3, and H3K27ac enrichment in 
TCF-1 RV NIH3T3 cells was calculated as well (Figure 6C-D). Furthermore, the 
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enrichment of ATAC-seq in NIH3T3 TCF-1 RV versus Empty RV cells and vice versa 
has also been calculated around summits. 
These enrichment results facilitated the assessment of correlations between the 
chromatin status and chromatin accessibility before and after Tcf7 overexpression 
(Figure 6, Figure S5). Additionally, k-means clustering has been applied on TCF-1 
summits based on the enrichment level of the 5 chromatin marks in pre-induced cells 
resulting in the formation of 11 clusters (Figure 6B, Figure S5D, Table S6), following 
silhouette coefficient analysis (Figure S5C). For visualization purposes, the normalized 
histone mark ChIP-seq as well as ATAC-seq enrichment was also calculated for 10bp 
non-overlapping bins spanning the +/- 3kb region centered around TCF-1 summits 
separately for each cluster. 
Deregulated genes in NIH3T3 TCF-1 RV cells were linked to TCF-1 binding sites based 
on the proximity strategy described in previous sections. Consequently, genes were also 
connected to chromatin states. This enabled the calculation of the significance of up- 
and down-regulated genes enrichment in each chromatin state using Fisher’s exact test 
(Figures 7E and S6G). To assess differences in the enrichment of H3K9me3, 
H3K27me3 and H3K27ac ChIP-seq signal around TCF-1 binding events between pre-
induced and TCF-1 RV NIH3T3 cells, we used diffR function from normR package using 
an FDR threshold of 5e-2. 
Gene set enrichment analysis: Pre-ranked lists of genes were used by ranking genes 
using estimated log2 fold-change in DESeq2. GSEA v2.2.4 with default parameters was 
used to perform gene set enrichment analysis. 
76 
 
Quantification and Statistical Analysis: All statistical analyses were performed from 
packages from R’s basic installation. 
Data and Software Availability: The accession number for the ChIP-seq, RNA-seq and 




CHAPTER 3: Differentiation of a distinct and stable T-bet+ memory B cell subset 
3.1 PREFACE 
 
The manuscript presented in this chapter was originally published in Immunity (172). It 
has been reformatted here in accordance with the University of Pennsylvania 
dissertation formatting guidelines and the introduction has been expanded. 
Authors: 
John L. Johnson1†, Rebecca L. Rosenthal1†, James J. Knox1†, Arpita Myles1†, Martin S. 
Naradikian2, Joanna Madej1, Mariya Kostiv1, Aaron M. Rosenfeld1, Wenzhao Meng1, 
Shannon R. Christensen3, Scott E. Hensley3, Jonathan Yewdell4, David H. Canaday5, 
Jinfang Zhu6, Adrian B. McDermott7, Yoav Dori8, Max Itkin9, E. John Wherry10, Norbert 
Pardi11, Drew Weissman11, Ali Naji12, Eline T. Luning Prak1, Michael R. Betts3, and 
Michael P. Cancro1 
Affiliations: 
1Department of Pathology and Laboratory Medicine, University of Pennsylvania, 
Philadelphia, PA 19104, USA; 2La Jolla Institute For Allergy and Immunology, La Jolla, 
CA 92037, USA;  3Department of Microbiology, University of Pennsylvania, Philadelphia, 
PA 19104, USA; 4Laboratory of Viral Diseases, National Institute of Allergy and 
Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA; 5Division 
of Infectious Disease, Case Western Reserve University School of Medicine, and 
Cleveland VA Hospital, Cleveland, OH 45106, USA; 6Laboratory of Immune System 
Biology, National Institute of Allergy and Infectious Diseases, National Institutes of 
Health, Bethesda, MD 20892, USA; 7Vaccine Research Center, National Institute of 
Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, 
USA; 8Center for Lymphatic Imaging and Intervention, Children’s Hospital of 
Philadelphia, Philadelphia, PA 19104, USA; 9Division of Interventional Radiology, 
Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA 
19104, USA; 10Department of Systems Pharmacology and Translational Therapeutics, 
78 
 
University of Pennsylvania, 19104, USA; 11Department of Medicine, University of 
Pennsylvania, Philadelphia, PA 19104, USA; 12Department of Surgery, Hospital of the 
University of Pennsylvania, Philadelphia, PA 19104, USA. 
† Co-first authors 
Respective Contributions: 
JLJ, RLR, AM, MPC designed the murine portion of the study; JJK, MRB designed the 
human portion; JLJ, RLR, JJK, AM, MPC wrote the manuscript; DHC, YD, MI, AN, MRB 
provided human tissues; JLJ, JJK, RLR, MN, JM, MK, SRC performed experiments; JLJ, 
RLR, JJK analyzed the data; WM, AR and ELP generated and analyzed the immune 
repertoire profiling data, contributed the immune repertoire models, and helped edit the 
manuscript; AM, NP, DW, SH, ABM, JZ helped secure reagents critical to the study; 




3.2.1 The innate and adaptive immune responses 
 
Protective immunity depends on selecting appropriate effector function and 
perpetuating those choices in long-lived memory cells. While non-specialized effector 
function may afford some degree of protection, the adaptive immune response is most 
protective when effector function is pathogen-tailored and subsequent memory cells 
develop sustained specialization. These fate choices are set early in the immune 
response due to the interplay between the innate and adaptive immune systems (173). 
The signals exchanged between these two systems are often classified as activating and 
regulatory interactions but can also include interactions that specify effector cell identity 
and function. Cells of the innate immune system are the first line of defense and can 
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respond rapidly to the presence of a pathogen. Innate cells such as macrophages and 
DCs express a variety of germ-line encoded PRRs that bind evolutionarily conserved 
PAMPs (174). The engagement of PAMPs with PRRs transmits an activation signal that 
triggers an immediate innate cell response. Once activated, the innate cell response 
provides inductive signals to cells of the adaptive immune response to direct effector 
choices (175, 176). 
Unlike the innate immune response, the adaptive immune response is directed 
by antigen-specific lymphocytes. T cells and B cells bear antigen receptors (TCRs and 
BCRs, respectively) that are assembled by gene rearrangement during their 
development in the thymus and bone marrow. According to the clonal selection theory 
(6), these unique antigen receptors are clonally distributed throughout T and B cell 
populations. The interactions of antigen receptor with antigens are reversible, but 
receptor occupation needs to exceed a threshold for lymphocyte activation to occur. This 
requirement provides selectivity, as only the antigens with the right stereochemical and 
electrostatic configuration will bind the receptor with a high enough affinity to cross-link 
receptors or engage co-receptors (177). Antigen binding to the receptor triggers a 
cascade of intracellular signaling events that culminates in the activation of transcription 
factors to induce mitosis. Activated T and B cell clones retain their antigen specificity as 
they expand by 10- to 100-fold and gain effector function. A fraction of these cells 
persists indefinitely as memory cells, sustaining ongoing effector functions and 
participating in responses to subsequent pathogen challenges. Deleting cells with 
antigen receptors that respond to self-antigens or the preventing their acquisition of 
effector function sustains immunological tolerance. These four pillars of the adaptive 
immune response—inducibility, specificity, memory, and non-responsiveness to self—
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are shared between the cell-mediated and humoral aspects of the immune response, 
mediated by T and B cells, respectively. 
The T cells of the cell-mediated immune response coordinate their effector 
functions via interactions of their TCR with peptide:MHC complexes on antigen 
presenting cells. T cells are subdivided based on the mutually exclusive expression of 
either CD8 or CD4, co-receptors involved in the binding of TCR to MHC I or MHC II, 
respectively. The distribution of MHC I and MHC II expression varies amongst cells. 
Essentially all nucleated cells express MHC I and peptides derived from cytosolic protein 
synthesis are presented on MHC I. The immune surveillance of intracellular activity is 
therefore carried out by CD8+ cytotoxic T cells, or CTL, that lyse cells presenting non-
self peptides on MHC I. Conversely, extracellular activity is monitored by CD4+ T cells 
that bind peptides derived from the endocytic pathway presented on MHC II. Thus, MHC 
II expression and presentation are limited to antigen presenting cells that regularly 
internalize components of the extracellular environment, such as B cells, macrophages, 
and DCs. CD4+ T cells, or helper T cells, produce membrane-associated proteins and 
cytokines to orchestrate the immune response and are capable of differentiating into 
effector subsets such as TH1, TH2, TH17, TFH, or Tregs (178-180). The differentiation 
programs associated with these effector subsets are carried out by master 
transcriptional regulators in response to certain cues shaped by the nature of the 
pathogen and its PAMPs, the PRRs that are engaged, and the interactions between 
innate and adaptive immune cells. TCR signal strength, costimulation, and cytokine 
milieu guide CD4+ helper T cells to adopt effector fates (181-184). 




The humoral response is mediated by B cells that, following activation and 
differentiation to plasma cells, produce highly specific antibodies. Antibodies serve as 
the antigen receptor of B cells, but their exacting specificity for the molecular 
conformation of the antigen means that a highly diverse set of antibodies need to be 
represented in the primary pool of B cells (185). To achieve this diversity, antibodies are 
composed of two chains, the heavy and light chain, and gene rearrangement of V, D, 
and J gene segments for the heavy chain and V, J segments for the light chain greatly 
diversifies the coding sequence (186). When translated, the recombined VDJ and VJ 
regions of the heavy and light chains fold and come together to create an antigen 
binding region called the combining site. The junctional sequence spanning the 
recombined segments, known as the complementarity defining region 3, or CDR3, is the 
most variable sequence of the antibody and plays a major role in determining specificity 
(187). Further, an antibody is bivalent being comprised of two pairs of heavy and light 
chains joined together by disulfide bonds (188). For antigen binding, the heavy and light 
chains are made up of a variable region and a constant region. The joining of the heavy 
and light chain variable regions contacts the antigen and confers specificity whereas the 
constant region of the heavy chain, but not the light chain, dictates effector function. 
There are five Ig heavy chain constant region isotypes, μ, δ, α, γ, ε that combine 
with λ or κ side chains to make an IgM, IgD, IgA, IgG, or IgE antibody, respectively. The 
IgG isotypes can be further subdivided into IgG1, IgG2a/c (IgG2a in BALB/c and IgG2c 
for C57Bl/6 (189)), IgG2b, or IgG3. The selection of the Ig heavy chain isotype has 
profound implications for the response quality. Antibodies can protect through multiple 
mechanisms such as neutralization, opsonization, complement deposition, 
degranulation, and ADCC, and it is the heavy chain constant region that dictates this 
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effector action. The heavy chain constant region links the adaptive immune system with 
the innate immune system as innate and other cell types express isotype-specific Fc 
receptors (FcR). FcRs can be activating or inhibitory and can modulate cell behavior 
based on the FcR expression profile (190). Moreover, the selection of isotype is based 
on the cytokine milieu and the expression of master transcriptional regulators. 
Immunoglobulin class switching, also known as class switch recombination (CSR) or 
isotype switching, is the process by which antibody heavy chain constant regions are 
changed in an ongoing immune response, involves gene rearrangement and is thus 
irreversible. Therefore, tight regulation of isotype switching is critical for effective 
humoral immunity and to avoid effector mechanisms that cause autoimmune or 
inflammatory disease. Generating a protective antibody response of the proper effector 
isotype requires strict regulation of B cell development, commitment, and homeostasis. 
There are two major types of mature B cells: B1 and B2 cells. B1 B cells develop 
from fetal liver precursors during embryogenesis and contribute to the bulk of IgM titers 
to “natural” antigens as an extension of the innate immune system (191-193). B2 B cells 
are derived from bone marrow stem cells and are constantly produced throughout life 
except during old age when lymphopoiesis declines (194, 195). Multiple transcription 
factors coordinate the transcriptional network of B cell development. The transcription 
factor PU.1 (196) is expressed in B cell precursors to establish a regulatory state for E2A 
(197) and EBF (198) to carry out the transcriptional program of early B cell specification 
with PAX5 (199, 200) maintaining B cell identity. As B cells develop in the bone marrow, 
they migrate from the endosteum to the central sinus of the bone marrow and become 
immature B cells when they acquire IgM. At this time, immature B cells exit the bone 
marrow and become transitional B cells (201, 202). In the periphery, transitional B cells 
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undergo the final stage of development into mature B cells and can differentiate into 
either marginal zone B cells or follicular B cells which occupy different niches in the 
peripheral lymphatics (203-205). The cues required to adopt the MZ instead of the FO B 
cell fate are the strength of tonic BCR signals, transcriptional programs from Notch2 
(206), and interactions with Delta-Like-1 (207). 
Millions of B cells are produced every day, but a small proportion of them enter 
into the mature pool. A tenth of developing B cells become immature B cells and only a 
third of those immature B cells will make it through the transitional B cell stage and 
become mature B cells (202). This loss is due to stringent selection based on BCR 
specificity at the immature and transitional stages (208-210). Negative selection and 
positive selection reduce the frequency of polyreactive and self-reactive specificities 
(209-211) while also selecting for BCRs with near threshold signal strength (212-215). 
Therefore, autoreactive specificities decrease with differentiation (216, 217), and even 
among peripheral B cells, transitional B cells are a source of autoreactive BCR 
specificities (218, 219). 
3.2.3 Thymus dependent and independent B cell responses 
 
 The immunoglobulin constructed by recombination during development serves as 
the extracellular B cell receptor (BCR) driving antigen-specific B cell responses. The 
chemical structures recognized by the BCR include proteins, glycoproteins, 
polysaccharides, viral particles, and bacterial cells. Cross-linking of BCRs through 
binding to epitopes on these multivalent chemical structures leads to the internalization 
of the BCR as well as the bound antigen and initiates intracellular signaling events that 
culminate in the activation of nuclear transcription factors and gene expression for B cell 
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activation (reviewed in (220)). B cells also express PRRs internally and externally and 
can become activated by the binding of PRRs to PAMPs to produce an innate-like 
immune response or to tune the adaptive response (221). Thus, the internalization of 
antigen by BCR cross-linking serves two purposes: 1) to deliver antigen to the endocytic 
compartment for protein degradation and the loading of peptides onto MHC II and 2) to 
expose PAMPS to intracellular PRRs. The quality of the ensuing B cell response 
depends on the mode of interaction of the antigen with the BCR and the chemical 
composition of the antigen. The integration of these parameters follows the two-signal 
model whereby the cross-linking of the BCR provides Signal 1 and additional activation 
or survival signals delivered by other receptors provide Signal 2 (222). There are two 
major types of B cell responses that are largely determined by the nature of Signal 2.  In 
thymus-dependent (TD) responses, Signal 2 is provided by antigen-specific CD4+ T 
cells that bind peptide:MHC presented by B cells in the form of surface receptor 
engagement or cytokine secretion. In thymus-independent (TI) responses, Signal 2 can 
come from B cell engagement of PRRs with PAMPs (TI-1) or through extensive cross-
linking of the BCR itself (TI-2) to foster a short-lived response composed of low affinity 
antibodies to microbial antigens (223, 224). 
 There are substantial differences between TI and TD responses in terms of 
antibody affinity, isotype production, effector differentiation, and memory cell generation, 
and different subsets of B cells contribute differentially to each type of response. In the 
B-2 lineage, follicular B cells make up the bulk of TD responses. Conversely, marginal 
zone B cells of the B-2 lineage and B-1 B cells primarily give rise to TI responses (225) 
likely because of the characteristics of their BCR signaling, their differentiative potential, 
and their enhanced sensitivity to detect PAMPs. Activated B cells in TI responses rapidly 
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differentiate into extrafollicular plasmablasts for the short-lived secretion of low-affinity 
antibody, primarily of the IgM isotype (226, 227). Conversely, B cell activity in TD 
responses is protracted and eventually produces IgG (228). Intriguingly, the antibody 
affinity of a TD response is not static but gradually increases over time in a process 
known as affinity maturation (229). As with TI responses, B cells in a TD response 
differentiate into extrafollicular PCs, relatively long-lived antibody secreting cells, and 
memory cell B cells (MBCs) (230-233). Some activated B cells in a TD response will 
migrate to the border between the follicle and the T cell zone to seek out cognate help 
from CD4 T cells primed by dendritic cells (234, 235). Once engaged, B cell proliferation 
continues and forms a germinal center, a transient structure composed of proliferating B 
cells, CD4 T cells, and other myeloid cells such as follicular dendritic cells. 
The germinal center is a structure unique to TD responses and fosters the affinity 
maturation of germinal center B (GCB) cells (236, 237) and their differentiation to MBCs 
and LLPCs (238). The exchange of signals between B cells and T cells is limited to the 
CD4 T cells with specificity for the peptide antigens derived from the antigen internalized 
by the B cell (239, 240). Thus, cognate interactions are provided by the CD4 T cell and 
includes the engagement of CD40/CD40L and the production of key cytokines. These 
signals foster the upregulation of BCL6 in B cells to drive a germinal center 
transcriptional program (241-244). Another critical gene to be upregulated in GCB cells 
is activation-induced deaminase (AID), which creates point mutations in the variable (V) 
regions of the Ig (245, 246). The process of accumulating these point mutations is 
referred to as somatic hypermutation (SHM) and results in clonal variants with altered B 
cell receptors (247). An altered receptor can change the affinity and specificity of the 
receptor and thereby influence the fate of GCB cells. In the GC, clones compete for 
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survival signals and those with high-affinity receptors are preserved to continue SHM or 
to differentiate whereas the clones with low-affinity receptors die (248). SHM and affinity 
maturation is thought to be more efficient in GCs, but instances of SHM occurring in 
extrafollicular sites have been reported (249, 250). How selective competition is created 
between clones of differing affinities is still a matter of intense investigation, but clearly 
clones compete for antigen and the opportunity to present that antigen (251). In the 
cyclic reentry model, somatic hypermutation is thought to occur in the proliferating B 
cells of the dark zone of the GC before upregulating the altered BCR and migrating to 
the light zone (251). In the light zone, B cells find FDCs bearing antigen and compete 
with other clones for the antigen. Successful acquisition of antigen allows the B cell to 
present antigen to nearby CD4 T cells to receive survival signals and instructive cues. 
The CD4 T cell subset guiding the GC reaction is transcriptionally distinct from other T 
helper cells (252) and are known as T follicular helper (TFH) cells, which migrate to the 
border of the B cell follicle via CXCR5 (253) and select high affinity GC clones through 
BLyS secretion (239). 
3.2.4 Plasma cells and memory B cells in humoral immunity 
 
Humoral immunity depends on the continual production of circulating antibody as 
antibodies only have half-lives measured in days or weeks. Therefore, the differentiation 
of activated B cells into LLPCs or the sustained differentiation of SLPCs due to 
persistent antigen is critical for long term protective immunity (254-256). The 
differentiation of activated B cells into plasma cells depends on the integration of various 
instructive cues resulting in the upregulation of the transcription factor BLIMP-1 (257, 
258) and extinguishing the B lineage transcription factor PAX5 (259, 260). These 
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transcription factor dynamics facilitate a gene expression program that direct B cells to 
terminally differentiate into plasma cells and acquire the specialized functions associated 
with antibody production. The heterogeneity in the lifespan of PCs has been elucidated 
in recent years as well. T cell independent PCs are longer lived than initially thought and 
the turnover kinetics in BM PC pools is more complex than previously appreciated (261, 
262). Moreover, PCs are heterogeneous and have additional functions beyond antibody 
production including cytokine and antimicrobial secretion (263, 264). 
Similarly, accumulating evidence shows that memory cells are not monolithic 
populations, but instead consist of functionally distinct subsets that play different roles in 
protective immunity. Thus, several subsets of memory T cells have been defined, 
reflecting differences in phenotype, function, and migration patterns (265, 266). Memory 
B cell (MBC) subsets have also been described based on differential expression of 
CD73, CD80 and PD-L2 (267); MBCs expressing both CD80 and PD-L2 form plasma 
cells upon re-challenge, whereas the double-negative cells join germinal centers (268).    
 Different memory fates can be determined by cytokine milieu, metabolic cues 
and transcriptional programs. For example, reciprocal patterns of T-bet and 
Eomesodermin expression underlie differentiation of T cells to effector versus memory 
subsets (269, 270).  While the demarcation of T cell memory subsets by transcription 
factor expression is well established, analogous relationships have not been extensively 
explored in MBCs. 
3.2.5 A T-bet expressing B cell subset accumulates during aging 
 
 The discovery of a T-bet+ B cell subset in both mice and humans has piqued 
interest in the origin and role of these cells in primary and secondary humoral immune 
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responses. T-bet+ B cells were first described in the context of murine aging and were 
thus termed “Age-associated B Cells,” or ABCs (271, 272). Subsequent analyses 
revealed roles for cognate T cell help and antigen presentation in their development. 
This, as well as a high frequency of somatically mutated immunoglobulin (Ig) genes in 
these cells, suggested that T-bet+ ABCs are MBCs formed during T-dependent B cell 
responses (273). Whether T-bet+ versus T-bet- MBCs differ in their origins, kinetics of 
generation, trafficking patterns, and functional roles remains unclear. We previously 
showed that T-bet+ B cells appear and persist following influenza immunization or 
infection in mice (273, 274), providing a means to track T-bet+ and T-bet- MBCs in a 
defined antigen system. Moreover, most humans have been exposed to influenza 
through immunization and infection and thus have standing influenza hemagglutinin 




Our results reveal multiple MBC subsets distinguished by T-bet expression, 
whose phenotypic and functional attributes are largely shared between mice and 
humans.  We show that T-bet expression divides influenza-specific MBCs into T-bet-, T-
betlo, and T-bethi populations with differing anatomic localization, residency patterns, and 
antigenic specificity.  Upon infection, all three subsets are initially observed in draining 
lymph nodes, spleen, and infected tissues, whereas T-bethi MBCs are selectively 
maintained in the spleen, remain resident, and are excluded from the lymphatics. In 
addition, B cell receptor sequencing shows that HA-specific T-bet+ and T-bet- MBCs are 
largely clonally distinct, with infrequent sharing of clones. Divergence within clonal 
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lineages, in conjunction with genetic fate-mapping, demonstrates that T-bet expression 
in T-bet+ MBCs is stable.  Finally, we show in mice that T-bet expression in the B lineage 
is required for the development of HA-specific IgG2c and nearly all HA stalk-specific 
antibody. Together, these results establish T-bet expression as a distinguishing feature 
of MBC subsets that have profoundly different homing and functional properties and 
mediate distinct aspects of humoral immune memory.  
3.3 RESULTS 
 
3.3.1 T-bet expression distinguishes unique influenza-specific memory B cell populations 
 
  Prior studies suggested T-bet-expressing B cells are an antigen-experienced 
population, but the functional differences between T-bet+ and T-bet- MBC subsets 
remain unclear. Thus, we set out to define T-bet- and T-bet+ B cell generation and 
persistence using influenza infection in a T-bet-ZsGreen reporter system (275). We 
infected T-bet-ZsGreen reporter mice with 30 TCID50 of influenza A/Puerto Rico/8/1934 
(PR8) and observed weight loss and recovery over a period of 4 weeks post infection, 
with the nadir at 9 days post infection (dpi; Figure S7A). We harvested mediastinal, 
mesenteric, and pooled peripheral (superficial cervical, axillary, brachial, and inguinal) 
lymph nodes (LN), spleen, lungs, and blood from infected mice at multiple time points, 
and identified influenza hemagglutinin (HA)-specific B cells using biotinylated PR8 HA 
probes modified to prevent sialic acid binding (276). The HA probes were separately 
conjugated to two streptavidin-fluorophore conjugates to exclude fluorophore-specific B 
cells during flow cytometric analysis (Figure S7B).  
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 We identified low numbers of HA-specific B cells in lymphoid organs of naïve 
mice, in agreement with previous estimates of the primary HA-responsive repertoire 
(277); these were uniformly T-bet- (Figure S7B). To exclude this primary pool, we 
focused subsequent analyses on IgD- B cells (Figure S7C). IgD- HA-specific B cells 
were detected in spleen, mediastinal LN, and lungs of all mice at both acute infection 
and memory time points (Figure 8A). Examination of T-bet-ZsGreen and CD11c 
expression in HA-specific B cells indicated that T-bet+ B cells can be phenotypically 
subdivided into T-bethi and T-betlo subsets with different tissues being variably comprised 
of T-bet-, T-betlo, and T-bethi subsets across infection (Figure 8A). The T-bethi subset 
contained both CD11c+ and CD11c- cells with a phenotype and level of T-bet expression 
matching Age-associated B Cells (Figure S7C). Furthermore, we confirmed that T-betlo 
B cells expressed increased T-bet mRNA transcripts versus T-bet- B cells (Figure S7D). 
In agreement with prior studies (278, 279), HA-specific B cells were readily 
identified in spleen and mediastinal LN by 7 days post infection (dpi), peaked in number 
and frequency at 15 dpi in spleen and 22 dpi in mediastinal LNs, and then declined to 
steady state numbers in both organs by 40 dpi (Figure 8B). HA-specific B cells were 
occasionally detected in the lungs of some mice as early as day 7, but cell numbers 
peaked in lungs of all mice by 15 dpi and displayed a gradual decline continuing at least 
through 100 dpi (Figure 8B). Small numbers of HA+ B cells were also detected in 
mesenteric and peripheral LNs, but these were dwarfed by spleen, mediastinal LN, and 
lung responses (Figure S7E).  
Our longitudinal analysis of the HA-specific B cell pool identified differential 
induction and maintenance properties for the T-bet-, T-betlo, and T-bethi B cell subsets 
across tissues. The lung HA-specific response was entirely comprised of T-bethi cells at 
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7 dpi; however, HA-specific cells were not detected in lungs of all mice at this time 
(Figure 8B). The lung HA-specific population remained T-bet-dominated throughout 
acute infection but was primarily T-bet- by 100 dpi (Figures 8A and 8B). The majority of 
mediastinal LN HA+ B cells also expressed T-bet at 7 dpi, but T-bethi cells rapidly 
declined by 15 dpi, suggesting rapid tissue exit or differentiation.  T-betlo B cells similarly 
declined by 15 dpi, albeit more slowly, and were nearly undetectable by 100 dpi in this 
tissue.  In accord with possible tissue egress, blood T-bethi cells peaked in frequency by 
22 dpi and rapidly declined to undetectable levels by 40 dpi. In contrast, T-betlo and T-
bethi subsets were consistently maintained in the spleen from 7 to 100 dpi comprising 
27% to 52% (with an average of 37%) of the splenic HA-specific B cell response 
(Figures 8A and 8B). These findings identify early but transient T-bet+ B cell responses 
in lungs and mediastinal LN and suggest T-bet+ HA-specific B cell memory is primarily 
sustained in the spleen. 
We also assessed germinal center B (GCB) cells and MBC marker expression in 
splenic HA-specific cells at each time-point. T-betlo and T-bethi cells were pooled for 
these analyses since they displayed similar memory marker expression throughout 
infection (data not shown). We delineated GCB cells as CD38–GL7+ and presumptive 
MBCs as CD38+GL7– (280) (Figure 8C).   Notably, GL7 expression closely correlated 
with other established GCB markers including CD95 and Peanut Agglutinin (PNA) 
(Figure S7F; data not shown).  At 7 dpi, GL7 was present primarily on T-bet+ cells 
without concomitant CD38 downregulation (Figure 8C), suggesting a pre-GC phenotype 
(281-283).  Nearly all HA-specific cells exhibited a GCB phenotype by 15 dpi and 
maintained this through 22 dpi, at which time an MBC population begins to emerge 
(Figure 8C). At 40 dpi, the majority of T-bet+ cells have a memory phenotype, whereas 
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nearly half of T-bet- cells still maintain GC markers (Figure 8C). Regardless of T-bet 
expression, nearly all splenic HA-specific B cells acquired an MBC phenotype by 100 
dpi. In contrast, GCB cells persisted in the mediastinal LN, and to a lesser extent in the 
lung, out to 100 dpi; however, these were T-bet-. (Figure S7G).  Further analyses of 
splenic MBC-phenotype cells at each time point identified upregulation of the previously 
characterized MBC markers CD80, PD-L2, and CD73 (268) beginning by 15-22 dpi and 
increasing further by 100 dpi, suggesting formation of stable T-bet- and T-bet+ memory 
pools by the latter time point (Figure 8D). We also observed early expression of CD80 in 
CD38+GL7– cells as early as 7 dpi (Figure 8D); these may represent other non-GC cells 
such as extrafollicular plasmablasts, since they were not omitted by our gating strategy. 
These findings indicate that GC and MBC differentiation is similar between T-bet- and T-
bet+ subsets during the influenza response, except the T-bet+ subset loses GC 
characteristics and transitions to a memory phenotype earlier than the T-bet- population. 
Moreover, T-bethi HA-specific MBCs appear to be spleen-compartmentalized upon 








Figure 8. T-bet expression identifies memory B cell populations with unique tissue 
distribution.  
T-bet-ZsGreen reporters were intranasally infected with 30 TCID50 influenza A/Puerto 
Rico/8/1934 (PR8). (A) Fluorescently-conjugated PR8 hemagglutinin (HA) detects HA-
specific (HA+) B cells, and T-bet-ZsGreen expression in HA+ B cells resolves T-bet-, T-
betlo, and T-bethi subsets across tissues at acute (day 15) and memory (day 100) 
timepoints. (B) Number of HA+ B cells in spleen, pooled mediastinal lymph nodes 
(medLN), lungs, and blood at different time points after infection (left column), and 
proportions of HA+ B cells that are T-bet-, T-betlo, and T-bethi in each tissue (right 
column). The number of HA+ B cells in blood was estimated by calculating their 
frequency per 100,000 B cells, and proportions of T-bet-defined subsets in blood were 
calculated after concatenation due to low cell number. (C) Gating scheme identifies 
splenic HA+ GCB cell (GL7+CD38-), MBC (GL7-CD38+), and pre-GC cell (CD38+GL7+) 
subsets; concatenated flow plots (bottom) depict CD38 and GL7 expression of T-bet+ 
(pooled T-betlo and T-bethi; green) and T-bet- (purple) HA+ B cells at each time point 
(bottom). Line plots (top) depict number of HA+ GCB cells and MBCs separated by T-bet 
expression phenotype over time. (D) Expression of memory markers (CD80, PD-L2, 
CD73) in T-bet+ (green) and T-bet- (purple) splenic HA+ MBCs (GL7-CD38+) and naive 
follicular B cells (IgD+; grey). Data in (B) and (C) are compiled from 2 independent 
experiments with at least 3 mice per experiment. Data in (A) and (D) are representative 
of 2 independent experiments with at least 3 mice per experiment. Data in (B) and (C) 
are plotted as mean ± SEM. HA+ B cells were identified as live, singlet, DUMP-, B220+, 





Table I: Number of hemagglutinin-specific B cells after influenza infection 
subset by level of T-bet expression. Related to Figure 8. 
 
Tissue Days p.i. 
T-bet– T-betlo T-bethi 
Average SEM Average SEM Average SEM 
Spleen 
0 199 60 0 0 0 0 
7 565 240 87 29 91 47 
15 63,118 20,498 24,923 5,878 5,874 770 
22 36,188 10,807 10,795 3,649 6,468 2,317 
40 3,077 2,056 565 176 701 224 
100 1,937 532 862 431 603 238 
medLN 
0 14 14 0 0 0 0 
7 146 119 199 167 78 58 
15 4,283 1,339 1,057 271 162 43 
22 13,484 1,735 1,868 956 397 143 
40 5,520 2,050 557 173 104 24 
100 4,740 2,027 105 38 62 15 
Lungs 
0 0 0 0 0 0 0 
7 0 0 0 0 9 6 
15 1,529 885 2,844 1,241 3,798 1,701 
22 1,067 293 990 186 1,137 347 
40 531 215 382 93 87 54 
100 217 112 21 21 42 42 
mesLN 
0 6 6 0 0 0 0 
7 11 5 2 2 0 0 
15 55 27 20 17 5 5 
22 69 16 23 7 39 19 
40 70 23 26 4 26 4 
100 57 17 34 11 7 5 
pLN 
0 8 5 0 0 0 0 
7 15 8 2 2 10 7 
15 48 23 16 13 26 11 
22 50 13 41 6 30 13 
40 30 13 23 8 24 11 






3.3.2 Human T-bethi B cells are an anatomically compartmentalized component of 
influenza-specific memory 
 
The following section on the distribution of human B cell subsets is the work of 
James J. Knox who acquired this data as a PhD student in Michael Bett’s lab and as a 
post-doc in the lab of Michael P. Cancro. 
Having identified discrete influenza-specific MBC subsets with differential tissue 
localization properties in mice, we questioned whether analogous human T-bet-
expressing MBCs show a similar anatomical distribution. In humans, T-bet-expressing B 
cells have been identified alongside T-bet- MBCs in peripheral blood during active viral 
infections and vaccinations, malaria infection, and autoimmune disease (284-288). Since 
T-bethi B cells (CD21-T-bethigh) display a unique trafficking receptor profile 
(CD11c+CXCR3+/-CXCR5lowCD62Llow) compared to classical MBCs (287, 288), we 
hypothesized, as in mice, human T-bethi B cells might have a distinct tissue distribution 
pattern. To test this, we obtained peripheral blood, tonsil, iliac and mesenteric lymph 
nodes, spleen, and bone marrow as donated or discarded surgical tissue and examined 
B cell phenotypes in these tissues (gating in Figure S8A). In agreement with our 
previous study (288), we observed T-bethi B cells in the peripheral blood of all subjects 
(Figures 9A and 9B). We also readily identified T-bethi B cells within spleen and bone 
marrow compartments (Figures 9A and 9B) and confirmed their antigen-experienced 
phenotype in spleen (Figure S8B).  Conversely, T-bethi B cells were largely absent from 
tonsils and both iliac and mesenteric lymph nodes (Figures 9A and 9B).  
These findings suggested restricted trafficking properties of the T-bethi B cell 
subset. To determine whether human peripheral blood T-bethi B cells recirculate through 
tissues, we obtained matched peripheral blood and thoracic duct fluid (chyle) samples 
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from individuals undergoing thoracic duct cannulation. The thoracic duct is the body’s 
largest lymphatic vessel that collects draining lymph from both lymphoid and non-
lymphoid tissues for return to the blood; thus, its contents represent cells undergoing 
lymphatic recirculation. Despite consistent identification of T-bethi B cells in the 
peripheral blood of these individuals, these cells were essentially absent in matched 
thoracic duct fluid (Figures 9C and 9D). In contrast, naïve B cells and various CD21+ 
MBC subsets (IgM+CD27+, IgM-CD27+, and IgM-CD27-) were detected at similar 
frequencies in both peripheral blood and thoracic duct fluid of all subjects, suggesting 
this anatomical compartmentalization is a feature specific to T-bethi B cells, analogous to 
what we had observed in mice (Figures S8C-E).  
We next asked whether T-bet expression per se is associated with tissue 
restriction. We previously identified two distinct populations of T-bet-expressing B cells in 
blood of healthy individuals: T-bethi B cells (CD21-T-bethigh) and T-betlo B cells (CD21+T-
betlow; (288)), which likely correspond to the observed T-bethi and T-betlo MBC pools in 
mice (Figure 8). Here, we extended these findings to show that CXCR3 expression 
enriches for T-betlo cells within the greater CD21+ memory population (Figure 9E). Using 
the CD21+CXCR3+ phenotype, we find that T-betlo B cells are present in human blood, 
thoracic duct fluid, and lymph nodes (Figure 9E), and at similar frequencies between 
matched blood and thoracic duct fluid samples (Figure 9F). Thus, human T-betlo B cells 
recirculate through all lymphoid tissues, while T-bethi B cells are restricted to the spleen, 
blood, and bone marrow in healthy individuals. Further analyses will be necessary to 
determine the relationship between T-betlo and T-bethi B cells; however, we propose that 
these CD21+T-betlo cells represent the human equivalent of the T-betlo B cells observed 
in T-bet-ZsGreen reporter mice (Figure 8). Taken together, these findings identify 
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human T-bethi B cells as a unique, tissue-restricted subset that does not recirculate via 
the lymphatic system. 
Since murine T-bethi HA-specific B cells preferentially populate the spleen at 
memory time points (Figure 8), we next asked whether the human spleen harbors an 
HA-specific T-bethi MBC population. Using fluorophore-conjugated HA probes from two 
distantly-related influenza strains, A/California/07/2009 (H1) and A/Wisconsin/67/2005 
(H3) (276, 289), we assessed T-bet expression by HA-specific class-switched (IgD-IgM-) 
B cells in the spleen (Figure 9G) and mesenteric lymph nodes (Figure S8F). Despite 
our efforts, we were unable to obtain human mediastinal lymph node samples without 
significant blood contamination for analysis of lung-draining lymphoid tissue.  HA-specific 
T-bethi B cells recognizing H1 or H3 strains were identified in the spleens of all donors 
but were rarely detected in mesenteric lymph nodes, whereas T-betloCD21+ and T-bet-
CD21+ HA-specific memory B cells were present in all assessed tissues (Figures 9H-J; 
data not shown). The relative representation of T-bethi B cells within the splenic HA-
specific population varied considerably (~3-80% of H1+ B cells and ~3-53% of H3+ B 
cells; Figure 9I) and positively correlated with age (Figures S8G and S8H). Lastly, we 
assessed the isotype distribution of the human splenic HA-specific MBC compartment 
and found that human IgG1, the analog of murine IgG2a/c, dominated the class-
switched memory response to influenza (Figure 9K; isotype gating in Figure S8I). IgG3+ 
and IgA+ HA-specific cells could be detected at low levels in some donors; however, 
IgG2+ HA-specific B cells were rarely identified (Figure 9K, Figure S8I). Together, these 
findings suggest T-bet expressing B cells are a critical component of human influenza 
HA-specific B cell memory and, as in mice, identify the human T-bethi HA-specific MBC 
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Figure 9. Human T-bethi B cells do not recirculate via the lymphatics and maintain 
influenza-specific memory in the spleen.  
(A) Identification of human CD21-T-bethi B cells within total CD19+ B cells from peripheral 
blood (PB), tonsil, iliac lymph node (iLN), mesenteric lymph node (mesLN), spleen, and 
bone marrow (BM) of representative donors. Different tissue types in (A) or (B) are not 
matched. (B) Frequency of T-bethi B cells in various tissues (n=6 per tissue group). 
Statistics represent comparisons between PB, spleen, or BM with tonsil, iLN, and mLN; 
frequencies within PB, spleen, and BM are not statistically different from one another. 
(C) Identification of T-bethi B cells in matched peripheral blood (PB) and thoracic duct 
fluid (TD) samples from a representative donor. (D) Frequency of T-bethi B cells in 
matched PB and TD samples (n=8). (E) Identification of CD21+CXCR3+T-betlo (blue) and 
CD21+CXCR3-T-bet- (black) subsets of memory (IgD-/IgD+CD27+) B cells in matched PB 
and TD from a representative donor, and mesLN from another donor; T-bet expression 
by these populations is shown as a histogram. Blood T-bethi B cells are included for 
comparison in grey. (F) Frequency of the CD21+CXCR3+ population within PB and TD 
CD19+ B cell pools from an 8-donor cohort. (G) Identification of HA-specific, IgD-IgM- B 
cells within CD19+CD38low splenic B cells using two fluorescently-labelled 
A/California/07/2009 HA probes (H1 strain) or a single fluorescently-labelled 
A/Wisconsin/67/2005 HA probe (H3 strain). (H) CD21 and T-bet expression in IgD-IgM-
HA+ B cells in spleens and mesLNs from representative donors using H1 or H3 probes. 
(I) Frequency of T-bethi phenotype within IgD-IgM-H1+ or H3+ B cells in spleens from two 
10-donor cohorts and mLN from a 6-donor cohort. (J) T-bet MFI of splenic naïve 
(IgD+CD27-) B cells and switched (IgD-IgM-) H1-HA-specific CD21+ and CD21-T-bethi B 
cells from a representative donor. (K) Frequency of isotype expression within human 
splenic IgD-IgM-HA+ B cells (n=6). Statistical comparisons performed using one-way 
ANOVA with Tukey post-test (B), paired t-test (D and F), unpaired t-test (I), and 
repeated measures ANOVA with Tukey post-test (K). Lines depict mean ± SEM. N.S. = 
not significant, *p<0.05; **p<0.01; ***p<0.001. Credit goes to James J. Knox for 




3.3.3 T-bethi HA-specific memory B cells are resident in the spleen 
 
 The apparent splenic localization of T-bethi HA-specific MBCs in both mice and 
humans led us to rigorously assess tissue residency using a parabiosis-based approach.  
Thus, T-bet-ZsGreen reporter mice infected ≥ 40 days prior with PR8 were surgically 
joined to naïve congenic B6.SJL partners. We reasoned that all HA-specific MBC will 
originate in the T-bet-ZsGreen partner, so their presence in the B6.SJL partner would 
indicate that they are a recirculating population. Conjoined mice were monitored by 
serial bleeds to assess the portion of circulating CD45.2+ (T-bet-ZsGreen reporter origin) 
versus CD45.1+ (B6.SJL origin) B cells in each partner. Both partners demonstrated 
mixing of CD45.1+ and CD45.2+ B cells in the blood as early as day 7, achieving stable 
proportions between the partners by day 14 (Figure 10A). Accordingly, parabiosed pairs 
were euthanized ≥ 17 days post-surgery. We observed similar frequencies of 
CD45.2+IgD+ B cells – a pool anticipated to circulate freely – in spleen, lungs, and 
mediastinal lymph nodes of each partner (Figure 10B), suggesting equilibration of 
recirculating B cells by day 17.  
HA-specific MBCs were observed in the spleens of both partners, and virtually all 
of these were CD45.2+ (Figure 10C), consistent with their origin in the previously 
infected T-bet-ZsGreen partner.  T-bet- and T-betlo HA-specific B cells were identified in 
the spleens of both partners, suggesting these subsets recirculate (Figures 10D-F, 
Figure S9A). In contrast, T-bethi HA-specific MBCs were absent from the naïve B6.SJL 
partner spleens but remained in spleens of previously infected T-bet-ZsGreen mice 
(Figures 10E, 10F, S9A), even when data were concatenated from 7 parabiotic pairs 
(Figure 10D).  To confirm that ZsGreen-expressing cells were not being rejected in the 
B6.SJL mice, we measured frequencies of donor T-bet-ZsGreen+CXCR3+CD8+ 
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lymphocytes, which highly express the ZsGreen protein, and found similar frequencies of 
these cells in both partners (Figure S9B).  Moreover, T-betlo HA-specific B cells were 
also present in spleens of both mice (Figures 10D and 10E).   Thus, broad rejection of 
ZsGreen+ cells is not occurring, consistent with previous studies (290).  Taken together, 
these findings identify splenic T-bethi HA+ MBCs as a tissue-resident memory pool.  
We also investigated whether HA-specific B cells showed evidence of residency 
in mediastinal LNs and lung, the other primary locations of influenza memory cells, as 
others recently demonstrated (291). We identified significant HA-specific B cell numbers 
in mediastinal LNs of the previously infected partner that were absent in the naïve 
partner (Figure 10G). We suspect this reflects the extended maintenance of HA-specific 
GCs in mediastinal LNs, as the local HA-specific B cell population retains a GC 
phenotype at least through 100 dpi (Figure S7G). This phenomenon appears to be 
mediastinal LN-specific, as HA-specific GC B cells were not identified at this late time 
point in any other lymphoid tissues examined. We also identified HA-specific MBCs in 
the lungs of the previously infected partner (Figure 10H), but these cells were absent in 
the naïve partner. Notably, nearly all mediastinal LN- and lung-localized cells were T-bet- 
(Figures 10I-J). Thus, HA-specific memory is anatomically compartmentalized, 
encompassing tissue-resident T-bethi B cells in the spleen and circulating T-bet- and T-







Figure 10. T-bet expression resolves spleen resident versus recirculating MBC 
pools. 
(A). T-bet-ZsGreen reporters (CD45.2+; ≥ 40 dpi) and naïve B6.SJL (CD45.1+) were 
surgically conjoined and showed evidence of blood sharing by day 7, with equilibrium 
reached by day 14. Parabionts were euthanized at ≥ 17 days post-surgery for analysis. 
(B) Frequencies of naïve follicular (IgD+) B cells expressing CD45.2 in lymphoid and 
non-lymphoid tissues from each parabiosis pair. (C) Identification of HA+IgD- B cells 
expressing either CD45.1 or CD45.2 in parabiosis partners. (D) Identification of T-bet-
ZsGreen reporter-derived (CD45.2+) T-bet-, T-betlo, and T-bethi HA+ MBCs in spleens of 
T-bet-ZsGreen and B6.SJL partners; data concatenated from 7 pairs. (E) Numbers of T-
bet-, T-betlo, and T-bethi HA+ splenic MBCs in T-bet-ZsGreen (red) and B6.SJL (black) 
partners. (F) Percentage of splenic HA+ MBCs that are T-bet-, T-betlo, or T-bethi in each 
partner. (G and H) Number of HA+ MBCs in medLN (G) and lungs (H) of parabiosis 
partners. (I and J) T-bet-ZsGreen expression in HA+ MBCs from medLN (I) and lungs (J) 
of T-bet-ZsGreen partner. HA+ MBCs were not detected in the medLN or lung of the 
B6.SJL partner. Data displayed are from 8 pairs across three independent experiments 
for spleen and 4 pairs across two-independent experiments for medLN and lungs. HA+ B 
cells were identified as live, singlet, DUMP-, B220+, CD19+, CD45.2+, IgD-, HA-BV421+, 
HA-AF647+ cells. Data in (E), (F), (G), and (H) show individual points with the mean ± 
SEM indicated. Statistical comparisons performed using paired two-tailed t-test. ns = not 
significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.001  
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3.3.4 Established T-bet+ and T-bet- memory B cells undergo minimal interconversion 
 
The different residency and recirculation properties of T-bet- and T-bet+ MBCs 
raised the question of how T-bet- and T-bet+ MBCs arise.   We considered four 
possibilities (Figure S10A):  1) T-bet- and T-bet+ MBCs arise independently and are 
stable, separate subsets; 2) T-bet+ cells give rise to T-bet- cells (or vice versa); 3) T-bet+ 
and T-bet- cells undergo shared selection followed by stable commitment to either a T-
bet+ or T-bet- long-lived MBC population; 4) T-bet+ and T-bet- MBCs interconvert by 
modifying T-bet expression as needed to change localization or functional properties. 
Immune repertoire profiling of antibody heavy chain variable region gene (VH) 
rearrangements can be used to distinguish between these four models, as each model 
makes distinct predictions regarding differences in VH usage (model 1), somatic 
hypermutation (model 2) and clonal overlap (models 3 and 4; Figure S10A). 
We therefore sequenced VH rearrangements of HA-specific MBCs separated by 
T-bet expression (Figure S10B) in T-bet-ZsGreen reporter mice immunized 
intradermally with 30 μg of lipid nano particles (LNP) loaded with HA mRNA (292). The 
LNP platform generates both T-bet- and T-bet+ MBCs (Figure S10B), and we confirmed 
an HA-antibody response by hemagglutination inhibition (Figure S10C). At 90 days post 
immunization, all splenic IgD- HA-specific B cells were sorted based upon T-bet-ZsGreen 
expression into T-bet- and T-bet+ memory subsets, and antibody VH rearrangements of 
both subsets and IgD+ naïve follicular control B cells were sequenced. Similarly, we used 
the CD21-CD85jhi surface phenotype, which specifically identifies human T-bethi B cells 
(288), to sort human splenic HA-specific IgD-IgM- MBCs into CD21-CD85jhi and CD21+ 
subsets (Figure S10D) and sequenced the VH rearrangements of these populations 
along with control bulk splenocytes.  
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VH analysis revealed comparable VH usage (Figures S10E and S10F) and 
CDR3 length distributions (Figures 11A and 11B) in T-bet+ and T-bet- populations, and 
there was some clonal overlap between the two populations (Figures 11C and 11D), 
ruling out a strict separate lineage model (model 1).  T-bet+ and T-bet- MBCs harbored 
similar levels of somatic hypermutation, suggesting that one population was not a 
precursor to the other (model 2), and both populations showed significantly more 
mutations than naïve B cells or unsorted splenocytes (Figures 11E and 11F).  
Next, we scrutinized the lineage trees of clones that contained T-bet+ and T-bet- 
members. In mice, overlapping clones between T-bet+ and T-bet- populations were not 
as frequent as they were within replicate sequencing libraries from the same subset 
(Figure S10G), suggesting that many T-bet+ and T-bet- clones arise independently, 
rather than being fully intermingled. The same clonal analysis in humans did not reach 
statistical significance, likely due to our restricted sample size – we sampled a small 
portion of the spleen and therefore missed many clonal members (Figure S10H). In 
further support of this separation, analyses of mouse clonal lineages containing both T-
bet+ and T-bet- cells revealed that nearly all exhibited segregation of T-bet+ and T-bet- 
sequences onto separate branches (Figure 11G). Taken together, these findings in mice 
following immunization and in established HA+ MBCs in human spleen favor model 3, in 
which T-bet+ and T-bet- MBC precursors undergo shared selection, subsequently commit 
to a T-bet+ or T-bet- MBC population, and thereafter remain stable with respect to T-bet 
expression status, with minimal, if any, interconversion between established T-bet+ and 
T-bet- MBCs. 
To further verify the stability of T-bet+ B cells, we used a combined reporter/fate 
mapper mouse (293).  These T-bet-sufficient mice contain the ZsGreen construct fused 
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to creERT2 under control of the T-bet promoter, such that treatment with tamoxifen during 
active T-bet transcription causes irreversible tdTomato expression.  Using these mice, 
one can delineate cells that expressed T-bet during the tamoxifen treatment period and 
have subsequently lost expression (tdTomato+T-bet-ZsGreen-) from those that retained it 
(tdTomato+ZsGreen+). We treated ≥ 20-week-old T-bet-ZsGreen/tdTomato mice with 
tamoxifen on days 0, 2, and 4 and performed serial bleeds to assess stability of 
tdTomato+ZsGreen+ B cells. All mice demonstrated tdTomato labeling at day 10, with T-
bet+ cells outnumbering T-bet- cells 10:1 within the tdTomato+ B cell population (Figure 
11H). The ratio of T-bet+ to T-bet- cells was maintained steadily in all mice (Figure 11H), 
suggesting most B cells expressing T-bet at day 0 maintained expression for 40 days, 
interconverting rarely if at all during this period. In combination with our clonal overlap 
and lineage tree analyses, these data show that established T-bet+ MBCs represent a 








Figure 11. T-bet+ and T-bet- MBCs are selected from a shared pre-immune lineage 
but do not interconvert.  
HA-specific splenic MBCs from T-bet-ZsGreen reporters (day 100 post immunization) 
were sorted into T-bet- and T-bet+ subsets, with naïve follicular (IgD+) B cell controls, for 
immunoglobulin heavy chain genomic sequencing. Human HA-specific splenic MBCs 
were similarly sorted into CD21+ and CD21-CD85jhi subsets; CD21-CD85jhi phenotype 
identifies human T-bethi B cells (288) subsets. (A) CDR3 lengths (in nucleotides) of in-
frame sequences from murine T-bet- and T-bet+ HA+ MBCs and naïve follicular (IgD+) B 
cell controls after all replicates were pooled. (B) CDR3 lengths of in-frame sequences 
from CD21+ and CD21-CD85jhi HA+ MBC subsets were quantified (in nucleotides). Bulk 
splenocytes (largely naive follicular B cells) served as a control. (C) The number of 
clones that overlap between T-bet- (blue) and T-bet+ (red) HA+ MBCs in mouse (M. mus, 
MM). (D) The number of clones that overlap between CD21+ (blue) and CD21-CD85jhi 
(red) HA+ MBCs in humans (H. sap; HS). (E) Percentages of clones binned by the level 
of somatic mutation (expressed as the percent difference in nucleotide sequence to the 
nearest germline VH gene) in mouse T-bet- and T-bet+ HA+ MBCs and naïve follicular B 
cells. (F) Percent of the heavy chain V-gene that is mutated from germline in CD21+ and 
CD21-CD85jhi HA+ MBCs and bulk splenocytes in humans. (G) Representative lineage 
trees of shared clones between T-bet- and T-bet+ HA+ murine MBCs, with inferred nodes 
(black), T-bet- nodes (blue), and T-bet+ nodes (red). Trees were generated in ImmuneDB 
and visualized with ETE3 (see Methods). Lineages had to contain at least 10 copies of 
T-bet+ and T-bet- and have at least 4 trunk mutations (shared SHMs) to be included. 
Numbers indicate the number of mutations compared to the preceding vertical node. The 
inferred node at the top of the tree indicates the nearest germline sequence. (H) T-bet-
ZsGreen fate-mapping mice (293) were treated with tamoxifen to mark T-bet expressing 
cells with permanent, Rosa21-driven, tdTomato expression and the status of T-bet 
expression of marked B cells in the blood was tracked over 40 days. For panels (A), (C), 
(E), and (G), two independent experiments were carried out with at least 4 mice per 
group. Each gave similar results, and the results for the more recent experiment are 
shown. For panels (B), (D), and (F), the splenocytes from 4 adult subjects were sorted 
and sequenced. For genetic fate mapping (H), two independent experiments were 
carried out with at least 4 mice per group; one experiment is shown here. 
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3.3.5 HA stalk-specific antibody is derived primarily from the T-bet-expressing B cell 
compartment 
 
The distinct localization and phenotypic stability of T-bet+ HA-specific MBCs led 
us to assess the contribution of the T-bet-expressing B cell compartment to the influenza 
humoral response.  In mice, T-bet promotes antibody class-switching to IgG2a/c (294-
301), the dominant isotype in influenza and other anti-viral responses (298, 302). In 
accordance with this, we observed a greater increase in PR8-specific and HA-specific 
IgG2c (Figures 12A and 12B) compared to IgG1, evident by day 12 and 15, 
respectively. This isotype bias confirmed previous studies (279) and suggested a key 
role for T-bet in regulating influenza antibody production (303). Therefore, we tested the 
contribution of T-bet in the B lineage to HA-specific humoral responses by infecting B 
cell-specific conditional T-bet knockouts (T-betflox/flox CD19Cre/WT; hereafter referred to as 
cKOs), CD19-Cre controls (CD19Cre/WTT-betWT/WT), and wild type mice with PR8 and 
examined antibody levels and characteristics. All three groups showed similar weight 
loss kinetics (Figure 12C), total HA-specific B cell numbers (Figure 12D), and HA-
specific GCB cell numbers (Figure 12E), although CD19-cre controls recovered weight 
more quickly (Figure 12C).  As such, CD19 heterozygosity does not appear to 
significantly impair the influenza response, and initiation of the humoral response does 
not require T-bet expression in B cells.  
To assess the functionality of antibodies generated in the absence of B lineage 
T-bet expression, we performed hemagglutination inhibition (HAI) assays from serum. At 
15 dpi, the majority of mice displayed HAI titers greater than 40, the level associated in 
human studies with protection (304, 305), although one wild type and several cKO mice 
had titers ranging from 20 to undetectable (Figure 12F). HAI titers declined in all groups 
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by 40 dpi (Figure 12F), likely due to the loss of acute infection-generated IgM titers 
(302). However, cKOs displayed significantly reduced HAI titers versus the wild type and 
CD19-Cre groups at 40 dpi, with 70% of mice showing titers below 40 (Figure 12F). 
These findings suggest T-bet expression in B cells may be necessary for the 
development of sustained protective influenza-specific titers. 
We hypothesized that decreased HAI titers in cKOs may reflect a loss of specific 
components of the antibody response. We next assessed antibody titers and found a 
significant reduction in total PR8-specific IgG2c in cKOs, as expected (Figure 12G). Low 
IgG2c titers remained in cKOs at 15 dpi but were nearly absent by 40 dpi, suggesting T-
bet-independent mechanisms can initiate a degree of IgG2c switching during acute 
infection (Figure 12G). We focused subsequent analyses on the HA protein, the 
antigenic target relevant for protective humoral immunity to influenza and identified 
significantly reduced IgG2c titers to full-length HA in cKOs at both 15 and 40 dpi 
compared to wild type and CD19-Cre control groups (Figure 12H). PR8- and HA-
specific titers of IgG1, a T-bet-independent isotype, were unaffected in cKOs and did not 
increase to compensate for IgG2c loss (Figures 12G and 12H). These findings confirm 
that the majority of HA-specific IgG2c antibody is derived from T-bet-expressing B cells.  
Lastly, we questioned whether T-bet expressing B cells are important for 
influenza antibody responses to certain specificities. Recent studies highlight a critical 
role for HA-specific IgG2a/c antibodies for in vivo influenza protection, which are 
primarily skewed toward stalk recognition (306, 307). Thus, we assessed stalk reactivity 
of IgG1 and IgG2c using a chimeric construct comprised of the PR8-related H1 stalk and 
unrelated H6 head (308-310). This chimera is bound primarily by stalk-specific 
antibodies since most PR8-generated HA head-binding antibodies are strain-specific 
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and do not recognize H6 head. We found that the stalk response is dominated by IgG2c 
in wild type mice at both 15 and 40 dpi, while IgG1 stalk titers were negligible (Figure 
12I). Moreover, cKOs largely lost IgG2c stalk-reactive titers (Figure 12I), indicating that 






Figure 12. T-bet+ B cells are required for optimal influenza antibody responses and 
HA stalk-specific antibody in mice. 
(A and B) Total betapropiolactone (BPL)-inactvated PR8-specific IgG1 and IgG2c (A) 
and PR8 hemagglutinin (HA)-specific IgG1 and IgG2c (B) in sera from infected T-bet-
ZsGreen mice over time. (C). Weight loss and recovery from influenza infection in wild 
type C57Bl/6, CD19cre/WTT-betfl/fl, and CD19cre/WT mice compared to PBS-treated controls. 
(D) Number of HA-specific splenic B cells at day 15 and 40 dpi. (E) Number of HA-
specific splenic GCB cells at 15 dpi. (F) Hemagglutination inhibition (HAI) titers at 15 and 
40 dpi. (G-I) Antibody titers to BPL-inactivated PR8 (G), full-length PR8-HA (H), or 
chimeric construct comprised of H1 stalk and H6 head (I). Wild type C57Bl/6 were used 
for naïve controls in (F-I). Data are represented as mean ± SEM from 3 independent 
experiments with at least 3-5 mice in each group. Statistical comparisons performed 
using two-sided t-test (G-I) and Wilcoxon rank-sum test (F). *p<0.05, **p<0.01, 
***p<0.001. Cells in (D, E) were identified as DUMP-, CD19+, B220+, CD138-, IgD-, HA-






























































































































































































Table II: Serum antibody titers to various influenza antigens after infection. Related to Figure 12. 
 
Antigen Isotype Day 15 p.i. Day 40 p.i. 
(μg/mL) CD19cre/WT CD19cre/WTTbetfl/fl C57Bl/6 CD19cre/WT CD19cre/WTTbetfl/fl C57Bl/6 
BPL-PR8 
IgG2c 45.1 ± 8.7 14.0 ± 5.4 37.5 ± 2.6 12.7 ± 1.8 2.6 ± 0.5 18.6 ± 6.5 
IgG1 8.2 ± 0.7 4.8 ± 0.8 5.8 ± 0.7 11.7 ± 3.2 8.9 ± 2.4 14.7 ± 3.2 
                            
HA IgG2c 13.6 ± 2.4 2.8 ± 0.9 8.5 ± 0.7 8.5 ± 1.3 0.8 ± 0.4 8.3 ± 3.5 
IgG1 0.9 ± 0.3 0.5 ± 0.2 0.9 ± 0.2 1.1 ± 0.3 2.1 ± 0.7 2.7 ± 0.5 
                            
HA-stalk IgG2c 1.5 ± 0.4 0.2 ± 0.1 1.2 ± 0.3 0.6 ± 0.2 0.1 ± 0.0 1.2 ± 0.5 
IgG1 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.1 0.1 ± 0.0 0.0 ± 0.0 






Our study reveals multiple MBC subsets delineated by T-bet expression, whose 
distinct phenotypic and functional attributes are shared by mice and humans. T-bet 
expression status divides MBCs by anatomic localization and residency, as well as 
effector function and epitope specificity. Thus, T-bet- and T-betlo MBCs originate in all 
secondary lymphoid tissues and freely recirculate, whereas T-bethi MBCs reside in the 
spleen and are excluded from the lymphatics.  Further, clonal and in vivo lineage tracing 
analyses show that while T-bet+ and T-bet- MBCs likely arise from common pre-immune 
pools, they diverge after antigen encounter and thereafter remain as separate and stable 
pools.  Finally, we show that the development of mouse IgG2c HA- and HA stalk-specific 
antibodies, as well as durable neutralizing titers, require T-bet expression in the B 
lineage. Taken together, these findings show that T-bet expression is a conserved 
feature of an MBC subset with differential circulatory properties, tissue-residency, and 
epitope specificity.  
Pathogen-driven responses generate both isotype-switched and unswitched T-
bet expressing B cells (301, 311, 312), but detailed analyses of the generation, fate and 
anatomic characteristics of T-bet+ B cells have not been conducted. Our results formally 
demonstrate antigen-mediated and antigen-specific generation of T-bet+ GC B cells 
during viral infection, followed by the establishment of somatically mutated, antigen-
specific T-bet+ and T-bet- MBC pools whose numbers are maintained indefinitely. 
Consistent with memory character, both T-bet+ and T-bet- HA-specific B cells express 
the MBC markers CD73, CD80 and PD-L2 with kinetics similar to those in hapten-carrier 
responses (280). Despite these surface phenotypic similarities, our clonal analyses and 
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genetic fate-mapping experiments suggest it is unlikely that a progenitor-successor 
relationship exists, or that frequent interconversion occurs, between T-bet+ and T-bet- 
MBCs. Thus, while T-bet+ and T-bet- MBCs both result from antigen-driven naïve B cell 
activation, they most often arise independently and remain distinct, rather than 
representing different stages in a common differentiation pathway. In addition, the role 
for these HA-specific MBC subsets in recall responses remains an open question.  
Rechallenge studies in multiple mouse models have found that both CD80+PD-L2+ 
MBCs and HA-specific MBCs preferentially differentiate into early antibody-secreting 
cells (ASCs) as opposed to re-entering germinal centers following antigen encounter 
(268). These studies suggest that T-bet+ MBCs are primed for ASC differentiation, but 
what influence T-bet has on this fate decision compared to T-bet independent factors 
such as receptor affinity remains to be determined.  
Our tissue distribution analyses indicate that memory B cells are anatomically 
compartmentalized: T-bet- and T-betlo MBCs are found in all secondary lymphoid 
tissues, whereas T-bethi MBCs are primarily in the spleen, blood, and bone marrow. 
Parabiosis experiments further confirmed that established influenza-specific T-bethi 
MBCs neither exit the spleen to populate the lymphatic system, nor home to the spleen 
from blood or other anatomical locations.  However, T-bethi B cells were identified 
transiently in mediastinal LN and lungs early after infection, suggesting T-bethi B cell 
generation can occur outside the spleen. We have previously reported the critical role of 
innate sensors, such as nucleic acid sensing Toll-like receptors (TLRs), and common 
gamma chain cytokines in regulating T-bet+ B cell fate (274). Thus, the generative 
signals for T-bet expressing B cells are not spleen-specific per se, and the differential 
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anatomic distribution of established T-bethi MBCs is not an immediate consequence of 
early antigen encounter specifically within the spleen.  
Chemokine receptors and integrins regulate the anatomic distribution of immune 
cells and may contribute to T-bethi B cells’ characteristic localization properties. Studies 
examining human peripheral blood samples found that T-bet+ B cells express the integrin 
CD11c, the chemokine receptor CXCR3, and low levels of CXCR4, CXCR5, and CCR7, 
chemokine receptors associated with homing to lymphoid organs (285, 287, 313). Thus, 
the specific combination of these and other surface receptors may impede lymphatic 
entry and help recruit T-bethi B cells to the spleen. Via mechanisms that are unclear, T-
bethi B cells also appear to enter the blood following activation or recent tissue egress. 
Consistent with this idea, we observed early loss of HA-specific T-bethi B cells in the 
mediastinal LN and lungs in infected mice, coupled with a temporary wave of HA-specific 
T-bethi B cells in blood, and we previously described an increase in peripheral blood HA-
specific T-bethi B cells following influenza vaccination in humans (314). While they are 
normally absent from the lymphatics, recent evidence suggests consistent viremia 
and/or chronic immune activation may be able to override T-bethi MBC 
compartmentalization: lymphoid tissue infections with pathogens such as HIV and 
Toxoplasma gondii are associated with a local enrichment of T-bet-expressing B cells in 
lymph nodes (315, 316).  
The splenic residency associated with T-bethi MBCs leads to some intriguing 
possibilities regarding the role of T-bet+ MBCs in immune surveillance.  While tissue 
residency may be critical to protect from local reinfection, this role seems unlikely for 
spleen-resident HA-specific T-bethi MBCs, inasmuch as influenza is a respiratory 
infection and the virus is not known to replicate in the spleen (317).  Instead, T-bethi 
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splenic resident MBCs may be uniquely positioned to support broad immune 
surveillance and rapidly produce antibody for systemic dissemination upon reinfection. In 
support of this notion, T-bet+ B cells express elevated quantities of BLIMP-1 (287) and, 
when isolated from the blood of SLE patients, quickly differentiate into plasma cells upon 
TLR7 stimulation without obligate division (318). It is tempting to speculate that 
circulating T-betlo B cells are short-lived cells derived from a stationary, self-renewing T-
bethi population; indeed, the possibility of self-renewal and multipotency of T-bet+ MBCs 
has been reported by others (311), and our findings confirm that T-bet+ MBCs are a 
persistent population. Alternatively, T-betlo B cells might be a stable and persistent 
population with separate maintenance requirements from the T-bethi subset.  These 
possibilities are not mutually exclusive and resolving their relative merits and 
contributions will require examination of the turnover rates and clonal composition of 
these MBC subsets.  
Given the striking parallels between human and mouse T-bet+ MBCs, we 
propose that T-bet expression is a conserved divisor for memory B cell subsets, and that 
the relative contributions of T-bet+ vs T-bet- memory B cells to various aspects of 
humoral immunity merits detailed investigation.  Importantly, in addition to their 
differences in anatomic localization, T-bet+ and T-bet- B cells differ in the quality and 
specificity of antibodies they generate. Our studies with conditional knockout mice show 
that T-bet drives influenza-specific IgG2c production to HA and the HA stalk. It is 
tempting to speculate that these subsets could differentially contribute to 
immunodominance, cross-reactivity, or original antigenic sin, and may thus play distinct 
roles in immune responses to heterologous challenges. The loss of the IgG2c 
component of anti-influenza responses in cKOs suggests a link between T-bet+ MBCs 
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and influenza-specific antibody production; however, the direct contribution of these 
established memory cells to antibody titer maintenance is unclear, as are the 
implications of tissue-restriction. T-bet+ B cells are known to arise post influenza 
vaccination in humans (287, 314, 319); therefore, based on recent interest in developing 
HA-stalk-reactive vaccines for broad protection against influenza, we posit that focusing 
vaccine design efforts on driving T-bet expression in HA-specific B cells and maintaining 
this population long-term might lead to the development of more effective prophylactic 
agents and vaccination regimens for influenza.  
3.5 MATERIALS AND METHODS 
 
Mice: C57BL/6 and B6.SJL (10-12 weeks old, females, purchased from The Jackson 
Laboratory) T-betflox/flox CD19Cre/WT (from the laboratory of E. John Wherry, University of 
Pennsylvania) and T-bet-ZsGreen (as previously reported (275)) were maintained and 
used in accordance with the University of Pennsylvania Institutional Animal Care and 
Use Committee guidelines.  
Infections: Mice were infected by intranasal infection with 30 tissue culture infectious 
dose50 (TCID50) of influenza strain A/Puerto Rico/8/1934 (PR8; American Type Culture 
Collection).  
Human samples: All study participants provided written informed consent. Tissue 
samples were collected with IRB approval at the University of Pennsylvania (809316; 
815056; 822686) and Case Western Reserve University (10-09-12). Human peripheral 
blood mononuclear cell samples were obtained from the University of Pennsylvania 
Human Immunology core. Human bone marrow mononuclear cell samples were 
obtained from the University of Pennsylvania Stem Cell and Xenograft core. Paired 
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blood and thoracic duct fluid samples were obtained from individuals with idiopathic or 
trauma-based chylopericardium or chylothorax requiring intervention at the Hospital of 
the University of Pennsylvania. Lymphoid tissue samples (mesenteric lymph node, iliac 
lymph node, tonsil, and spleen) were obtained at the Hospital of the University of 
Pennsylvania and Case Western Reserve University: mesenteric and iliac lymph nodes 
were obtained during abdominal surgery and kidney transplant surgery, respectively. 
Non-enlarged tonsils were obtained from sleep apnea patients. Spleens were removed 
and obtained due to trauma or surgical intervention. Additional spleen samples were 
obtained from the Human Pancreas Analysis Program (HPAP) at the University of 
Pennsylvania. Mononuclear cells were mechanically separated from solid tissues and 
enriched using a ficoll gradient. 
Parabiotic surgery: Age-matched T-bet-ZsGreen reporters and B6.SJL adult female 
mice were conjoined as described previously (320). Briefly, a skin incision was made 
from the olecranon to the knee of each of the mice to be joined. The elbows and knees 
of the two paired mice were then tied together with surgical suture, followed by 
connecting of the skin with surgical sutures and staples. For pain control, mice were 
given buprenorphine (0.1 mg/kg every 6 hours for 36 hours) and meloxicam (5 mg/kg 
every 12 hours for 72 hours) and provided with sulfamexathole (400mg/L) and 
trimethoprim (800mg/L) antibiotics in their drinking water to prevent infection. Mice were 
monitored for signs of pain, infection, or damage to sutures. Blood was periodically 
drawn from the tail to check for anastomoses, which appeared complete by d14, 
therefore, mice were euthanized at day 17. The spleen was harvested from both 
partners for all pairs, and the lungs and mediastinal lymph nodes were also collected 




Flow cytometry: Flow cytometry reagents were purchased from BioLegend (BL), BD 
Biosciences (BD), eBioscience (eBio), Southern Biotech (SB), or Invitrogen (Inv). The 
following antibodies were used for mouse studies: T-bet (4B10; BL), CD11c (N418; BL), 
IgM (R6-60.2; BD), CD38 (90; eBio), CD73 (TY/11.8; BL), CD80 (16-10A1; BD or BL), 
PD-L2 (TY25; BL), CD138 (281-2; BL), IgD (11–26c.2a; BL), B220 (RA3-6B2; BL or 
eBio), CD19 (1D3; BD or eBio), CD19 (6D5; BL) peanut agglutinin–FITC (Sigma), 
CD45.1 (A20; BL), CD45.2 (104; BL), CD183/CXCR3 (CXCR3-173; BL) and CD3 (17A2; 
BL). DUMP gate comprised CD8 (53-6.7; eBio), CD4 (H129.19; BL), F4/80 (BM8; eBio), 
Ly-6G/GR1 (RB6-8C5; eBio). The following antibodies were used for human studies: 
CD38 (HIT2; BL), CD85j (GHI/75; BD; HP-F1; eBio), T-bet (4B10; eBio and BL), IgM 
(MHM-88; BL), IgD (IA6-2; BD), CD10 (CB-CALLA; eBio), CD27 (O323; BL), CXCR3 
(G025H7; BL), IgG (G18-145, BD), CD21 (Bu32, BL; B-ly4, BD), CD19 (HIB19, BL), CD3 
(UCHT1, BL), CD14 (MÆP9, BD), CD16 (3G8, BD), CD11c (3.9, eBio), Bcl-6 (K112-91, 
BD), Ki67 (56, BD), IgG1 (HP6069, Inv), IgG2 (HP6002, SB), IgG3 (HP6050, SB), and 
IgA (polyclonal, Inv). For detection of murine influenza-binding B cells, recombinant HA 
PR8 (276) was obtained from the laboratory of Dr. Barney Graham, National Institute of 
Allergy and Infectious Disease, biotinylated, and conjugated to streptavidin-fluorophores 
as previously described (276), or was directly conjugated using the R-phycoerythrin 
conjugation kit from Abcam (catalog ab102918) as per manufacturer’s instruction. 
Human HA-specific B cell staining was performed using A/California/07/2009 and 
A/Wisconsin/67/2005 HA probes prepared as previously described (276, 289). Mouse 
samples were prepared for flow cytometry as follows: Mouse Fc fragment (Jackson 
ImmunoResearch; 015-000-008) was added to all staining cocktails at a final 
concentration of 1:200. Mouse spleens were homogenized, on ice, in staining buffer 
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(PBS + 0.5%BSA + 2mM EDTA) and passed through nylon mesh (50μM) to obtain 
single cell suspension. Red blood cells were lysed using ACK lysing buffer (Lonza, cat 
10-548E) as per manufacturer’s instructions. Cells were washed with PBS and stained 
as described previously(271, 274). Live/dead discrimination was done using Zombie 
Aqua fixable viability kit (BL). Prior to T-bet staining, cells were fixed and permeabilized 
using eBioscience™ Foxp3 / Transcription Factor Staining Buffer Set, at 4°C for 45min-
1hr. Human samples were prepared for flow cytometry as previously described (288). 
Data were acquired on BD LSR II flow cytometer and FACS analyses were performed 
using FlowJo v9 and v10 (Becton Dickinson Co., Ashland, OR). 
 
Serum antibody titers: Serum was harvested by spinning whole blood at 13000g for 10 
minutes and stored at -20°C until use. Antibody titers were assessed using ELISA as 
previously described(271, 274) with the following modifications: 96-well medium-binding 
plates were coated with either 20HAU/well of BPL-inactivated PR8, 2 μg/mL of PR8 HA, 
or 2 μg/mL of H6/H1 chimeric constructs (expressed in baculovirus system as previously 
described (321)). HA-specific monoclonal antibodies (from Dr. Jonathan Yewdell, 
National Institute of Allergy and Infectious Diseases) were used as standards to 
determine concentration of IgG1 and IgG2a/c. Standards were used at a starting 
concentration of 100 ng/mL for IgG2a and 10 ng/mL for IgG1 and diluted 2-fold across.  
 
HAU (hemagglutination unit) and HAI assays: Viral HAU titers were determined 
before every HAI assay. All dilutions were prepared in PBS. 50 μL diluted virus, 50 μL 
heat-inactivated sera and 12.5 μL of 2% turkey erythrocytes were used per well for all 




Starting with a 1:100 dilution of live virus, 2-fold dilutions were mixed with 2% turkey 
erythrocytes (Lampire biologicals) and incubated for 1 hour at room temperature. 
Agglutination dose (AD) was determined at the end of the incubation period, and 
confirmed by repeating the process with a 2-fold dilution series of virus, ranging from 
4AD to 0.25 AD. This dose was subsequently used for the HAI assay. 
 
Sera were heat-treated at 55°C for 30 minutes, diluted 2-fold in PBS (staring dilution 
1:20), mixed with 4AD and 2% turkey erythrocytes, and incubated as for HAU assay. 
HAI titers are expressed as inverse of the highest dilution that inhibited agglutination. 
 
mRNA production: The sequence of the Puerto Rico/8/1934 influenza virus 
hemagglutinin (pTEV-PR8 HA-A101) was codon-optimized, synthetized and cloned to 
the mRNA production plasmid. The mRNA was produced using T7 RNA polymerase 
(Megascript, Ambion) on linearized plasmids. The mRNA was transcribed to contain 101 
nucleotide-long poly(A) tails. One-methylpseudouridine (m1Ψ)-5’-triphosphate (TriLink) 
instead of UTP was used to generate modified nucleoside-containing mRNA. Capping of 
the in vitro transcribed mRNAs was performed co-transcriptionally using the trinucleotide 
cap1 analog, CleanCap (TriLink). mRNA was purified by cellulose purification, as 
described (322). All mRNAs were analyzed by denaturing or native agarose gel 
electrophoresis and were stored frozen at -20°C. 
LNP formulation of the mRNA: Cellulose-purified m1Ψ-containing RNAs were 
encapsulated in LNPs using a self-assembly process as previously described wherein 
an ethanolic lipid mixture of ionizable cationic lipid, phosphatidylcholine, cholesterol and 
polyethylene glycol-lipid was rapidly mixed with an aqueous solution containing mRNA at 
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acidic pH (323). The RNA-loaded particles were characterized and subsequently stored 
at -80°C at a concentration of 1 µg µl-1. The mean hydrodynamic diameter of these 
mRNA-LNP was ~80 nm with a polydispersity index of 0.02-0.06 and an encapsulation 
efficiency of ~95%. 
Mouse B cell receptor sequencing: Genomic DNA was extracted from sorted cells 
using the Qiagen Gentra DNA purification kit (Qiagen, Germantown, MD, Cat. 
No.158689). Primers used were adapted from Wang et al. (324) at the beginning of the 
FW1 region of VH and were modified to include adaptor sequences for the Illumina 
NexteraXT kit (sequences are provided below). Samples were amplified in duplicate (2 
biological replicates per sample). 
Primers: 
VHmix (MH1) 5’- GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGSARGTNMAGCTGSAGSAGTC-3’ 
 
JH1,JH4 mix 5’- TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGCTANTGAGGAGACGGTGAC-3’ 
 
JH2 5’ -TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGAGGAGACTGTGAGAGTGG-3’.  
 
The mouse IgH library was generated with one VH primer and a cocktail of JH1,2,4 
primers. The VH and JH primer mixes were used at 0.6 µM in a reaction volume of 25 µL 
using a Multiplex PCR kit (Qiagen, Valencia, CA, Cat. No. 158388).  Amplification 
conditions for the PCR were: primary denaturation at 95oC for 10 minutes, cycling at 
95°C 45s, 60°C 45s, and 72°C for 90s for 35 cycles, and a final extension step at 72°C 
for 10 minutes. 
Amplicons were purified using the Agencourt AMPure XP beads system (Beckman 
Coulter, Inc., Indianapolis, IN), and second-round PCRs were performed as described 
(325) to add Illumina NexteraXT adaptors to the IgH library. Final sequencing libraries 
were quantified by Qubit Fluorometric Quantitation (Thermo Fisher Scientific, Grand 
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Island, NY) and loaded onto an Illumina MiSeq instrument in the Human Immunology 
Core facility at the University of Pennsylvania and sequenced using 2x300 bp paired end 
kits (Illumina MiSeq Reagent Kit v3, 600 cycle, Illumina Inc., San Diego, Cat. No. MS-
102-3003).  
Human B cell receptor sequencing: Genomic DNA was extracted from sorted cells 
using the Qiagen Gentra DNA purification kit. Sequences were generated from genomic 
DNA using primers that were situated at FR1 and JH (BIOMED2) for IgH V region 
sequencing.  Samples were amplified in duplicate (2 biological replicates per sample). 
Second-round amplification to generate sequencing libraries used Illumina Nextera XT 
kit as previously described (325, 326).  Sequencing were performed on an Illumina 
MiSeq instrument in the Human Immunology Core facility at the University of 
Pennsylvania using a 2x300 bp paired end kit.  
 
Sequencing data analysis: Raw sequence data (FASTQ files) were processed through 
pRESTO version 0.5.10 (327). First, paired reads (R1 & R2) were aligned.  Then 
sequences with an average Phred quality score of less than 30 (an error rate of 1 in 
1000 bases) were removed.  Of the remaining sequences, the 5’ and 3’ ends were 
trimmed until a window of 20 nucleotides had an average quality score of at least 30.  
Short reads of less than 100 bases were discarded after the trimming.  Finally, 
nucleotides with a quality score of less than 30 were masked with an “N,” and any 
sequence with more than 10 such N’s were discarded. 
Code 1 shows a script performing these filtering steps.	
PairSeq.py -1 *R1* *R2* 
AssemblePairs.py align -1 *R1_pair-pass* -2 *R2_pair-pass* --coord illumina --rc tail 
FilterSeq.py quality -s *assemble-pass* -q 30 
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FilterSeq.py trimqual -s *quality-pass* -q 30 --win 20 
FilterSeq.py length -s *trimqual-pass* -n 100 
FilterSeq.py maskqual -s *length-pass* -q 30 
FilterSeq.py missing -s *maskqual-pass* -n 10 
ImmuneDB (328) was used for gene identification and clonal inference of heavy chain 
sequencing data in both humans (using v0.26.0) and mice (using v0.28.0).  Sequences 
were trimmed to IMGT position 20 in mice and 80 in humans to remove 5’ primer 
sequences.  Clones were assembled by grouping sequences with the same V-gene, J-
gene, and 85% CDR3 amino-acid similarity as described in (326). 
In the murine dataset, all mice contained a common CDR3 amino-acid string, 
CARGNRYWYFDVW (or a truncated variant of CARGNRYWYFDV or 
CARGNRYWYFD), possibly due to contamination, and were excluded from further 
analysis.  Further excluded were two clones that had over 20% mutation in the V-region, 
due to incorrect V-gene assignment. 
For all further analysis of both human and murine data, clones in each subject/subset 
combination were only included if they contained more than half the mean frequency of 
copies in that subject/subset. 
Quantification and statistical analyses: All p values were determined using one of the 
following as mentioned in figure legends: unpaired non-parametric t-test or one-way 
ANOVA with Tukey post hoc test, paired t-test or repeated measures ANOVA with Tukey 
post hoc test, or Spearman correlation, using GraphPad Prism version 7 or version 8 
(GraphPad Software, La Jolla, CA 92037 USA). *p < 0.05, **p < 0.01, ***p < 0.001. Data 
are represented as mean ± SEM. The number of mice and human subjects used in each 
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experiment, as well as the exact number of times an experiment was repeated, is 




CHAPTER 4: PERSPECTIVE 
 
4.1 Investigating cellular differentiation in the immune system 
 
Cellular differentiation is the principle problem in metazoan biology, and in my 
graduate work I have tried to address the question of how and to what extent 
lymphocytes differentiate in the establishment and functioning of the adaptive immune 
system. In order to function properly, the immune system requires the establishment of 
diverse cell-types. These cell-types result from the continual differentiation of 
hematopoietic stem cells throughout life, but the mechanisms that forge unique cell 
identity are still unclear. Despite the diversity, this range of cell-types alone is not 
sufficient to ensure functional immune responses to the wide variety of pathogenic 
insults encountered. As such, further differentiation and specialization of effector and 
memory immune cells is required to carry out the type of immune response best suited 
to the specifics of the pathogen challenge. However, extending the hematopoietic tree 
beyond the naïve lymphocyte stage to the mature subsets of an ongoing immune 
response cannot be done without firmly understanding their differentiative relationships 
and the stability of their identity. The problem of differentiation in the immune system is 
then two-fold: 1) to uncover the mechanisms leading to unique and stable cell identity 
and 2) to identify new subsets and define the developmental relationships between the 
diverse cell-types. 
Questions about the control of cell identity have been long on the minds of 
embryologists and seeking answers to these questions has led to the understanding that 
chromatin acts as a biochemical filter for developmental cell-types by determining which 
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genes are transcribed into RNA (329). The application of genome-wide techniques such 
as ChIP-seq and ATAC-seq to differentiated cell-types in the hematopoietic system 
reveal that chromatin states vary profoundly between hematopoietic lineages and are 
more closely tied to cell identity than gene expression (119, 330). However, the 
chromatin states of mature cell-types are not pre-established in progenitors, begging the 
question of how they are established. Therefore, I first set out to address the question of 
how the chromatin state of a cell identity is shaped during development. Significant work 
had been done on erythrocyte (331, 332), macrophage (106), and B cell development 
(104, 333), but comparatively little work had been done on T cell development. As such, 
I focused my attention on T lymphopoiesis. As the proteins that modify histones are non-
specific, they must be guided by sequence-specific transcription factors to cell-specific 
loci (334, 335). However, sequence-specific transcription factors are occluded by 
nucleosomes and cell-specific loci are not accessible in progenitors (119, 336-338). We 
hypothesized that a special class of transcription factors, uninhibited by nucleosomal 
DNA, acts during T cell development to create chromatin accessibility for the 
establishment of a T cell chromatin state and the activation of a T cell program. 
Therefore, we set out to examine the DNA sequences of developmentally regulated T 
cell chromatin to identify this mystery transcription factor. 
4.2 Mechanisms of shaping epigenetic cellular identity in T cell development 
 
By investigating genome-wide measurements of accessibility at multiple T cell 
developmental stages we found that T cell-specific accessible chromatin defining T cell 
identity is more enriched for TCF motifs compared to the motifs of other developmentally 
important transcription factors. Further, T cell-specific chromatin was highly bound by 
TCF-1 and deletion of TCF-1 severely abrogated the accessibility of T cell chromatin in 
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the few surviving DP T cells. The chromatin accessibility mediated by TCF-1 regulated 
components of the T cell gene program and changes to accessibility were reflected by a 
compromised transcriptome including downregulation of important T cell genes such as 
Bcl11b and others. At the single cell level, TCF-1 enforced a coordinate accessibility 
among individual cells whereas sites bound by other transcription factors were more 
heterogeneous in the population. Finally, ectopic expression of TCF-1 in fibroblasts 
converted inaccessible T cell-specific heterochromatin into active and accessible 
chromatin and induced expression of T cell-specific genes. 
Previously, TCF-1 was shown to induce the gene program of T cell specification 
in bone marrow progenitors even in the absence of Notch signaling (121). The question 
then arises of whether TCF-1 initiates a T cell gene program that has been primed in the 
chromatin of bone marrow progenitors prior to settling in the thymus. Our results indicate 
the opposite. Inasmuch as we could measure it, chromatin accessibility in bone marrow 
progenitors (as measured in CLPs in this study) was devoid of most T cell accessible 
chromatin. Thus, it is likely that the T cell specification events mediated by TCF-1 is the 
result of sweeping changes to chromatin that make the T cell gene program possible. 
Consistent with this notion, we observed a profound increase in accessibility between 
the CLP and ETP stage where TCF-1 is first induced to high levels of expression from 
Notch1 signaling (136). 
Together, our results indicate that TCF-1 acts as a lineage-determining 
transcription factor to create accessible T cell chromatin and shape the epigenetic 
identity of T cells. More broadly, our results suggest that the adoption of cell identity 
during hematopoiesis is more than just the adoption of a specific gene program but is 
established through extensive chromatin changes outnumbering even gene expression 
changes. Similar conclusions have been drawn in other developmental contexts in 
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hematopoiesis and embryogenesis (330, 338, 339). Moreover, our results indicate that 
this process of development is carried out by lineage-specific transcription factors that 
make lineage-specific chromatin accessible to organize the more ubiquitous transcription 
factors to function at lineage-specific gene loci. 
Transcription factors that mediate the selection and accessibility of chromatin 
have been termed ‘pioneer transcription factors’ (PTFs) (2) or ‘lineage-determining 
transcription factors’ (LDTFs) (3). Both labels describe transcription factors that act 
before other transcription factors to establish lineage-specific accessible chromatin. The 
difference between them is that PTFs have been shown to have an intrinsic biochemical 
affinity to nucleosomal DNA (340), usually mediated through a special protein domain 
(341), whereas LDTFs have not. The activity of TCF-1 during T cell development is 
consistent with these descriptions, especially of the LDTF class. Although we have not 
yet shown the binding of purified TCF-1 to nucleosomal DNA arrays in vitro, our results 
in the fibroblast model demonstrated that almost half of TCF-1 binding events occurred 
at a known nucleosome position, near the dyad. Thus, it is likely that TCF-1 will be 
classified as a PTF in the future. In fact, a recent publication by Howard Xue’s group 
demonstrated a vestigial, but functional histone deacetylase (HDAC) domain in TCF-1 
(125), providing evidence of a biochemical link to the histone proteins comprising the 
nucleosome. Whether this HDAC domain is required for TCF-1 to create de novo 
chromatin accessibility remains to be determined. 
Surprisingly, we found that β-catenin and Wnt signaling was not required for 
TCF-1 to create accessible chromatin in the fibroblast model because we used the p33 
isoform that does not bind β-catenin (97). The Wnt/TCF pathway is an evolutionarily 
ancient signaling pathway used in multiple developmental contexts (91). The role of β-
catenin in T cell development is a complex one with conflicting reports. One study found 
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that β-catenin was essential for T cell development (342) whereas others show that T 
cell development is largely intact in the absence of β-catenin (95, 96). Moreover, the p33 
isoform has been assumed to be transcriptionally repressive because β-catenin is not 
able to displace the recruitment of the Groucho/TLE family of transcriptional repressors 
(93). Again, our results conflicted with this classification. We found that expression of the 
p33 isoform in fibroblasts was able to create de novo chromatin accessibility and 
activate T cell genes suggesting that β-catenin is not required for either function. Another 
study by Howard Xue’s group suggests the role of β-catenin is limited to the regulation of 
cell survival signals during positive selection but is dispensable for T cell differentiation 
(343). Thus, it is possible that the effect of TCF-1 on shaping T cell chromatin and 
activating T cell gene expression is largely independent from β-catenin except to 
regulate a small suite of survival genes at a specific stage of development. 
Because we utilized an unbiased, genome-wide approach, our analysis turned up 
other unexpected findings. We found the chromatin that becomes accessible during T 
cell development is dynamically regulated and becomes accessible in waves, occurring 
at the ETP stage, the DN3-DN4 stage, and the mature single positive stage. The timing 
corresponds to important developmental events occurring at these stages including T 
cell specification, β-selection, and MHC restriction, respectively (45, 50, 121). 
Importantly, TCF-1 binding events and motifs were enriched in all three waves of 
accessible chromatin. Although this observation seems incongruous with the role of 
TCF-1 in creating accessible chromatin, PTFs and LDTFs are known to require 
additional regulatory events to specify their activity as even PTFs bind only a fraction of 
their total binding sites (344). Such events could include the cooperation of other 
transcription factors functioning in a combinatorial manner with TCF-1 (3). PTFs are 
repelled by highly condensed heterochromatin (144), but we found that TCF-1 could 
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overcome the repressive heterochromatin and establish accessibility. However, other 
epigenetic factors including DNA methylation and chromatin folding could be responsible 
in limiting the ability of TCF-1 to create accessible chromatin. In support of this idea, a 
paper published in the same issue of Immunity by Keji Zhao’s group showed that the 3-
dimensional organization of the chromatin is dynamically regulated at key stages of T 
cell development suggesting that the coordinated accessibility of these waves could be 
the result of positive changes to the higher-order chromatin architecture (345). 
4.3 TCF-1 establishes T cell chromatin during T cell development 
 
In summary, my studies on the transcription factor TCF-1 in T cell development 
has strengthened our understanding of how cell identity is managed at the chromatin 
level during development. The role of TCF-1 in activating the gene program of T cell 
specification has been known for several years, but our work has expanded the role of 
TCF-1 beyond a simple model of gene activation. Our expanded model argues that TCF-
1 opens unprimed or repressed chromatin in progenitor cells to establish an accessible 
and active chromatin state for the execution of a T cell gene program, and a graphical 
depiction of our model is shown in Figure 13. Although our work sheds light on the 











Figure 13: Current working model: Forging T cell epigenetic identity using TCF-1. 
In the thymus, Notch signals induce TCF-1 expression in thymic settling progenitors 
such as CLP or LMPP. TCF-1 carries out T lineage specification by finding T cell-specific 
CRMs buried in closed chromatin by binding its motif on nucleosome wrapped DNA. 
Through an uncharacterized mechanism, TCF-1 establishes accessible chromatin at T 
cell-specific CRMs, allowing the binding of additional transcription factors that are 
normally repelled by the chromatin. The addition of new CRMs transforms the gene 
program to induce the expression of Bcl11b for T cell commitment and Gata3 for further 
T cell development. TCF-1 guides individual cells along the T cell trajectory by reducing 
heterogeneity of accessibility at T cell specific CRMs and the germline removal of TCF-1 
severely abrogates chromatin accessibility, reduces the T cell gene program, and 
negatively impacts mature T cell function. TCF-1 is sufficient to create de novo 
accessibility even in unrelated cell types such as fibroblasts suggesting that modulation 















4.4 Perspective on epigenetic engineering to control differentiation in immune responses 
 
The T cell chromatin state is dependent on TCF-1, and the requirement of TCF-1 
expression for robust memory CD8+ T cell responses suggests cell function beyond the 
naïve stage is a function of the chromatin state established during development (122). 
Recent work demonstrates that naïve, memory, effector, and exhausted CD8+ T cells 
have unique chromatin identities, but the epigenetic profile of naïve and memory CD8+ T 
cells share many features including enrichment for TCF motifs (113-115). Conversely, 
the accessible chromatin of effector and exhausted CD8+ T cells, which do not express 
TCF-1, lack TCF motifs suggesting that restoring TCF-1 expression could revert the 
chromatin state of these cells to a naïve or memory state and restore immune function 
and durability. The epigenetic reprogramming of immune cells to modulate aspects of 
their function and survival has major therapeutic potential. 
However, the transcription factors and regulatory events responsible for creating 
different chromatin states between effector and memory subsets are not fully elucidated. 
Unique chromatin states are established in a stepwise fashion through the hierarchical 
activity of transcription factors to induce a distinct and stable gene program. Thus, 
identifying the transcription factors that define cell identity requires an understanding of 
the developmental sequence and the relationship between subsets. Generally, there is 
much less acceptance over the developmental relationships of effector and memory cell 
subsets beyond the naïve stage for both T and B cells. Part of the reason for this is the 
many different types of effector and memory cells that can develop from the different 
types of pathogens that can be encountered, Therefore, defining the developmental 
trajectory of these subsets is a major open-ended question. In the second half of my 
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graduate work I set to work on defining the differentiative relationships between subsets 
of memory B cells resolved by the transcription factor T-bet. 
4.4 Cellular differentiation in the memory B cell response 
 
We used a Tbx21 transcriptional reporter to track T-bet expression in influenza 
hemagglutinin (HA)-specific B cells at various time-points after PR8 infection. We 
determined that T-bet- and T-bet+ HA-specific B cells arose early, acquired a germinal 
center phenotype, and persisted long-term where both subsets acquired the memory B 
cell markers CD73, PD-L2, and CD80. We also noted that the T-bet+ population was 
composed of T-bethi and T-betlo subsets with T-bethi memory B cells (MBCs) having a 
different anatomic distribution and recirculation properties in mice and humans 
compared to T-betlo and T-bet- MBCs. Thus, we found that T-bethi MBCs were restricted 
to the spleen while T-betlo and T-bet- MBCs circulated throughout all secondary lymphoid 
organs.  Through parabiosis, we determined that T-bethi MBCs were spleen-resident 
whereas T-betlo and T-bet- MBCs circulated freely. To assess the differentiative 
relationship between T-bet+ and T-bet- MBCs we performed a clonal analysis by IgH 
sequencing and found that most clones were not shared between the subsets. In the 
instances where we found clonal sharing, lineage tree analysis revealed that clonal 
daughters eventually adopted either T-bet+ or a T-bet- fate. Further fate-mapping using 
an inducible Tbx21 fate-mapping mouse confirmed the stability of the T-bet+ fate. Finally, 
B cell expression of T-bet was important for the humoral response to influenza and B 
lineage deletion of T-bet caused a reduction in influenza-specific antibody titers, 
especially to the HA stalk. 
Previously, Naradikian et al. (274) determined that the signals necessary to 
engender a T-bet+ B cell phenotype include BCR signaling, B cell intrinsic nucleic-acid 
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detection through TLR engagement, and TH1 inflammatory cytokine signals. Moreover, a 
TH2-mediated response does not produce T-bet+ B cells. Influenza is an RNA virus that 
produces a TH1-mediated response (346), and our results confirm that influenza infection 
meets the conditions necessary to generate T-bet+ B cells. In the presence of IFNγ and 
TLR7/9 agonists, T-bet expression occurs within 48 hours of B cell activation in vitro 
suggesting that T-bet expression is an effector phenotype linked to the events of B cell 
activation. Analogously, B cells in vivo adopt an activated T-bet+ effector phenotype 
likely driven by BCR cross-linking with TLR7/9 signals and induced by IFNγ or IL-21 
produced by TFH during a TH1-type response (274). The events of signaling, and not an 
intrinsic activation program, drive the differentiation of T-bet+ B cells, and the adoption of 
a T-bet+ effector phenotype does not appear to be confined to a certain pre-immune or 
antigen-experienced subset of B cells. Thus, the differentiation of T-bet+ effector B cells 
result from the integration of innate and adaptive activation signals with inflammatory 
cytokines in unrestricted B cell populations. 
By tracking antigen-specific B cells, our results extend previous findings by 
demonstrating that T-bet+ B cells that arise during infection persist as a stable memory 
pool. Therefore, the description of T-bet+ B cells is not confined to recently activated 
effector B cells but also encompasses bona fide memory cells in both mice and humans. 
Although definitive MBC markers in mice are lacking, expression of CD73, CD80, and 
PD-L2 have been demonstrated on MBCs generated with an alum-adjuvanted hapten-
carrier response (267, 268). In mice, we found that nearly all HA-specific T-bet+ and T-
bet- B cells express these MBC markers by day 100 post infection and are maintained at 
a steady state, consistent with memory cell identity. Our results indicate MBCs are not a 
monolithic population but are composed of discrete subsets that reflect fate choices 
shaped by the events of early infection and differentiate according to pathogen-driven 
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cues. However, our results also indicate that T-bet+ and T-bet- memory pools are distinct 
and do not interchange, and T-bet+ MBCs do not arise from T-bet- MBCs or vice versa. 
Thus, the effector functions selected during the humoral response are perpetuated by 
the differentiation of distinct pools of long-lived memory cells. 
B cells expressing T-bet have been described as “Age-associated B cells” 
(ABCs) and are driven by similar innate and adaptive signals in both normal and 
autoimmune humoral responses (347). Moreover, ABCs require cognate help from 
CD40/CD40L interactions to form, suggesting they are the product of T dependent B cell 
responses. Confirming this notion, we observed that T-bet+ B cells had a GC phenotype, 
formed long-lived memory cells, and were hypermutated—processes that require T cell 
help. Using the immune response to influenza, our results suggest that ABCs, 
regardless of their setting of generation, are a durable MBC population. Moreover, we 
found that T-bethi MBCs were spleen-resident in mice and increased in proportion with 
age in human spleens suggesting that studies on T-bethi B cells isolated from the blood 
alone may not be an accurate representation of the ABC pool in either settings of normal 
immune responses or autoimmunity. Indeed, some have noted that T-bethi ABCs 
isolated from the blood reflect an activated, effector phenotype rather than a memory 
phenotype and, when isolated from the blood, do not demonstrate a proportional 
increase with age in humans (348). Thus, studies on this critical population underlying 
normal and autoimmune humoral responses need to be conducted in the tissues such 
as the spleen rather than the circulation where possible. 
The function of the T-bet+ MBC subset is unknown as of yet. The role of memory 
B cells in humoral immunity may appear redundant alongside established plasma cells 
and elevated antibody titers. However, memory B cells act as a second line of defense 
through rapid reactivation and differentiation into plasma cells (349-351). Thus, the 
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secondary humoral response is typically faster, of greater magnitude, and consists of 
isotype-switched antibodies of higher affinity. The characteristics of the secondary 
response are thought to be the consequence of the activity of MBCs, although some 
aspects have been challenged recently (352). Nonetheless, MBCs make up a large 
proportion of the peripheral B cell pool in adults. Moreover, the role of MBCs in recall 
responses may contribute to the phenomenon of Original Antigenic Sin (OAS) or the re-
emergence of autoimmune antibodies after B cell depletion (353-356). Thus, the role of 
T-bet+ MBCs in these aspects of the recall response needs to be addressed. 
We show that MBC subsets are functionally divided by their anatomic distribution 
and recirculation properties with T-bet- and T-betlo MBCs recirculating freely and T-bethi 
MBCs residing in the spleen. The functional significance of T-bethi tissue residency is 
unknown. Tissue-resident memory T cells, which survey intracellular environments, are 
thought to mediate rapid effector responses to local antigen reencounter (357). 
Presumably, soluble antigen recirculates more rapidly than the migration of cells and 
antibodies freely diffuse through the blood. Therefore, the significance of resident 
memory B cells is unclear, but is an emerging and active area of research (291). 
However, the residency of T-bethi MBCs in the spleen may be related to their function. 
The spleen is a unique secondary lymphoid organ that surveys both the circulatory and 
lymphatic systems. Thus, we speculate the splenic-residency of T-bethi MBCs may 
function to support rapid recall and differentiation to antibody secreting cells, especially 
when antigens are mobilized in circulating lymph and/or blood in a manner similar to the 
function of marginal zone B cells. Indeed, a study by Shlomchik’s group has 
demonstrated that T-bet+ MBCs reside in the marginal sinus and appear to displace 
marginal zone B cells (358). Degradation of the marginal sinus structure with age has 
been reported previously, and we speculate the accumulation of ABCs may be at least 
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partially responsible for this decline (359, 360). Experiments addressing the tissue 
localization and the plasma cell potential of T-bethi MBCs can help answer these 
questions. 
4.5 T-bet+ memory B cells arise independently from T-bet- memory B cells 
 
A clear function for B cell expression of T-bet in the humoral response is to 
facilitate isotype-switching to IgG2c (294-301), and our results were consistent with this 
function. Importantly, we did not see an increase in IgG1 titers, a T-bet independent 
isotype, in the absence of B lineage T-bet expression. Moreover, nearly all of the 
antibodies specific to the HA-stalk were IgG2c. In conjunction with the clonal and fate-
mapping analysis, these results suggest that T-bet+ B cells do not develop from the T-
bet- pool. Instead, we propose that T-bet+ and T-bet- B cells mostly arise independently, 
and our model is described in Figure 14. In a linear model of differentiation, cells adopt 
an alternative identity from the accumulation of, or increased exposure to, a 
differentiative factor. In the absence of the differentiative factor, cells do not differentiate 
but remain, nonetheless. Our results indicate that the development of T-bet+ MBCs does 
not follow a linear differentiation model but instead follows an ‘all-or-none’ model. Thus, 
when T-bet is deleted in the B lineage, most HA-specific titers are absent and are not 








Figure 14: Current working model: The differentiation of T-bet+ memory B cell 
subsets 
T-bet+ B cells differentiate early as a distinct pool from T-bet- B cells after influenza 
infection. T-bet+ B cells possess unique specificities including the stalk of influenza 
hemagglutinin, and the expression of T-bet facilitates isotype switching to IgG2a/c. Both 
T-bet+ and T-bet- pools enter germinal centers, undergo somatic hypermutation, and 
persist indefinitely as memory B cells. However, they possess different recirculation 
properties and tissue distributions in mice and humans. T-betlo and T-bet- memory B 
cells recirculate through the blood and lymphatics whereas T-bethi memory B cells are 
spleen resident. Without B cell expression of T-bet, neutralizing titers to influenza fail to 





4.6 Perspective on the future research of T-bet+ B cells 
 
An alternative explanation to the reduced HA-specific titers in the absence of B 
lineage T-bet expression is a potential role of T-bet+ MBCs in generating or maintaining 
plasma cells (318). In the humoral response, pathogen-specific titers can remain 
elevated and provide protection either through the establishment of LLPCs or the 
continual differentiation of SLPCs from an effector or memory pool (256). No T-bet+ 
plasma cell subset has been identified and it is well accepted that plasma cells do not 
express T-bet. Thus, T-bet dependent antibody responses depend on the differentiation 
of T-bet+ B cells into plasma cells while losing T-bet expression in the process. We 
identified T-betlo and T-bethi subsets with different circulatory properties and hypothesize 
that T-bethi B cells are a tissue-resident stem-like pool that populate the circulating T-
betlo pool on the way to plasma cell differentiation. A recent study by the Winslow group 
demonstrates that T-bet+ memory B cells are multipotent, supporting this hypothesis 
(311). Indeed, preliminary results in the lab indicate established T-bethi MBCs turnover 
and differentiate into T-betlo MBCs and eventually plasma cells when adoptively 
transferred. A progenitor-successor relationship between T-bethi MBCs, T-betlo MBCs, 
and plasma cells suggests that supporting or reducing antibody production from T-bet+ B 
cell populations requires targeting the spleen-resident T-bethi MBC pool. 
Finally, what is the nuclear role of T-bet? As a transcription factor, T-bet binds to 
the DNA in a sequence-specific manner to regulate the expression of genes (361). 
However, transcription factor activity is filtered by the chromatin state and T-bet does not 
appear to be sufficient or necessary to alter the chromatin state (111). A recent study by 
the Lund group (362) has demonstrated that the chromatin state of T-bet+ B cells is 
considerably different from the chromatin state of T-bet- B cells in an influenza response 
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suggesting that unique modes of gene regulation operate in T-bet+ cells. Identifying the 
transcription factors that act in the T-bet+ chromatin landscape and the gene loci 
regulated by unique T-bet+ B cell CRMs will provide insight into their regulatory program 
as well their function. 
Naturally, future research will likely focus on the mechanisms that establish the 
unique T-bet+ chromatin state. However, when setting out to understand the regulatory 
events leading to the divergent chromatin states of T-bet+ and T-bet- B cells, it must be 
noted that our results demonstrate that T-bet+ MBCs do not develop from T-bet- MBCs. 
Epigenetic cell identity is built progressively by the incremental activity of transcription 
factors on the chromatin. Therefore, an in-depth analysis of the establishment of T-bet+ 
cells should not focus primarily on the chromatin differences between T-bet+ and T-bet- 
MBCs, but on the events leading to the adoption of a T-bet+ fate. The transcriptional 
events downstream of TLR signaling and/or inflammatory cytokine signaling are a good 
place to start because STATs can shape the chromatin landscape (111). As suggested 
by my investigation on immune cell identity at the chromatin level and the differentiative 
relationships between immune cell subsets as outlined in this thesis, the establishment 
of unique chromatin identity is best decoded when the fate choices and lineage 
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Figure S1. TCF-1 binding occurs at three waves of chromatin remodeling during T 
cell development, Related to Figure 2  
(A) Accessible regulatory elements were identified in mouse across multiple cell types 
including progenitors (HSC, MPP and CLP), T cell development (ETP, DN2a, DN2b, 
DN3, DN4, DP, CD4+ and CD8+ SP) and non-T cell lineages (B and NK) using bulk 
ATAC-seq data. Peaks were called with macs2 and their reproducibility was assessed 
using IDR. Accessible regions were filtered based on annotated gene promoters (see 
STAR methods) into distal and proximal regulatory elements. Proximal elements were 
filtered out and the remaining 55,481 regions were clustered into 24 groups with k-
means using the FDR value in each sample as a proxy of ATAC-seq enrichment. Black 
arrows indicate clusters that have been filtered out from the final set of regions shown in 
Figure 2A. 
(B) ATAC-seq profiles (+/- 2kb window) around summits of all 20 k-means clusters 
identified in mouse from Figure 2A. 
(C) Top three enriched motifs from de novo motif analysis using HOMER on all clusters 
in Figure 2A.  
(D) Clustering of accessible regulatory elements based on public ATAC-seq data in 
human HSC, MPP, CLP, B, NK, CD4+ and CD8+ T cells. Peaks were called with macs2. 
Due to the lack of replicates, IDR assessment of peak reproducibility was not feasible. 
Normalized tag counts were used as a proxy of ATAC-seq enrichment to identify clusters 
(see STAR methods). HOMER facilitated the de novo motif discovery in different 
clusters. 
(E) Pathway analysis for genes proximal to clusters 9, 19, and 10 (see Figure 2A). 
(F) Distribution of the expression levels for genes proximal to clusters 9, 19, and 10 





Figure S2. TCF-1-deficient DP T cells cannot establish the open chromatin 
landscape and transcriptional output of normal DP T cells, Related to Figure 3 
(A-B) Pairwise Pearson correlation plots for replicates in (A) ATAC-seq and (B) RNA-
seq experiments in WT and Tcf7–/– DP T cells. 
(C) Volcano plot demonstrating differentially regulated gene expression in WT and Tcf7–
/– DP T cells. DESeq2 was used to identify 1,167 down- and 1,293 up-regulated (fold-
change > 1.5 and p-value < 1e-3) in Tcf7–/– DP T cells. 
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Figure S3. TCF-1 binding coordinates open chromatin between single DP T cells, 
Related to Figure 4 
(A-B) Examples of live/dead stained cells captured with Fluidigm C1 platform.  
(C) Fragment size periodicity from scATAC-seq data derived from single DP T cells.   
(D) Single DP T cells plotted based on two quality assessment metrics derived from 
scATAC-seq samples. Single cell libraries containing less than 10,000 fragments or with 
less than 15% of their fragments falling in open chromatin did not reach the minimum 
quality criteria. Together, we performed three independent single-cell captures and 110 
T cells at the DP stage passed various quality control thresholds. 
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Figure S4. TCF-1 can bind to nucleosomes and create chromatin accessibility in 
fibroblasts, Related to Figure 5 
(A) Ectopic expression of TCF-1 in NIH3T3 using retroviral transduction and subsequent 
verification of expression by intracellular staining and flow cytometry. 
(B) Log10 TCF-1 peak score as defined by the IDR package in replicates of ChIP-seq in 
TCF-1 RV NIHT3T3. Red signifies peaks that fail to pass the IDR cutoff while black 
reflects the reproducible subset of TCF-1 peaks in multiple thresholds. 
(C) K-means clustering (k=3) of TCF-1 summits based on the normalized MNase-seq 
enrichment in three non-overlapping 200bp windows centered around summits (see 
Figure 5). 
(D) Distribution of distance between TCF motifs unbound by TCF-1 (red) and uniquely 
bound by TCF-1 ChIP-seq (green) in TCF-1 RV NIH3T3 cells (upper panel) or DP T cells 
(lower panel). Nucleosome summits were identified using Danpos2 on public MNase-seq 
data in fibroblasts (see STAR methods). TCF motif occurrences were identified genome-
wide using FIMO and the TCF-1 PWM derived from JASPAR database. Statistical 
significance of the difference between the TCF-1 bound and unbound motifs to the 
nucleosome summits was calculated using a bootstrap approach (see STAR methods). 
(E) Pairwise Pearson correlation plots between ATAC-seq replicates in Empty and TCF-
1 RV NIH3T3 cells. 
(F) Nucleosome enrichment profile around TCF-1 ChIP-seq binding summits assessed 
using the NucleoATAC algorithm in Empty and TCF-1 RV NIH3T3 cells (see STAR 
methods). 
(G) Normalized TCF-1 ChIP-seq enrichment profile around merged TCF-1 binding 
events in TCF-1 RV NIH3T3 and DP T cells with a Pearson correlation coefficient of 0.3. 
(H) Regions that gained accessibility in TCF-1 RV NIH3T3 were overlapped with ATAC-
seq peaks specific to HSC, MPP, CLP, B, NK, naïve CD4+, naïve CD8+, effector CD8+ 
and memory CD8+ cells. “Union T cells” was generated by merging the open chromatin 
regions of all T cell datasets. 
(I) Enrichment analysis of TCF-1 ChIP-seq binding events in: (1) DP T cells, (2) genomic 
loci that lose accessibility in Tcf7-/- DP T cells and (3) regions that gained accessibility in 
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Figure S5. TCF-1 can bind to repressed chromatin and promote accessibility, 
Related to Figure 6 
(A) Two replicates of H3K9me3 and H3K27me3 ChIP-seq from NIH3T3 cells were 
generated as well as an input control (see STAR methods) and combined with public 
H3K4me3, H3K4me1 and H3K27ac in NIH3T3 and their corresponding control input. 
The enrichment of histone mark signal was calculated in a window (+/- 250bp) around 
TCF-1 ChIP-seq summits from TCF-1 RV NIH3T3 cells with normR algorithm and used 
as input for the Principal component analysis (see Figure 6A). The enrichment of ATAC-
seq in TCF-1 RV vs Empty RV NIH3T3 and vice versa was also calculated and used in 
the same analysis. 
(B) Pairwise Spearman correlation coefficient between the enrichment (A) of different 
histone marks and chromatin accessibility surrounding TCF-1 ChIP-seq binding sites. 
(C) Average silhouette width plot for the identification of the optimal number of clusters 
when applying k-means on the adjusted significance level of enrichment of H3K4me1, 
H3K4me3, H3K9me3, H3K27me3 and H3K27ac ChIP-seq signal in the 2kbp window 
centered on TCF-1 ChIP-seq summits. 
(D) Heatmap of the adjusted significance level of histone mark enrichment around TCF-1 
summits separated into the identified 11 clusters (C). Chromatin states were defined 
based on the enrichment level of each histone mark in each cluster. 
(E) Wilcoxon rank-sum test to assess the statistical significance of the difference in 
ATAC-seq signal enrichment between Empty and TCF-1 RV NIH3T3 in the chromatin 








Figure S6. T cell-specific genes innately repressed in fibroblasts are upregulated 
by TCF-1, Related to Figure 7 
(A) Pearson correlation plots between RNA-seq replicates in Empty RV NIH3T3 and 
TCF-1 RV NIH3T3 cells for assessing the reproducibility of the data. 
(B) Volcano plot demonstrating differential gene expression using DEseq2 in three RNA-
seq replicates of Empty RV and TCF-1 RV NIH3T3 cells with the upregulation of 1,477 
genes and the downregulation of 1,295 genes (fold-change > 1.5 and p-value < 1e-3). 
(C) Gene ontology analysis for thymocyte-specific genes (see Figure 7D) overlapping 
TCF-1 upregulated genes in NIH3T3 (top) and thymocyte-specific genes not upregulated 
by TCF-1 in TCF-1 RV NIH3T3 (bottom). 
(D) RNA-seq counts on gene exons from HSC, MPP, CLP, DP, naïve CD4+ SP, naïve 
CD8+ SP, effector CD8+ and memory CD8+ T cells were calculated for genes 
upregulated by TCF-1 in TCF-1 RV NIH3T3 cells (B). Genes were clustered in 12 groups 
using k-means after reducing the heteroskedasticity of the data by applying variance-
stabilizing transformation with DESeq2. We subsequently calculated normalized 
expression values (RPKM) for filtering lowly expressed genes (RPKM < 0.5 in all 
hematopoietic cell types) and visualizing the results. Cluster 1 was excluded from any 
further analysis due to low expression levels. 
(E) Boxplots of the normalized gene expression levels (D) with representative examples 
for each cluster. 
(F) TCF-1 is sufficient to upregulate TCF-1 dependent T cell genes in fibroblasts. Genes 
downregulated in Tcf7-/- DP T cells (see Figure S2) were overlapped with genes 
upregulated by TCF-1 RV in NIH3T3 and the statistical significance of the enrichment 
was calculated with Fisher’s exact test. 
(G) TCF-1 ChIP-seq summits (see Figure 5A) were assigned to chromatin states (see 
Figure 6B) and linked to proximal genes (STAR methods). The enrichment of 
downregulated genes by TCF-1 within each chromatin state was assessed with Fisher’s 
exact test. 
(H) A statistically significant (tested with Fisher’s exact test) higher proportion of genes 
were proximal to TCF-1 binding events that led to gain in H3K27ac and loss of 
H3K27me3/H3K9me3 modifications (Figure 6D) in contrast to those binding events that 
did not alter the chromatin state. 
(I) The enrichment of T cell genes in different levels of nucleosome occupancy (see 
Figure 7B, S4C, and STAR methods) was calculated using Fisher’s exact test. 
(J) ATAC-, RNA- and ChIP-seq (histones and TCF-1) profiles in Empty and TCF-1 RV 
NIH3T3 cells in Rorc locus as an example of a key T cell gene that is innately not 







Figure S7. Characterization of HA-specific B cells after influenza infection, Related 
to Figure 8. 
(A) Weight loss and recovery from PR8 influenza infection in T-bet-ZsGreen mice 
compared to PBS-treated controls. (B) Fluorescently-conjugated PR8 hemagglutinin 
(HA) detects the precursor frequency of HA-specific B cells in naïve T-bet-ZsGreen 
mice, which are uniformly T-bet-. The naïve precursor frequency per 100,000 B cells is 
plotted. (C) Gating scheme for the identification of T-bet-ZsGreen mouse HA+ B cells 
and subsetting into T-bet-, T-betlo, and T-bethi populations via flow cytometry. C57Bl/6 
mice are included in the T-bet-ZsGreen expression plot as a control. An identical gating 
scheme was used for all tissues in Figure 8. (D) Tbx21 expression in sorted T-bet-, T-
betlo, and T-bethi B cell subsets via qPCR. CD19+ B cells were sorted into the 
corresponding subsets according to ZsGreen expression (C), and RNA was isolated and 
cDNA prepared for qRT-PCR analysis. (E) Number of HA+ B cells in peripheral and 
mesenteric lymph nodes by T-bet expression phenotype at different time points after 
infection; mice are the same as in Figure 8B. (F) Expression of GL7 and CD95 on T-bet- 
and T-bet+ splenic HA+ B cells at the indicated time points post PR8 infection. (G) The 
percentage of HA+ B cells that are GL7+CD38- in the mediastinal LN and lungs of T-bet-
ZsGreen mice 100 days post PR8 infection, and the percentage that are T-bet+ in each 
tissue (top). Data in (D) are plotted as mean ± SEM. HA+ B cells were identified as live, 
singlet, DUMP-, B220+, CD19+, IgD-, HA-AF647+, HA-BV421+ cells. DUMP gate includes 





















































































































































Figure S8. Characterization of human B cell subsets, Related to Figure 9. 
(A) Gating scheme for the identification of human peripheral blood CD19+ B cells via 
flow cytometry. An identical gating scheme and identical gates were used for all tissues 
in Figure 9. (B) Memory (IgD-/IgD+CD27+) phenotype of total CD19+ and T-bethi B cells 
from spleen of a representative donor. (C) Identification of naïve (CD21+IgD+CD27-) and 
CD21+ memory (IgD-/IgD+CD27+) B cells in paired peripheral blood (PB) and thoracic 
duct fluid (TD) from a representative donor. Memory cells are further subsetted into 
IgM+CD27+, IgM-CD27+, and IgM-CD27-. (D and E) Frequency of naive B cells (D) and 
CD21+ memory subsets (E) gated in (C) within paired PB and TD sample cohort (n=8). 
(F) Identification of HA-specific, class-switched (IgD-IgM-) B cells within CD19+CD38low 
mesLN B cells using fluorescently-labelled A/California/07/2009 HA probe (H1 strain) or 
a A/Wisconsin/67/2005 HA probe (H3 strain). (G and H) Correlation between frequency 
of T-bethi phenotype within class-switched H1-binding (G) or H3-binding (H) B cells and 
subject age. Subjects are the same as in Figure 9I; those without age information were 
omitted from this analysis. (I) IgG1, IgG2, IgG3, and IgA expression profile by class-
switched H1-HA+ splenic B cells from a representative human donor. Statistical 
comparisons performed using paired t-test (D and E) and Spearman correlation (G and 






Figure S9. Enumeration of HA-specific B cells in parabiotic partners, Related to 
Figure 10. 
(A) Absolute numbers of T-bet-, T-betlo and T-bethi HA+ splenic MBCs in ZSGreen (red) 
and B6.SJL (black) parabiosis partners from Figure 10. (B) The percent of splenic donor-
derived CD8+ T cells that are T-bet-ZsGreen+CXCR3+ in each partner ≥17 days of 
parabiosis from 8 parabiotic pairs. Statistical comparisons performed using paired two-







































































































































































































Figure S10. Immune repertoire analysis by IgH sequencing, Related to Figure 11.  
(A) Models regarding the possible origin of T-bet+ and T-bet- MBCs and their 
distinguishing characteristics. (B) Scheme for sorting T-bet+ and T-bet- HA-specific 
MBCs from negatively depleted, CD19+IgD-HA+ splenocytes 90 days post HA mRNA 
LNP immunization. (C) HAI titers at 21 days post immunization. (D) Gating scheme for 
the sorting of human splenic IgD-IgM-HA+ memory B cell subsets, defined by CD21 and 
CD85j expression. (E and F) VH gene usage in mice (E) and humans (F) computed 
based upon clonal usage (each clone is only counted once). Sequencing libraries from 
the same subject (human or mouse) and subset were pooled. Clones having less than 
half the mean copy number frequency within that subject/subset sequencing library were 
excluded from the analysis. Clones from the same species and subset were then pooled. 
Gray cells indicate no data and the VH usage was normalized by subset in both panels. 
Clone counts for mice (E) are HA+T-bet+ 1,605; HA+T-bet- 1,993; and IgD+ 21,889. Clone 
counts for humans (F) are HA+CD21+ 5,739; HA+CD21-CD85jhi 2,018; HA-CD21+ 31,396; 
HA-CD21-CD85jhi 21,442; and SPL 10,125. (G and H) Cosine similarity between 
sequencing replicates of each subset and between subsets in mice (G) and humans (H). 
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